Nucleic acids encoding zinc metalloproteases

ABSTRACT

Isolated mammalian proteins having disintegrin-like and metalloprotease domains with thrombospondin type I motifs, i.e., ADAMTS proteins, are provided. The proteins are ADAMTS-5, ADAMTS-6, ADAMTS-7, ADAMTS-8, ADAMTS-9 and ADAMTS-10, collectively referred to as 5 “ADAMTS-N”. The present invention also provides isolated polynucleotides which encode an ADAMTS-N protein or a variant thereof, polynucleotide sequences complementary to such polynucleotides, vectors containing such polynucleotides, and host cells transformed or transfected with such vectors. The present invention also relates to antibodies which are immunospecific for one or more of the ADAMTS-N proteins. The present invention also relates to a protein referred to hereinafter as ADAMTS-R1 (ADAM-TS Related protein-1) and the polynucleotides which encode such protein.

BACKGROUND OF THE INVENTION

[0001] This invention relates to isolated nucleic acid molecules which encode proteins belonging to a zinc metalloprotease family. The zinc metalloproteases have been implicated in a variety of diseases and development disorders that involve enhanced or depressed proteolysis of components of the extracellular matrix, receptors, or other extracellular molecules.

[0002] More particularly, the invention relates to isolated nucleic acid molecules encoding proteins belonging to a subfamily of zinc metalloproteases referred to as “ADAMTS”, an abbreviation for A Disintegrin-like And Metalloprotease domain with ThromboSpondin type I motifs. Proteins in the ADAMTS subfamily all possess a Zn protease catalytic site consensus sequence (HEXXH+H), which suggests an intact catalytic activity for each of these proteins. The ADAMTS proteins also have putative N-terminal signal peptides and lack transmembrane domains, which suggests that the proteins in this subfamily are secreted. The proteins in the ADAMTS subfamily also possess at least one thrombospondin type (TSP1) motif, which suggests a binding of these proteins to components of the extracellular matrix (ECM) or to cell surface components.

[0003] Members of the ADAMTS subfamily of proteins are ADAMTS-1, ADAMTS-2, ADAMTS-3, and ADAMTS-4. ADAMTS-1 protein is selectively expressed in colon 26 adenocarcinoma cachexigenic sublines. ADAMTS-1 mRNA is induced by the inflammatory cytokine interleukin-1 in vitro and by intravenous administration of lipopolysaccharide in vivo. Thus, the ADAMTS-1 protein is believed to play a role in tumor cachexia and inflammation.

[0004] The ADAMTS-2 protein is also known as procollagen I/II amino-propetide processing enzyme or PCINP. The ADAMTS-2 protein catalyzes cleavage of native triple-helical procollagen I and procollagen II. The ADAMTS-2 protein also has an affinity for collagen XIV. Lack of the ADAMTS-2 protein is known to cause dermatosparaxis in cattle, or Ehlers-Danlos syndrome type VIIC (EDS-VIIC) in humans. EDS-VIIC is characterized clinically by severe skin fragility, and biochemically by the presence in skin of procollagen which is incompletely processed at the amino terminus. Thus, it is believed that the ADAMTS-2 protein plays a role in processing of procollagen to mature collagen, an essential step for correct assembly of collagen into collagen fibrils. The ADAMTS-3 protein is similar in sequence to ADAMTS-2 and may have similar function.

[0005] The ADAMTS-4 protein catalyzes cleavage of the core protein of the extracellular matrix proteoglycan, aggrecan. Aggrecan degradation is an important factor in the erosion of articular cartilage in arthritic disease. Aggrecan fragments have been identified in cultures undergoing cartilage matrix degradation and in arthritic synovial fluids. Therefore, overexpression or activation of ADAMTS-4 protein may be related to both inflammatory and non-inflammatory arthritis.

[0006] On the basis of the structure, location, and the demonstrated proteolytic activity of ADAMTS proteins 1-4, it is expected that other members of the ADAMTS subfamily play a role in the cleavage of proteoglycan core proteins that are found in the extracellular matrix, such as, for example, versican, brevican, neuracan, NG-2, aggrecan, as well as molecules such as collagen. It is also expected that other members of the ADAMTS subfamily play a role in embryogenesis, implantation of a fertilized egg, angiogenesis, arthritic degradation of cartilage, inflammation, nerve regeneration, tumor growth, and metastases.

[0007] Thus, it is desirable to have other members of the ADAMTS subfamily of proteins, the nucleic acids that encode such proteins, and antibodies that are specific for such proteins. Such molecules are useful research tools for studying development of the extracellular matrix during embryogenesis and fetal development, and for studying disorders or diseases that are characterized by improper development of the extracellular matrix or enhanced or reduced destruction of the extracellular matrix. Such molecules, particularly the nucleic acids and the antibodies, are also useful tools for diagnosing such diseases or for monitoring the efficacy of therapeutic agents that have been developed to treat such diseases.

SUMMARY OF THE INVENTION

[0008] The present invention provides novel, isolated, and substantially purified proteins having the characteristics of an ADAMTS protein. The novel proteins are referred to hereinafter individually as “ADAMTS-5”, “ADAMTS-6”, “ADAMTS-7”, “ADAMTS-8”, “ADAMTS-9” and “ADAMTS-10”, and collectively as “ADAMTS-N”. In one embodiment, the ADAMTS-5 protein is a mature mouse protein which comprises amino acid 231 through amino acid 930 of the sequence set forth in SEQ ID NO: 2. In another embodiment, ADAMTS-5 is a human ADAMTS-5 protein which comprises amino acid 1 through amino acid 518 of the sequence set forth in SEQ ID NO: 4. In one embodiment, mature human ADAMTS-6 protein comprises amino acid 245 through amino acid 860 of SEQ ID NO: 6. In one embodiment, mature human ADAMTS-7 protein comprises amino acid 233 through amino acid 997 of the sequence set forth in SEQ ID NO: 8. In one embodiment, mature ADAMTS-8 protein is a mouse protein which comprises amino acid 229 through amino acid 905 of the sequence set forth in SEQ ID NO: 10. In another embodiment, ADAMTS-8 protein is a human protein which comprises amino acid 1 through amino acid 245 of the sequence set forth in SEQ ID NO: 12. In one embodiment, mature ADAMTS-9 protein is a human protein which comprises amino acid 236 through amino acid 1882 of the sequence set forth in SEQ ID NO: 14. In another embodiment, ADAMTS-9 protein is a mouse protein which comprises amino acid 1 through amino acid 874 of the sequence set forth in SEQ ID NO: 16. In one embodiment, mature ADAMTS 10 protein is a human protein which comprises amino acid 212 through amino acid 1081 of the sequence set forth in SEQ ID NO: 18. In another embodiment, ADAMTS-10 protein is a mouse protein which comprises amino acid 1 through amino acid 547 of the sequence set forth in SEQ ID NO: 20.

[0009] The present invention also provides isolated polynucleotides which encode an ADAMTS-N protein or a variant thereof, polynucleotide sequences complementary to such polynucleotides, vectors containing such polynucleotides, and host cells transformed or transfected with such vectors. The present invention also relates to antibodies which are immunospecific for one or more of the ADAMTS-N proteins. The present invention also relates to a protein referred to hereinafter as ADAMTS-R1 (ADAM-TS Related protein-1) and the polynucleotides which encode such protein. In one embodiment, the ADAMTS-R1 protein comprises amino acid 1 through amino acid 525 of the sequence set forth in SEQ. ID NO: 22.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010]FIG. 1 shows an amino acid sequence (SEQ ID NO: 2) of a full-length mouse ADAMTS-5 protein and a nucleic acid sequence (SEQ ID NO: 1) which encodes such protein.

[0011]FIG. 2 shows an amino acid sequence (SEQ ID NO: 4) of a partial human ADAMTS-5 protein and a nucleic acid sequence (SEQ ID NO: 3) which encodes such protein.

[0012]FIG. 3 shows an amino acid sequence (SEQ ID NO: 6) of a full-length human ADAMTS-6 protein and a nucleic acid sequence (SEQ ID NO: 5) which encodes such protein.

[0013]FIG. 4 shows an amino acid sequence (SEQ ID NO: 8) of a full-length human ADAMTS-7 protein and a nucleic acid sequence (SEQ ID NO: 7) which encodes such protein.

[0014]FIG. 5 shows an amino acid sequence (SEQ ID NO: 10) of a full-length mouse ADAMTS-8 protein and a nucleic acid sequence˜SEQ ID NO: 9) which encodes such protein.

[0015]FIG. 6 shows an amino acid sequence (SEQ ID NO: 12) of a partial human ADAMTS-8 protein and a nucleic acid sequence (SEQ ID NO: 11) which encodes such amino acid sequence.

[0016]FIG. 7 shows an amino acid sequence (SEQ ID NO: 14), of a full-length human ADAMTS-9 protein and a nucleic acid sequence (SEQ ID NO: 13) which encodes such protein.

[0017]FIG. 8 shows an amino acid sequence (SEQ ID NO: 16) of a partial mouse ADAMTS-9 protein and a nucleic acid sequence (SEQ ID NO: 15) which encodes such amino acid sequence.

[0018]FIG. 9 shows an amino acid sequence (SEQ ID NO: 18) of a full-length human ADAMTS-10 protein and a nucleic acid sequence (SEQ ID NO: 17) which encodes such protein.

[0019]FIG. 10 shows an amino acid sequence (SEQ ID NO: 20) of a partial mouse ADAMTS-10 protein and a nucleic acid sequence (SEQ ID NO: 19) which encodes such amino acid sequence.

[0020]FIG. 11 shows an amino acid sequence (SEQ ID NO: 22) of a full length ADAMTS-R1 protein and a nucleic acid sequence (SEQ ID NO: 21) which encodes such protein.

[0021]FIG. 12 depicts the cloning strategy used for isolation of a. mouse and human ADAMTS-5 cDNAs b. human ADAMTS-6 cDNA and c. human ADAMTS-7 cDNA. The domain organization of each protein relative to the cDNA clones (thin line) is shown as is the extent of overlap between clones. The original I.M.A.G.E. clones used are underlined. Intronic regions of incompletely spliced transcripts are shown by the angled dotted lines. DNA scale marker (in bp) and amino acid scale marker are at upper right. Location of the probe used for in situ hybridization (ISH) is shown in a. FIG. 13 shows the predicted amino acid sequences of a. the mouse and human ADAMTS-5 proteins(alignment shows mouse sequence above, partial human sequence below) b. ADAMTS-6, and c. ADAMTS-7. The active-site sequences and proposed Met-turn are enclosed in boxes. Potential furin cleavage site(s) are indicated by arrows. Thrombospondin type-1 modules are underlined. Potential sites for N-inked glycosylation are overlined. Cysteine residues within the context of an MMP-like “cysteine switch” are indicated by the solid circles. Other cysteine residues aRe indicated by asterisks. The prodomain extends until the furin cleavage site, and the catalytic domain extends from the furin cleavage site to the approximate start of the disintegrin-like sequence (Dis). The start of the spacer domain is indicated; the region between the N-terminal TS domain and the spacer domain is the cysteine-rich domain. The single letter amino acid code is used.

[0022]FIG. 14 shows Northern analysis of expression of ADAMTS-5, 6 and 7. RNA kilobase markers are shown at left of each autoradiogram, and tissue origin is indicated above each lane. a. Mouse embryo 5 northern blots. b. Human multiple adult tissue northern blots.

[0023]FIG. 15 is a schematic representation of the domain structure of ADAMTS-R1 protein as compared to ADAMTS-1 protein.

DETAILED DESCRIPTION OF THE INVENTION

[0024] ADAMTS-N Proteins

[0025] The present invention relates to novel, isolated, substantially purified, mammalian proteins belonging to the ADAMTS subfamily of metalloproteases. As used herein, the term “substantially purified” refers to a protein that is removed from its natural environment, isolated or separated, and at least 60% free, preferably 75% free, arid most preferably 90% free from other components with which it is naturally associated.

[0026] The novel mammalian proteins are ADAMTS-5, ADAMTS-6, ADAMTS-7, ADAMTS-8, ADAMTS-9 and ADAMTS-10, collectively ADAMTS-N. In one embodiment, the ADAMTS-5 protein is a mature mouse protein which comprises amino acid 231 through amino acid 930 of the sequence set forth in SEQ ID NO: 2. In another embodiment, the ADAMTS-5 protein is a human protein which comprises amino acid 1 through amino acid 518 of the sequence set forth in SEQ ID NO: 4. In one embodiment, ADAMTS-6 protein is a mature human protein which comprises amino acid 245 through amino acid 860 of SEQ ID NO: 6. In one embodiment, the ADAMTS-7 protein is a mature human protein which comprises amino acid 233 through amino acid 997 of the sequence set forth in SEQ ID NO: 8. In one embodiment, the ADAMTS-8 protein is a mature mouse protein which comprises amino acid 229 through amino acid 905 of the sequence set forth in SEQ ID NO: 10. In another embodiment, the ADAMTS-8 protein is a human protein which comprises amino acid 1 through amino acid 245 of the sequence set forth in SEQ ID NO: 12. In one embodiment, the ADAMTS-9 is a mature human protein which comprises amino acid 236 through amino acid 1882 of the sequence set forth in SEQ ID NO: 14. In another embodiment, the ADAMTS-9 protein is a mouse protein which comprises amino acid 1 through amino acid 874 of the sequence set forth in SEQ ID NO: 16. In one embodiment, the ADAMTS-10 protein is a mature human protein which comprises amino acid 212 through amino acid 1081 of the sequence set forth in SEQ ID NO: 18. In another embodiment the ADAMTS-10 protein is a mouse protein which comprises amino acid 1 through amino acid 525 of the sequence set forth in SEQ ID NO: 20.

[0027] All of the novel ADAMTS-N proteins starting at the amino terminus comprise a signal sequence followed by a putative pro region which contains a consensus sequence for furin cleavage (except for ADAMTS-10), a catalytic domain, a domain of 60-90 residues with 35 to 45% similarity to snake venom disintegrins, a TS module, a cysteine rich domain containing multiple conserved cysteine residues, a spacer domain, and one or multiple C. terminal TS modules. (See FIG. 12.) As determined using the BLAST software from the National Center for Biotechnology Information, the predicted mature forms of the ADAMTS-N proteins show an overall 20-30% similarity to each other and to ADAMTS-1-4, although this may be considerably higher or lower for individual domains as described below.

[0028] The ADAMTS-N proteins also encompass variants of the ADAMTS-N proteins shown in FIGS. 1-10. A “variant” as used herein, refers to a protein whose amino acid sequence is similar to one of the amino acid sequences shown in FIGS. 1-10, hereinafter referred to as the reference amino acid sequence, but does not have 100% identity with the reference sequence. The variant protein has an altered sequence in which one or more of the amino acids in the reference sequence is deleted or substituted, or one or more amino acids are inserted into the sequence of the reference amino acid sequence. As a result of the alterations, the variant protein has an amino acid sequence which is at least 95% identical to the reference sequence, preferably, at least 97% identical, more preferably at least 98% identical, most preferably at least 99% identical to the reference sequence. Variant sequences which are at least 95% identical have no more than 5 alterations, i.e. any combination of deletions, insertions or substitutions, per 100 amino acids of the reference sequence. Percent identity is determined by comparing the amino acid sequence of the variant with the reference sequence using MEGALIGN project in the DNA STAR program. Sequences are aligned for identity calculations using the method of the software basic local alignment search tool in the BLAST network service (the National Center for Biotechnology Information, Bethesda, Md.) which employs the method of Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) J. Mol. Biol. 215, 403 410. Identities are calculated by the Align program (DNAstar, Inc.) In all cases, internal gaps and amino acid insertions in the candidate sequence as aligned are not ignored when making the identity calculation.

[0029] While it is possible to have nonconservative amino acid substitutions, it is preferred that the substitutions be conservative amino acid substitutions, in which the substituted amino acid has similar structural or chemical properties with the corresponding amino acid in the reference sequence. By way of example, conservative amino acid substitutions involve substitution of one aliphatic or hydrophobic amino acids, e.g. alanine, valine, leucine and isoleucine, with another; substitution of one hydroxyl-containing amino acid, e.g. serine and threonine, with another; substitution of one acidic residue, e.g. glutamic acid or aspartic acid, with another; replacement of one amide-containing residue, e.g. asparagine and glutamine, with another; replacement of one aromatic residue, e.g. phenylalanine and tyrosine, with another; replacement of one basic residue, e.g. lysine, arginine and histidine, with another; and replacement of one small amino acid, e.g., alanine, serine, threonine, methionine, and glycine, with another.

[0030] The alterations are designed not to abolish the immunoreactivity of the variant protein with antibodies that bind to the reference protein. Guidance in determining which amino acid residues may be substituted, inserted or deleted without abolishing immunoreactivity of the variant protein with an antibody specific for the respective reference protein are found using computer programs well known in the art, for example, DNASTAR software.

[0031] The ADAMTS-N proteins also encompass fusion proteins comprising an ADAMTS-N protein and a tag, i.e., a second protein or one or more amino acids, preferably from about 2 to 65 amino acids, more preferably from about 34 to about 62 amino acids, which are added to the amino terminus of, the carboxy terminus of, or any point within the amino acid sequence of an ADAMTS-N protein, or a variant of such protein. Typically, such additions are made to stabilize the resulting fusion protein or to simplify purification of an expressed recombinant form of the corresponding ADAMTS-N protein or variant of such protein. Such tags are known in the art. Representative examples of such tags include sequences which encode a series of histidine residues, the epitope tag FLAG, the Herpes simplex glycoprotein D, beta-galactosidase, maltose binding protein, or glutathione S-transferase.

[0032] The ADAMTS-N proteins also encompass ADAMTS-N proteins in which one or more amino acids, preferably no more than 10 amino acids, in the respective ADAMTS-N protein are altered by posttranslation processes or synthetic methods. Examples of such modifications include, but are not limited to, acetylation, amidation, ADP-ribosylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or a lipid, cross-linking gammacarboxylation, glycosylation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, sulfation, and transfer-RNA mediated additions of amino acids to proteins such as arginylation and ubiquitination.

[0033] The ADAMTS-N proteins are immunogenic and, thus, are useful for preparing antibodies. Such antibodies are useful for identifying and diagnosing disorders which are associated with decreased expression or activity or increased expression of an ADAMTS-N protein. The ADAMTSN protein may also be useful for treating such disorder.

[0034] Diseases involving enhanced or depressed proteolyisis of the core proteins of the extracellular may involve enhanced expression or activity or decreased expression or activity of one or more ADAMTS-N proteins. Thus, ADAMST-N proteins may be used to identify drugs, polypeptides, auto-antibodies, or other natural compounds which bind to an ADAMTS-N protein with sufficient affinity to block or facilitate its activity. The activity of the ADAMTS-N protein is assayed in the presence and the absence of the putative inhibitor or facilitator using any of a variety of protease assays known in the art. In general, the activity of the ADAMTS-N protein is assayed through the use of a peptide or protein substrate having a known or putative cleavage site for the ADAMTS-N protein. To detect cleavage or to monitor the extent of cleavage, the substrate is tagged in a manner which provides a detectable signal upon cleavage. For example, the substrate may be tagged with a fluorescent group on one side of the cleavage site and with a fluorescence-quenching group on the opposite side of the cleavage site. Upon cleavage by the substrate, quenching is eliminated and a detectable signal is produced. Alternatively, the substrate is tagged with a colorimetric leaving group that more strongly absorbs upon cleavage. Agents which block ADAMTS-N-catalyzed cleavage of a protein substrate may be administered to a subject to block proteolysis of the corresponding protein substrate.

[0035] ADAMTS-R1 Protein

[0036] The present invention also relates to a protein, referred to hereinafter as “ADAMTS-R1”. From its amino to its carboxyl terminus, ADAMTS-R1 comprises a signal peptide sequence, a TS1 module, a cysteine-rich domain, a spacer domain, and three TS1 modules. Thus, ADAMTS-R1 has a structure which is related to or similar to an ADAMTS-N protein, but which lacks a catalytic domain and a disintegrin-like domain. In one embodiment, ADAMTS-R1protein comprises amino acid 1 through amino acid 525 of the amino acid sequence, SEQ ID N.0:22, shown in FIG. 11. Such protein has a 30-40% overall sequence identity with similar regions of the ADAMTS-N proteins. The ADAMTS-R1 proteins also encompass variants of the amino acid sequence shown in FIG. 11 and fusion proteins which contain the amino acid sequence shown in FIG. 11 or a variant thereof. On the basis of its domain organization, it is expected that ADAMTS-R1 can bind to extracellular matrix or cell surface molecules, including ADAMTS-N substrates. Thus, it is expected that ADAMTS-R1 can be used as an cell-matrix or cell-cell adhesion molecule or an ADAMTS-N competitive inhibitor. The ADAMTS-R1 proteins are also useful for preparing antibodies. Such antibodies are useful for identifying tissues where ADAMTS-R1 is expressed and for diagnosing disorders which are associated with decreased expression or increased expression of an ADAMTS-R1 protein.

[0037] Polynucleotides

[0038] The present invention also provides isolated palynucleotides which encode the mammalian ADAMTS-N proteins and the mammalian ADAMTS-R1 protein. FIG. 1 shows one embodiment of a polynucleotide, SEQ ID NO: 1, which encodes the full-length mouse ADAMTS-5 protein. FIG. 2 shows one embodiment of a polynucleotide; SEQ ID NO: 3, which encodes a partial human ADAMTS-5 protein. FIG. 3 shows one embodiment of a polynucleotide; SEQ ID NO: 5, which encodes a full-length human ADAMTS-6 protein. FIG. 4 shows one embodiment of a polynucleotide; SEQ ID NO: 7, which encodes a-full-length human ADAMTS-7 protein. FIG. 5 shows one embodiment of a polynucleotide; SEQ ID NO: 9, which encodes a full-length mouse ADAMTS-8 protein. FIG. 6 shows one embodiment of a polynucleotide; SEQ ID NO: 11, which encodes a partial human ADAMTS-8 protein. FIG. 7 shows one embodiment of a polyniicleotide; SEQ ID NO: 13, which encodes a full-length human ADAMTS-9 protein. FIG. 8 shows one embodiment of a polynucleotide; SEQ ID NO: 15, which encodes a partial ADAMTS-9 protein. FIG. 9 shows one embodiment of a polynucleotide; SEQ ID NO: 17, which encodes a full-length human ADAMTS-10 protein. FIG. 10 shows one embodiment of a polynucleotide; SEQ ID NO: 19, which encodes a partial mouse ADAMTS-10 protein. FIG. 11 shows one embodiment of a polynucleotide; SEQ ID NO: 21, which encodes a full-length ADAMTS-R1 protein.

[0039] Due to the known degeneracy of the genetic code wherein more than one codon can encode the same amino acid, a DNA sequence may vary from that shown in SEQ ID NO: 1 and still encode an ADAMTS-5 protein having the amino acid sequence of SEQ ID NO: 2. Similarly, a DNA sequence may vary from that shown in SEQ ID NO: ,5, and still encode an ADAMTS-6 protein having the amino acid sequence set forth in SEQ ID NO: 6. Similarly a DNA sequence may vary from that shown in SEQ ID NOS: 7, 9, 11, and 13, and still encode the amino acid sequences shown in SEQ ID NOS: 8, 10, 12, and 14, respectively. Such variant DNA sequence may result from silent mutations, such as for example those that occur during PCR amplification or from deliberate mutagenesis of a native sequence.

[0040] The present polynucleotides also encompass polynucleotides having sequences that are capable of hybridizing to the nucleotide sequences of FIGS. 1-11 under stringent conditions, preferably highly stringent conditions. Hybridization conditions are based on the melting temperature™ of the nucleic acid binding complex or probe, as described in Berger and Kimmel (1987) Guide to Molecular Cloning Techniques, Methods in Enzymology, vol 152, Academic Press. The term “stringent conditions, as used herein, is the “stringency” which occurs within a range from about Tm-5 (5° below the melting temperature of the probe) to about 20° C. below Tin. As used herein “highly stringent” conditions employ at least 0.2×SSC buffer and at least 65° C. As recognized in the art, stringency conditions can be attained by varying a number of factors such as the length and nature, Le, DNA or RNA, of the probe; the length and nature of the target sequence, the concentration of the salts and other components, such as formamide, dextran sulfate, and polyethylene glycol, of the hybridization solution. All of these factors may be varied to generate conditions of stringency which are equivalent to the conditions listed above.

[0041] The present polynucleotides also encompasses alleles of the ADAMTS-N and ADAMTS-R1 encoding sequences. As used herein, an allele or allelic sequence is an alternative form of an ADAMTS-N or ADAMTS-R1 encoding sequence which is present at the same gene locus. The allele may result from one or.more mutations in the ADAMTS-N or ADAMTS-RI encoding sequence. Such mutations typically arise from natural addition, deletion of substitution of nucleotides in the open reading frame sequences. Any gene which encodes an ADAMTS-N protein or ADAMTS-R1 protein may have none, one, or several allelic forms. Such alleles are identified using conventional techniques, such as for example screening libraries with probes having sequences identical to or complementary with one or more ADAMTS-N polynucleotides.

[0042] The present polynucleotides also encompass altered polynucleotides which encode ADAMTS-N proteins, ADAMTS-R1 proteins, and variants thereof. Such alterations include deletions, additions, or substitutions. Such alterations may produce a silent change and result in an ADAMTS-N protein having the same amino acid sequence as the ADAMTS-N protein encoded by the unaltered polynucleotide. Such alterations may produce a nucleotide sequence possessing nonnaturally occurring codons. For example, codons preferred by a particular prokaryotic or eucaryotic host may be incorporated into the nucleotide sequences shown in FIGS. 1-11 to increase the rate of expression of the proteins encoded by such sequences. Such alterations may also introduce new restriction sites into the sequence or result in the production of an ADAMTS-N or ADAMTS-R1 variant. Typically, such alterations are accomplished using site-directed mutagenesis.

[0043] The polynucleotides are useful for producing ADAMTS-N or ADAMTS-R1 proteins. For example, an RNA molecule encoding an ADAMTS-N protein is used in a cell-free translation systems to prepare such protein. Alternatively, a DNA molecule encoding an ADAMTS-N protein is introduced into an expression vector and used to transform cells. Suitable expression vectors include for example chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40, bacterial plasmids, phage DNAs; yeast plasmids, vectors derived from combinations of plasmids and phage DNAs, viral DNA such as vaccinia, adenovirus, fowl pox virus, pseudorabies, baculovirus, and retrovirus. The DNA sequence is introduced into the expression vector by conventional procedures.

[0044] Accordingly, the present invention also relates to recombinant constructs comprising one or more of the present polynucleotide sequences. Suitable constructs include, for example, vectors, such as a plasmid, phagemid, or viral vector, into which a sequence that encodes an ADAMTS-N protein or an ADAMTS-R1 protein has been inserted. In the expression vector, the DNA sequence which encodes the ADAMTS-N protein is operatively linked to an expression control sequence, i.e., a promoter, which directs mRNA synthesis. Representative examples of such promoters, include the LTR or SV40 promoter, the E. coli lac or trp, the phage lambda PL promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or in viruses. The promoter may also be the natural promoter of the ADAMTS-N encoding sequence. The expression vector, preferably, also contains a ribosome binding site for translation initiation and a transcription terminator. Preferably, the recombinant expression vectors also include an origin of replication and a selectable marker, such as for example, the ampicillin resistance gene of E. coli to permit selection of transformed cells, i.e. cells that are expressing the heterologous DNA sequences. The polynucleotide sequence encoding the ADAMTS-N protein is incorporated into the vector in frame with translation initiation and termination sequences.

[0045] The polynucleotides encoding an ADAMTS-N or ADAMTS-R1 protein are used to express recombinant protein using techniques well known in the art. Such techniques are described in Sambrook, J. et al (1989) Molecular Cloning A Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y. and Ausubel, F. M. et al. (1989) Cuurent Protocols in Molecular Biology, John Wile & Sons, New York, N.Y.

[0046] Polynucleotides encoding an ADAMTS-N or ADAMTS=R1 protein may also be used for diagnostic purposes. The polynucleotides may be used to detect and quantify ADAMTS-N or ADAMTS-R1 gene transcripts in biopsied tissues in which enhanced expression or reduced expression of the corresponding ADAMTS-N or ADAMTS-R1 gene is correlated with a disease. The diagnostic assay may be used to determine whether expression is absent, present, or altered and to determine whether certain therapeutic agents modulate expression of the corresponding ADAMTSN or ADAMTS-R1 gene.

[0047] Also encompassed by the present invention, are single stranded polynucleotides, hereinafter referred to as antisense polynucleotides, having sequences which are complementary to the DNA and RNA sequences which encode the ADAMTS-N or ADAMTS-R1, proteins. The term complementary as used herein refers to the natural binding of the polynucleotides under permissive salt and 5 temperature conditions by base pairing.

[0048] The present invention also encompasses oligonucleotides that are used as primers in polymerase chain reaction (PCR) technologies to amplify transcripts of the genes which encode the ADAMTS-N and ADAMTSR-1 proteins or portions of such transcripts. Preferably, the primers comprise 18-30 nucleotides, more preferably 19-25 nucleotides: Preferably, the primers have a G+C. content of 40% or greater. Such oligonucleotides are at least 98% complementary with a portion of the DNA strand, i.e., the sense strand, which encodes the respective ADAM-TS family protein or a portion of its corresponding antisense strand. Preferably, the primer has at least 99% complementarity, more preferably 100% complementarity, with such sense strand or its corresponding antisense strand. Primers which are which have 100% complementarity with the antisense strand of a double-stranded DNA molecule which encodes an ADAMTS-N protein have a sequence which is identical to a sequence contained within the sense strand. The identity of primers which are 15 nucleotides in length and have full complementarity with a portion of the antisense strand of a double-stranded DNA molecule which encodes the ADAMTS-N protein is determined using the nucleotide sequences, shown in FIG. 1-11 and described by the general formula a-b; where a is any integer between 1 and the position number of the nucleotide which-is located 15 residues upstream of the 3′ end of the sense or antisense strand of the cDNA sequences shown in FIG. 1-11; where b is equal to a+14; and where both a and b correspond to the positions of nucleotide residues of the cDNA sequences shown in FIGS. 1-11.

[0049] The present invention also encompasses oligonucleotides that are useful as hybridization probes for for isolating and identifying cDNA clones and genomic clones encoding the ADAMTS-N or ADAMTS-R1 protein or allelic forms thereof. Such hybridization probes are also useful for detecting transcripts of the genes which encode the ADAMTS-N family proteins or for mapping of the genes which encode the ADAMTS-N proteins Preferably, such oligonucleotides comprise at least 210 nucleotides, more preferably at least 230, most preferably from about 210 to 280 nucleotides. Such hybridization probes have a sequence which is at least 90% complementary with a sequence contained within the sense strand of a DNA molecule which encodes an ADAMTS-N protein or ADAMTS-R1 protein or with a sequence contained within its corresponding antisense strand. Such hybridization probes bind to the sense strand under stringent conditions. The term “stringent conditions” as used herein is the binding which occurs within a range from about Tm 5° C. (5° C. below the melting temperature Tm of the probe) to about 20° C. to 25° C. below Tm. The probes are used in Northern assays to detect transcripts of ADAMTS-N homologous genes and in Southern assays to detect ADAMTS-N homologous genes. The identity of probes which are 200 nucleotides in length and have fall complementarity with a portion. of the antisense strand of a double-stranded DNA molecule which encodes the ADAMTS-N protein is determined using the nucleotide sequences shown in FIG. 1-10 and described by the general formula a-b; where a is any integer between 1 and the position number of the nucleotide which is located 200 residues upstream of the 3′ end of the sense or antisense strand of the cDNA sequences shown in FIG. 1-10; b is equal to a +200; and where both a and b correspond to the positions of nucleotide residues of the cDNA sequences shown in FIG. 1-10.

[0050] Such probes or primers are also useful for identifying tissues or cells in which the corresponding ADAMTS-N or ADAMTS-R1 gene is preferentially expressed either constitutively or at particular state of tissue differentiation or development or in disease states. Expression of the ADAMTS-N or ADAMTS-R1 gene in a particular tissue or group of cells is determined using conventional procedures including, but not limited to, Northern analysis, in situ hybridization to RNA or RT-PCR amplification. Isolated polynucleotides encoding an ADAMTS-N or ADAMTS-R1 protein are also useful as chromosome markers to map linked gene positions, to identify chromosomal aberrations such as translocations, inversions and trisomies, to compare with endogenous DNA sequences in patients to identify potential genetic disorders, and as probes to hybridize and thus discover novel, related DNA sequences. For use in such studies and assays, the probes may be labeled with radioisotopes, fluorescent labels, or enzymatic labels. The assays include, but are not limited to, Southern blot, in situ hybridization to DNA in cells and chromosomes, PCR, and allele specific hybridization.

[0051] Antibodies

[0052] In another aspect, the present invention relates to antibodies which are specific for and bind to the ADAMTS-5 protein, the ADAMTS-6 protein, the ADAMTS-7 protein, the ADAMTS-8 protein, the ADAMTS-9 protein, the ADAMTS-10 protein, or the ADAMTS-R1 protein. Such antibodies are useful research tools for identifying tissues that contain elevated levels of the respective protein and for purifying the respective protein from cell or tissue extracts, medium of cultured cells, or partially purified preparations of intracellular and extracellular proteins by affinity chromatography. Such antibodies are also useful for identifying and diagnosing diseases associated with elevated or reduced levels of an ADAMTS-N protein or ADAMTS-R1 protein. Such antibodies are also useful for monitoring the effect of therapeutic agents on the synthesis and secretion of ADAMTS-N proteins by cells in vitro and in vivo. Such antibodies may also be employed in procedures, such as co-immunoprecipitation and co-affinity chromatography, for identifying other proteins, activators and inhibitors which bind to an ADAMTS-N or ADAMTS-R1 protein.

[0053] The present invention also provides a method for detecting an ADAMTS-N or ADAMTS-R1 protein in a bodily sample from a patient using antibodies immnunospecific for an ADAMTS-N or ADAMTS-R1 protein. The method comprises contacting the antibody with a sample taken from the patient; and assaying for the formation of a complex between the antibody and the corresponding ADAMTS-N or ADAMTS-R1 protein present in the sample. The sample may be a tissue or a biological fluid, including but not limited to whole blood, serum, synovial fluid, stool, urine, cerebrospinal fluid, semen, diagnostic washes from trachea, stomach and other bowel segments, tissue biopsies or excised tissue, cells obtained from swabs and smears. To monitor changes in expression of the ADAMTS-N protein during fetal development and pregnancy, it is preferred that the sample be amniotic fluid. To monitor changes in expression of the ADAMTS-N protein during joint disorders, the preferred sample is synovial fluid. To monitor changes in expression of ADAMTS-N proteins during cancer, the preferred samples include, but are not limited to, serum, body fluids, or biopsy tissue. To monitor changes in expression of ADAMTS-N proteins during inflammation the preferred samples include, but are not limited to, serum, body fluids, or biopsy tissue.

[0054] The sample may be untreated, or subjected to precipitation; fractionation, separation, or purification before combining with the anti-ADAMTS-N protein antibody. For ease of detection, it is preferred that isolated proteins from the sample be attached to a substrate such as a column, plastic dish, matrix, or membrane, preferably nitrocellulose. Preferably, the detection method employs an enzyme-linked immunosorbent assay (ELISA) or a Western immunoblot procedure.

[0055] Interactions between an ADAMTS-N protein in the sample and the corresponding anti ADAMTS-N antibody are detected by radiometric, calorimetric, or fluorometric means, size separation, or precipitation. Preferably, detection of the antibody-ADAMTS-N protein complex is by addition of a secondary antibody that is coupled to a detectable tag, such as for example, an enzyme, fluorophore, or chromophore. Formation of the complex is indicative of the presence of the ADAMTS-N protein in the test sample. Thus, the method is used to determine whether there is a decrease or increase in the levels of the ADAMTS-N protein in a test sample as compared to levels of the ADAMTS-N protein in a control sample and to quantify the amount of the ADAMTS-N protein in the test sample. Deviation between control and test values establishes the parameters for diagnosing the disease.

[0056] Preparing the ADAMTS-N Proteins and the ADAMTS-R1 Protein

[0057] The ADAMTS-N proteins and the ADAMT-SRI protein may be produced by conventional peptide synthesizers. The ADAMTS-N proteins and the ADAMTS-R1 protein may also be produced using cell-free translation systems and RNA molecules derived from DNA constructs that encode an ADAMTS-N protein or an ADAMTS-R1 protein. Alternatively, ADAMTS-N proteins are made by transfecting host cells with expression vectors that comprise a DNA sequence that encodes the respective ADAMTS-N protein and then inducing expression of the protein in the host. cells. For recombinant production, recombinant constructs comprising one or more of the sequences which encode the ADAMTS-N protein or a variant thereof are introduced into host cells by conventional methods such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape lading, ballistic introduction or infection.

[0058] The ADAMTS-N protein and the ADAMTS-R1 protein may be expressed in suitable host cells, such as for example, mammalian cells, yeast, bacteria, insect cells or other cells under the control of appropriate promoters using conventional techniques. Suitable hosts include, but are not limited to, E. coli, P. pastoris, Cos cells and 293 HEK cells. Following transformation of the suitable host strain and growth of the host strain to an appropriate cell density, the cells are harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification of the ADAMTS-N protein or the ADAMTS-R1 protein.

[0059] Conventional procedures for isolating recombinant proteins from transformed host cells, such as isolation by initial extraction from cell pellets or from cell culture medium, followed by salting-out, and one or more chromatography steps, including aqueous ion exchange chromatography, size exclusion chromatography steps, and high performance liquid chromatography (HPLC), and affinity chromatography may be used to isolate the recombinant ADAMTS-N protein or ADAMTS R1 protein

[0060] \Preparation of Antibodies

[0061] The ADAMTS-N proteins, and variants thereof axe used as immunogens to produce antibodies immunospecific for one or more ADAMTS-N protein. The term “immunospecific” means the antibodies have substantially greater affinity for one or more ADAMTS-N protein than for other proteins. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, and Fab fragments.

[0062] Antibodies are also prepared using an oligopeptide having a sequence which is identical to a portion of the amino acid sequence of an ADAMTS-N protein. Preferably the oligopeptide has an amino acid sequence of at least five amino acids, and more preferably, at least 10 amino acids that are identical to a portion-of the amino acid sequence of an ADAMTS-N protein. Such peptides are conventionally fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule. One preferred oligopeptide for preparing an antibody to mouse ADAMTS-5 has the sequence (C)HIKVRQFKAKDQTRF, SEQ ID NO: 30. Another preferred oligopeptide for preparing an antibody to ADAMTS-5 is CEAKNGYQSDAKGVKTFVEWVPKYAG, SEQ ID NO: 31. One preferred oligopeptide for preparing an antibody to ADAMTS-6 has the sequence SVSIERFVETLVVADK(C), SEQ ID NO: 23. One preferred oligopeptide for preparing an antibody to ADAMTS-7 has the sequence (C)EVAEAANFLALRSEDPEKY, SEQ ID NO: 24. One preferred oligopeptide for preparing an antibody to ADAMTS-8 has the sequence CVKEDVENPKAVVDGDWGP, SEQ ID NO: 25. One preferred oligopeptide for preparing an antibody to ADAMTS-9 has the sequence QHPFQNEDYRPRSASPSRTH, SEQ ID NO: 26. Another preferred oligopeptide for preparing an antibody to ADAMTS-9 has the sequence PQNCKEVKRLKGASEDGEYF, SEQ ID NO: 27. One preferred oligopeptide for preparing an antibody for ADAMTS-RL has the sequence QELEEGAAVSEEPS, SEQ ID NO: 28. Another preferred oligopeptide for preparing an antibody for ADAMTS-R1 has the sequence YYPENIKPKPKLQE; SEQ ID NO: 29.

[0063] Polyclonal antibodies are generated using conventional techniques by administering the ADAMTS-N protein or achimeric molecule to a host animal. Depending on the host species, various adjuvants may be used to increase immunological response. Among adjuvants used in humans, Bacilli Calmette-Guerin (BCG), and Corynebacterium parvum are especially preferable. Conventional protocols are also used to collect blood from the immunized animals and to isolate the serum and or the IgG fraction from the blood.

[0064] For preparation of monoclonal antibodies, conventional hybridoma techniques are used. Such antibodies are produced by continuous cell lines in culture. Suitable techniques for preparing monoclonal antibodies include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV hybridoma technique.

[0065] Various immunoassays may be used for screening to identify antibodies having the desired specificity. These include protocols which involve competitive binding or immunoradiometric assays and typically involve the measurement of complex formation between the respective ADAMTS-N protein and the antibody.

[0066] Polynucleotides That Encode ADAMTS-N Proteins

[0067] Polynucleotides comprising sequences encoding an ADAMTS-N protein or an ADAMTS-R1 protein may be synthesized in whole or in part using chemical methods. Polynucleotides which encode an ADAMTS-N protein, particularly alleles of the genes which encode the ADAMTS-N protein, may be obtained by screening a genomic library or cDNA library with a probe comprising sequences identical or complementary to the sequences shown in FIGS. 1-10 or with antibodies immunospecific for a ADAMTS-N protein to identify clones containing such polynucleotide.

EXAMPLE1

[0068] ADAMTS-5 protein

[0069] A cDNA encoding mouse ADAMTS-5 protein was obtained using IMAGE Clone 569515, purchased from Research Genetics, Huntsville, Alabama and 7 day old mouse embryo cDNA library from Clontech, Palo Alto, Calif. A cDNA encoding human ADAMTS-5 protein was obtained using IMAGE Clone 345484 purchased from Research Genetics, Huntsville, Alabama and a human fetal brain cDNA from Clontech. The clone inserts were sequenced in their entirety. Using oligonucleotide primers based on the sequences at the ends of the. clone inserts as template, successive rounds of RACE (Rapid Amplification of cDNA Ends) by PCR was performed at 5′ and 3 ends. RACE primers were generated 50-200 by from the ends of the sequences so that the contiguity of RACE clones with the I.M.A.G.E. clone could be clearly established. A single round of 5′ and 3′ RACE sufficed for cloning of the entire coding sequence of the mouse ADAMTS-5 protein and part of the catalytic zinc binding site through to the stop codon of the human ADAMTS-5 protein. Primers were designed with calculated T_(m)>72° C. and RACE was performed with nested primers for each amplification. PCR used the Advantage PCR reagents (Clontech, Palo Alto, Calif.); the polymerase mix contained both Taq polymerase as well as proofreading polymerase to minimize PCR errors and employed “hot-start” PCR for optimal efficiency. RACE used the following “touch-down” cycle conditions; 95° C. for 1 minute followed by 5 cycles of 95° C. for 0.5 minutes, 72° C. for 5 minutes, then 5 cycles of 95° for 0.5 minutes, 70° C. for 5 minutes and 20 cycles of 95° C. for 0.5 minutes, 68° C. for 5 minutes. The PCR products were analyzed by Southern blotting, initially using [α³²P]-dCTP labeled.

[0070] Hybridizing bands were ligated into pGEM-T Easy (Promega, Madison, Wis.) and individual clones were selected by another round of Southern analysis. Automated nucleotide sequencing of both strands of each clone were done at the Molecular Biotechnology Core of the Lerner Research Institute, Cleveland Clinic Foundation and nucleotide sequence data were analyzed using the DNAStar software. By integration of the overlapping sequences thus obtained, a contiguous nucleotide sequence was determined. The nucleotide sequence of the mouse ADAMTS-5 cDNA and the predicted amino acid sequence of the protein encoded by this cDNA are shown in FIG. 1. The nucleotide sequence of the human ADAMTS-5 cDNA and the predicted partial amino acid sequence of the protein encoded by this cDNA are shown in FIG. 2

[0071] The predicted molecular mass (Mr) of the mature ADAMTS-5 protein is 73717.50 daltons. It is expected that the actual Mr of the active ADAMTS-5 protein is different due to post-translational modification, which could potentially increase the Mr. The predicted domain organization of ADAMTS-5 protein relative to the cloned cDNA is shown in FIG. 12. The pro-domain of the fulllength mouse ADAMTS-5 protein has 3 consensus cleavage signals for furin. The most carboxylterminal furin cleavage site in ADAMTS-5 predicts the processing site for generation of the mature protein The catalytic domain of the ADAMTS-5 protein contains eight cysteine residues and a reprolysin-zinc binding signature sequence, i.e., HEIGHLLGLSHD. Five cysteine residues are upstream of the zinc binding sequence, while three residues are downstream, an arrangement that is shared with other ADAMTS members. The zinc binding signature is followed by a “Met-turn”. The catalytic domain is followed by a domain with 35% similarity to snake venom disintegrins The disintegrin domain contains eight cysteine residues. The first TS repeat contains 52 residues and is followed by a conserved cysteine-rich sequence termed the cysteine-rich domain, designated “CRD”, to distinguish it from the cysteine-free spacer domain. The CRD contains ten conserved cysteines and demonstrates high sequence homology with the CRD of other ADAMTS-N proteins. The spacer domain of mouse ADAMTS-5 is 158 amino acids in length and is followed by a second TS module. ADAMTS-5 contains three potential glycosylation sites in the mature protease one of which is just upstream of the start of the spacer domain and the second lies within the spacer domain and the third is near the start of the disintegrin domain. The human ADAMTS-protein and the mouse ADAMTS5 protein have 96% sequence identity. ADAMTS-5 bears 46% sequence identity to ADAMTS-4 (KLAA0688), which is characterized as being involved in catabolism of aggrecan core protein in arthritis and 60% identity to ADAMTS-1 which is involved in inflammation.

EXAMPLE 2

[0072] ADAMTS-6

[0073] The nucleotide sequence of a human cDNA encoding the full-length ADAMTS-6 protein was obtained using IMAGE clone 742630, which encodes EST AA400393, and a human fetal brain cDNA from Clontech. RACE was performed as described above in Example 1. The I.M.A.G.E. clone 742630 contained an ORF flanked by consensus splice sequences, indicating the presence of introns. Two successive rounds of RACE at the 5′ end and a single round of RACE at the 3′ end provided the complete coding sequence of ADAMTS-6. The putative ATG codon is within a Kozak consensus sequence and encodes the first methionine within the ORF.

[0074] The nucleotide sequence of the ADAMTS-6 DNA is shown in FIG. 3 The predicted amino acid sequence, SEQ ID NO: 6, of the ADAMTS-6 protein is also shown in FIG. 3. The predicted Mr of the full-length, unprocessed ADAMTS-6 protein is 97,115 daltons, and the predicted Mr of the mature ADAMTS-6 protein is 68412.10 daltons. The domain organization of the ADAMTS-6 protein is shown in FIG. 12. The pro-domain of the full-length ADAMTS-6 protein has one consensus cleavage signal for furin. The catalytic domain of the ADAMTS-6 contains six cysteine residues and the reprolysin-zinc binding signature sequence, HEIVHNFGMNHD, which is followed by a “Met-turn”. The catalytic domain is followed by a domain with 35% similarity to snake venom disintegrins The disintegrin domain contains eight cysteine residues. The first TS repeat contains 52 residues and is followed by a conserve CRD sequence which contains ten conserved cysteines and demonstrates high sequence homology with the CRD of other ADAMTS proteins. The spacer domain of ADAMTS-6 is 127 amino acids in length and is followed by a second TS module. ADAMTS-6 contains four potential glycosylation sites within the pro-domain and two in the mature protease one of which is in the cysteine rich domainand the other of which is in the spacer domain. ADAMTS-6 bears 46% sequence identity to ADAMTS-1, which is involved in inflammation.

EXAMPLE 3

[0075] ADAMTS-7.

[0076] The nucleotide sequence of a cDNA encoding an ADAMTS-7 protein was obtained using IMAGE clone 272098, which encodes EST N48032, and a human fetal brain cDNA from Clontech. RACE was performed as described above in Example 1. The I.M.A.G.E. clone 272098 encoded a putative pre-pro region and was extended in the 3′-direction by twd successive rounds of RACE. A typical signal peptide sequence lies downstream of the first methionine in the translated ORF. This methiontne cocton lies within a satisfactory Kozak consensus for translation initiation.

[0077] The nucleotide sequence of the ADAMTS-7 cDNA is shown in FIG. 4. The predicted amino acid sequence, SEQ ID NO: 8, of the ADAMTS-7 protein is also shown in FIG. 4. The predicted Mr of the full-length, unprocessed ADAMTS-7 protein is 116,607 daltons, and the predicted Mr of the mature ADAMTS-7 protein is 84005 daltons. The domain organization of the ADAMTS-7 protein is shown in FIG. 12. The pro-domain of the full-length ADAMTS-7 protein has one consensus cleavage signal for furin. The catalytic domain of the ADAMTS-7 protein contains eight cysteine residues and the reprolysin-zinc binding signature sequence, HELGHSFGIQHD, which is followed by a “Met-turn”. The catalytic domain is followed by a domain with 30% similarity to snake venom disintegrins The disintegrin domain contains eight cysteine residues. The first TS repeat contains 52 residues and is followed by a conserved CRD sequence which contains ten conserved cysteines. The spacer domain of ADAMTS-7 is 221 amino acids in length and is followed by a second TS module and a short sequence containing two cysteine residues. ADAMTS-7 contains three potential glycosylation sites within the mature protease; one of which is just upstream of the spacer domain and one of which is within the spacer domain. ADAMTS-7 bears 35% sequence identity to ADAMTS-1, which is characterized as being involved in inflammation and 32% identity to ADAMTS-2 which is a procollagen processing enzyme.

EXAMPLE 4

[0078] ADAMTS-8

[0079] The nucleotide sequence of a cDNA encoding a full-length, mouse ADAMTS-8 protein was obtained using IMAGE clone 1260693, which encodes EST AA855532, and a mouse embryo cDNA from Clonetech. The nucleotide sequence of a cDNA encoding a partial ADAMTS-8 human protein was obtained using IMAGE clone 2119838, which encodes EST AI400905, and a human fetal brain cDNA library from Clontech. RACE was performed as described above in Example 1. The nucleotide sequence of the cDNA encoding the full-length ADAMTS-8 mouse protein and the amino acid sequence of such protein is shown in FIG. 5. The nucleotide sequence of the cDNA encoding the partial ADAMTS-8 human protein and the amino acid sequence of such protein is shown in FIG. 6.

[0080] The predicted Mr of the full-length, unprocessed ADAMTS-8 mouse protein is 1260693 daltons, and the, predicted Mr of the mature ADAMTS-8 protein is 68412.10 daltons. The prodomain of the full-length ADAMTS-8 protein has one consensus cleavage signal for furin. The catalytic domain contains eight cysteine residues and the reprolyslh -zinc binding signature sequence, HELGHVLSMPHD, which is followed by a “Met-turn”. The catalytic domain is followed by a domain with 20-30 a/o similarity to snake venom disintegrins The disintegrin-like domain contains eight cysteine residues. The first TS repeat is followed by a conserved CRD sequence which contains 10 conserved cysteines. The spacer domain of ADAMTS-8 is 146 amino acids in length and is followed by a second TS module. The ADAMTS-8 protein contains 4 potential glycosylation sites within the mature protease: one is in the cyteine-rich domain; one is in the catalytic domain; and two are in the disintegrin-like domain. ADAMTS-8 bears 46% sequence identity to ADAMTS-1 and 42% identity to ADAMTS-4.

EXAMPLE 5

[0081] ADAMTS-9

[0082] The nucleotide sequence of a cDNA encoding a full-length, human ADAMTS-9 protein was obtained using IMEAGE clone 646675, which encodes EST AA205581, and a human fetal brain cDNA from Clonetech. The nucleotide sequence of a cDNA encoding a partial ADAMTS-9 mouse protein was obtained using IMAGE clone 535663, which encodes EST AA106215, and a mouse cDNA library obtained from Clonetech. RACE was performed as described above in Example 1. The nucleotide sequence of the cDNA encoding the full-length ADAMTS-9 human protein and the amino acid sequence of such protein is shown in FIG. 6. The nucleotide sequence of the cDNA encoding the partial ADAMTS-9 mouse protein and the amino acid sequence of such protein is shown in FIG. 7.

[0083] The predicted Mr of the mature human ADAMTS-9 protein is 189777.20 daltons. The prodomain of the predicted ADAMTS-9 protein has 3 consensus cleavage signal for furin. The catalytic domain of the ADAMTS-9 contains eight cysteine residues and the reprolysin -zinc binding signature sequence, HELGHVFNMPHD, which is followed by a “Met-turn”. The catalytic domain is followed by a domain with 25-30% similarity to snake venom disintegrins The disintegrin domain contains eight cysteine residues. The first TS repeat contains is followed by a conserved CRD sequence which contains 10 conserved cysteines. The spacer domain of ADAMTS-9 is 124 amino acids in length and is followed by 14 addistional TS modules and a C-terminal domain. The ADAMTS-9 protein contains 6 potential glycosylation sites within the mature protease: one in the spacer domain, one in TSP1-7, one in TSP1-8, and 3 in the C-terminal domain. The ADAMTS-9 bears 44% sequence identity to ADAMTS-4.

EXAMPLE 6

[0084] ADAMTS-10

[0085] The nucleotide sequence of a cDNA encoding a full-length ADAMTS-10 protein was obtained using IMAGE clone 110403, which encodes EST AA588434, and a human fetal brain cDNA from Clonetech. The nucleotide sequence of a cDNA encoding a partial, mouse ADAMTS-10 protein was obtained using IMAGE clone 1077653, which encodes EST AA822090, and a mouse embryo cDNA library from Clonetech. RACE was performed as described above in Example 1. The nucleotide sequence of the human ADAMTS-10 cDNA and the predicted amino acid sequence, SEQ ID 18, of the human ADAMTS-10 protein encoded by such DNA is shown in FIG. 9: The nucleotide sequence of the cDNA encoding the partial mouse ADAMTS-10 protein and the amino acid sequence of such protein is shown in FIG. 10. The predicted Mr of the mature ADAMTS-10 protein is 95238 daltons. The pro-domain of the full-length ADAMTS-10. protein has no consensus cleavage signal for furin. The catalytic domain of the ADAMTS-10 contains .eight cysteine residues and the reprolysin-zinc binding signature sequence, HEIGHTFGMNHD, which is followed by a “Met-turn”. The catalytic domain is followed by a domain with 30% similarity to snake venom disintegrins. The disintegrin-like domain contains eight cysteine residues. The first TS repeat is followed by a conserved CRD sequence which contains 8 conserved cysteines. The spacer domain of ADAMTS-10 is followed by 4 additional TS modules and a Kunitz domain. The ADAMTS-10 protein contains 2 potential glycosylation sites within the mature protease: one in the catalytic domain, and one in the TS 1-3 domain. ADAMTS-10 bears approximately 40% sequence identity to ADAM-TS 1, which is characterized as being involved in inflammation.

[0086] Comparison of the ADAMTS-N Proteins

[0087] As shown in FIG. 11, the ADAMTS-5, ADAMTS-6, and ADAMTS-7 proteins share a common domain organization. From amino to carboxyl termini, they are as follows:

[0088] 1. A pre-pro region. A typical signal sequence of variable length is followed by a putative proregion of variable length but demonstrating short stretches of sequence identity. Three cysteine residues axe predicted within each novel pro-domain, of which the most C-terminal is an “asymmetric” cysteine lying within a sequence context similar to the cysteine “switch” of the MMPs. All three novel cDNAs predict consensus cleavage signals for furin, three in the case of ADAMTS-5, and one each in the case of ADAMTS-6 and ADAMTS-7. The most carboxyl-terminal furin cleavage site in ADAMTS-5 predicts the processing site for generation of the mature protease. The amino terminus of the mature proteins is predicted to start at the residue immediately following the cleavage sites.

[0089] 2. A catalytic domain. The catalytic domains are very similar to each other and contain eight cysteine residues and a typical reprolysin-type zinc binding signature followed by a “Met-turn”. Five cysteine residues are upstream of the zinc binding sequence, while three residues are downstream, an arrangement that is shared with other ADAMTS members. The methionine of the met-turn is not at a constant distance from the zinc-binding signature, but in all three novel proteases, a constant cysteine residue is present in that interval.

[0090] 3. A disintegrin-like domain. The catalytic domain is followed by a domain of 60-90 residues with 35-45% similarity to snake venom disintegrins, but without the canonical cysteine arrangement seen in the latter. This disintegrin-like domain is of comparable length in ADAMTS-5 and ADAMTS-7, it is considerably shorter in ADAMTS-6.

[0091] 4. A TS module. The first TS repeat is very similar in all three novel proteases and very similar to the first TS repeat of other ADAMTSs. It contains the same number of residues (fifty-two) in all three novel proteins.

[0092] 5. The cysteine-rich domain. This TS domain is followed by a conserved cysteine-rich sequence termed the cysteine-rich domain (CRD).

[0093] 6. The spacer domain. This domain is of variable length, in all ADAMTSs and lacks the sequence landmarks so characteristic of all the other domains. It shows the least homology of all the domains

[0094] 7. A C-terminal TS module. The sequence of the second TS module is more variant between the members of the ADAMTS family than the first TS module, despite the conservation of the number and spacing of cysteine residues.

[0095] Overall, the predicted mature forms of these proteases show 20-30% similarity to each other and to ADAMTS 1-4 although this may be considerably higher or lower for individual domains as described above.

[0096] ADAM-TS9 and ADAM-TS 10 contain all the domains present in ADAMTS-5 through ADAMTS-8. In addition, ADAMTS-9 and ADAMTS-10 contain the following domains:

[0097] A. ADAMTS-9: After the c-terminal TS 1 domain which is present in ADAMTS5-8, ADAMTS-9 contains 13 additional and homologous TS 1 domains, thus, ADAMTS-9 contains a total of 15 TS 1 domains, of which 14 are adjacent to each other in the c-terminal half of the molecule. The 15th TS 1 domain from the N-terminus is followed by a unique c-terminal domain which does not possess recognizable domain structure and contains 196 residues including 9 cysteine residues.

[0098] B. ADAMTS-10: After the c-terminal TS 1 domain which is present in ADAMTS8, ADAMTS-10 contains 3 additional and homologous TS 1 domains, thus, that ADAMTS-10 contains a total of 5 TS 1 domains, of which 4 are adjacent to each other in the c-terminal half of the molecule. The 5th TS 1 domain from the N-terminus is followed by an additional 47 amino acid residues including six (6) cysteine residues. These 47 residues have sequence similarity of 30%-40% to the c terminus of pro-hormone convertase 5 and 6, and to the Kunitz family of inhibitors.

[0099] Northern Analysis

[0100] Mouse embryo northern blots and multiple tissue northern blots from human and mouse tissues (Clontech, Palo Alto, Calif.). were hybridized to the [a32P]-dCTP labeled inserts of I.M.A.G.E. clones as per the manufacturer's recommendations followed by autoradiographic exposure for 3-7 days.

[0101] In situ hybridization used cryosections of mouse embryos of gestational age 8.5 days and 10.5 days. Embryos were collected with the inclusion of the surrounding uterus and fixed overnight in 4% paraformaldehyde. Sense and anti-sense probes continuously labeled with digoxigenin-UTP (Boehringer-Mannheim, Indianapolis, Ind.) were transcribed with T7 and T3 RNA polymerases, respectively, using as template a 630 by EcoRI-Sacl fragment from the Adamis-5 clone 569515 (FIG. 14) cloned into pBluescript SK+(Stratagene, La Jolla, Calif.). In situ hybridization was done essentially as previously described in Apte, et al. (1997) J. Biol. Chem. 272:2551-25517, which is specifically incorporated herein by reference, except that sections were predigested with proteinase K (Boehringer-Mannheim, Indianapolis, Ind.) at a lower concentration (1-5 μg/ml) than reported in Apte, et al. Bound, digoxigenin-labeled probe was detected using an alkaline phosphatase tagged anti-digoxigenin antibody (Boehringer-Mannheim, Indianapolis, Ind.) and nuclei were counterstained with methyl green.

[0102] Specific hybridization of the antisense Adamts-5 probe to sections of 8.5 day-old mouse embryos was obtained, whereas only low background staining was noted with the control sense probe Staining was uniform throughout the 8.5 day old embryos. In addition, there was labeling of mRNA in trophoblastic cells lining the uterine cavity as well as in the developing placenta (FIG. 14). The decidual reaction within the uterus also showed upregulation of Adamts-5 mRNA relative to the negative controls. In sections from 10.5 day old embryos, labeling was widespread but less intense compared to the 8.5 day-old embryo. Labeled cells were seen in mesenchyme and somites as well as in the neural tube and developing hindgut. Northern analysis also indicated that mRNA encoding ADAMTS-5 was present in human placenta but was barely detectable in adult lung, heart, brain, liver, skeletal muscle, kidney and pancreas.

[0103] Northern analysis showed undetectable expression of Adamts-6 during mouse embryo development. Northern analysis indicated that mRNA encoding ADAMTS-6 was present in human placenta but was barely detectable in adult lung, heart, brain, liver, skeletal muscle, kidney and pancreas. Adamts-7 was expressed at low levels throughout mouse development. In adult human tissues examined with human cDNA probes, ADAMTS-7 mRNA was found in all tissues examined, i.e. in lung, heart, brain, liver, skeletal muscle, kidney, pancreas and placenta. The sizes of the mRNA species recognized by the probes varied. ADAMTS-5 mRNA was approximately 10 kbp in size in human tissue. The most prominent Adamts-5 species was estimated at 7.5 kbp together with additional bands at 10 kbp and 4.5 kbp. The lone mRNA species detected by ADAMTS-6 probe was approximately 8.5 kbp, whereas the most common mRNA species detected by ADAMTS-7 probe 5 was 5 kbp in size with an additional species seen at 7 kbp in skeletal muscle.

[0104] In mouse, ADAMTS-8 is expressed during fetal development (days 7, 11, 15, 17) and in adult mouse lung and heart with an mRNA size of approximately 3.8 kbp. In adult human tissue, ADAMTS-8 is expressed in lung and brain but not in heart, muscle, kidney, colon or thymus. The mRNA size is 3:8 kbp.

[0105] ADAMTS-9 is expressed in lung, ovary placenta, heart, brain, muscle, kidney and pancreas with a mRNA size of 8 kb. In addition, kidney and ovary contain additional transcripts of size 3 kb and 4.4 kb respectively. These additional transcripts may represent alternatively spliced or short forms of ADAMTS9.

[0106] ADAMTS-10 is expressed in thymus, prostate, testis, ovary, small intestine, colon, peripheral blood leukocytes, heart, brain, placenta, lung, liver, muscle, kidney and pancreas, as well as in many cell lines such as A549, HeLa and K562. There are two transcripts of 5 kb and 8kb present in all tissues.

EXAMPLE 7

[0107] ADAMTS-R1

[0108] The nucleotide sequence of a cDNA encoding a full-length ADAMTS-R1 protein was obtained using IMAGE clone 752797 which encodes EST AA, and a human fetal brain cDNA from Clontech. RACE was performed as described above in Example 1. The nucleotide sequence, SEQ ID NO: 21, of the ADAMTS-R1 cDNA and the predicted amino acid sequence, SEQ ID NO: 22, of the ADAMTS-R1 protein encoded by such DNA is shown in FIG. 11.

[0109] The predicted Mr of the full-length, unprocessed ADAMTS-R1 protein is 58358.20 daltons. The domain organization of the ADAMTS-10 protein is shown in FIG. 15. In contrast to the ADAMTS-N proteins of examples 1-6, ADAMTS-R1 protein does not have a pro-metalloprotease or disintegrin-like domain or a consensus cleavage signal for furin. ADAMTS-R1 has a signal(pre) peptide which is followed by a first TS module and a conserved CRD sequence which contains 10 conserved cysteines. The spacer domain of ADAMTS-R1 is 115 amino acids in length and is followed by 3 additional TS modules and a short sequence of 33 amino acids. The ADAMTS-R1 protein contains one potential glycosylation sites which is in the spacer domain. ADAMTS-R1 bears 30-40% sequence identity to ADAMTS 1 and ADAMTS4 in the related domains. ADAMTS-R1 mRNA is present in human heart, brain, kidney, muscle, lung, placenta, testis, ovary, colon, intestine, and prostate. There are three transcripts of 2.5 kb, 4.7 kb and 6.5 kbp present in all such tissues. In mouse, expression is seen in skeletal muscle, and the transcript size is 6.5 kb.

[0110] Although certain embodiments of this invention have been shown and described, various adaptations and modifications can be made without departing from the scope of the invention as defined in the appended claims.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 31 <210> SEQ ID NO 1 <211> LENGTH: 3002 <212> TYPE: DNA <213> ORGANISM: mus musculus ADAMTS-5 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (18)..(2810) <400> SEQUENCE: 1 ccggcgggca gcgcact atg cgg ctc gag tgg gcg tcc ttg ttg ctg cta 50 Met Arg Leu Glu Trp Ala Ser Leu Leu Leu Leu 1 5 10 ctg ctg ctg ctg agc gcg tcc tgc ctg tcc ctg gcc gct gac agc ccc 98 Leu Leu Leu Leu Ser Ala Ser Cys Leu Ser Leu Ala Ala Asp Ser Pro 15 20 25 gcc gcg gca cct gcc cag gat aaa acc agg cag cct cag gct gca gca 146 Ala Ala Ala Pro Ala Gln Asp Lys Thr Arg Gln Pro Gln Ala Ala Ala 30 35 40 gcg gcc gcc gag ccg gac cag ccg cag ggg gag gaa aca cgg gag cga 194 Ala Ala Ala Glu Pro Asp Gln Pro Gln Gly Glu Glu Thr Arg Glu Arg 45 50 55 ggc cat tta caa ccc ttg gcc ggg cag cgc agg agc ggc ggg ctg gtc 242 Gly His Leu Gln Pro Leu Ala Gly Gln Arg Arg Ser Gly Gly Leu Val 60 65 70 75 cat aat ata gac caa ctc tac tct ggc ggt ggc aaa gtg ggc tac ctt 290 His Asn Ile Asp Gln Leu Tyr Ser Gly Gly Gly Lys Val Gly Tyr Leu 80 85 90 gtc tac gcg ggc ggc cgg agg ttc ctg ctg gac ctg gag aga gat gac 338 Val Tyr Ala Gly Gly Arg Arg Phe Leu Leu Asp Leu Glu Arg Asp Asp 95 100 105 aca gtg ggt gct gct ggt agc atc gtt act gca gga gga ggg ctg agc 386 Thr Val Gly Ala Ala Gly Ser Ile Val Thr Ala Gly Gly Gly Leu Ser 110 115 120 gca tcc tct ggc cac cgg ggt cac tgt ttc tac aga ggc acc gtg gac 434 Ala Ser Ser Gly His Arg Gly His Cys Phe Tyr Arg Gly Thr Val Asp 125 130 135 ggc agc cct cga tcc cta gct gtc ttt gac ctc tgc ggg ggt ctc gat 482 Gly Ser Pro Arg Ser Leu Ala Val Phe Asp Leu Cys Gly Gly Leu Asp 140 145 150 155 ggc ttc ttt gca gtc aag cat gcg cgc tac act cta aag cca ctc ctg 530 Gly Phe Phe Ala Val Lys His Ala Arg Tyr Thr Leu Lys Pro Leu Leu 160 165 170 cgt ggg tcc tgg gca gag tat gaa cga att tat ggg gat gga tct tcc 578 Arg Gly Ser Trp Ala Glu Tyr Glu Arg Ile Tyr Gly Asp Gly Ser Ser 175 180 185 cgc atc ctg cat gtc tac aac cgc gag ggc ttt agc ttc gag gcc ctg 626 Arg Ile Leu His Val Tyr Asn Arg Glu Gly Phe Ser Phe Glu Ala Leu 190 195 200 ccg cca cgc gcc agt tgc gag act cct gca tcc cca tct ggg ccc caa 674 Pro Pro Arg Ala Ser Cys Glu Thr Pro Ala Ser Pro Ser Gly Pro Gln 205 210 215 gag agc ccc tcg gtg cac agt aga tct agg aga cgc tca gcg ctg gcc 722 Glu Ser Pro Ser Val His Ser Arg Ser Arg Arg Arg Ser Ala Leu Ala 220 225 230 235 ccg cag ctg ctg gac cac tca gct ttc tcg cca tct ggg aac gcg gga 770 Pro Gln Leu Leu Asp His Ser Ala Phe Ser Pro Ser Gly Asn Ala Gly 240 245 250 cct cag act tgg tgg agg cgt agg cgc cgt tcc atc tcc agg gcc cgc 818 Pro Gln Thr Trp Trp Arg Arg Arg Arg Arg Ser Ile Ser Arg Ala Arg 255 260 265 cag gtg gag ctc ctc ttg gtg gct gac tcg tcc atg gcc agg atg tat 866 Gln Val Glu Leu Leu Leu Val Ala Asp Ser Ser Met Ala Arg Met Tyr 270 275 280 ggg cgg ggc ctg cag cat tac ctg ctg acc atg gcc tcc atc gcc aac 914 Gly Arg Gly Leu Gln His Tyr Leu Leu Thr Met Ala Ser Ile Ala Asn 285 290 295 agg ctg tac agt cat gca agc att gag aac cac atc cgc ctg gcg gtg 962 Arg Leu Tyr Ser His Ala Ser Ile Glu Asn His Ile Arg Leu Ala Val 300 305 310 315 gtg aag gtg gtg gtg ctg acg gac aag gac acg agt ctg gag gtg agc 1010 Val Lys Val Val Val Leu Thr Asp Lys Asp Thr Ser Leu Glu Val Ser 320 325 330 aag aat gcg gcc acg acc ctc aag aac ttt tgc aaa tgg cag cac caa 1058 Lys Asn Ala Ala Thr Thr Leu Lys Asn Phe Cys Lys Trp Gln His Gln 335 340 345 cat aac cag cta ggg gat gat cac gaa gag cac tac gat gca gcc atc 1106 His Asn Gln Leu Gly Asp Asp His Glu Glu His Tyr Asp Ala Ala Ile 350 355 360 ctg ttc acc cga gag gat tta tgt ggg cat cat tca tgt gac acc ctg 1154 Leu Phe Thr Arg Glu Asp Leu Cys Gly His His Ser Cys Asp Thr Leu 365 370 375 gga atg gca gac gtt ggg acc ata tgt tct ccg gag cgc agc tgt gca 1202 Gly Met Ala Asp Val Gly Thr Ile Cys Ser Pro Glu Arg Ser Cys Ala 380 385 390 395 gtg att gaa gat gat ggc ctc cat gca gcc ttc act gtg gct cat gaa 1250 Val Ile Glu Asp Asp Gly Leu His Ala Ala Phe Thr Val Ala His Glu 400 405 410 att ggg cat cta ctt ggc ctt tct cat gac gat tcc aaa ttc tgt gaa 1298 Ile Gly His Leu Leu Gly Leu Ser His Asp Asp Ser Lys Phe Cys Glu 415 420 425 gag aac ttc ggt act aca gaa gac aag cgt tta atg tct tca atc ctt 1346 Glu Asn Phe Gly Thr Thr Glu Asp Lys Arg Leu Met Ser Ser Ile Leu 430 435 440 acc agc atc gat gca tcc aag ccc tgg tcc aaa tgc acg tca gcc acc 1394 Thr Ser Ile Asp Ala Ser Lys Pro Trp Ser Lys Cys Thr Ser Ala Thr 445 450 455 atc aca gaa ttc ctg gat gat ggt cat ggt aat tgt ttg cta gac cta 1442 Ile Thr Glu Phe Leu Asp Asp Gly His Gly Asn Cys Leu Leu Asp Leu 460 465 470 475 cca cgg aag cag att ttg ggt ccc gag gaa ctc cca gga cag acc tac 1490 Pro Arg Lys Gln Ile Leu Gly Pro Glu Glu Leu Pro Gly Gln Thr Tyr 480 485 490 gat gcc acc cag cag tgc aac ttg aca ttt ggg cct gag tac tcg gtg 1538 Asp Ala Thr Gln Gln Cys Asn Leu Thr Phe Gly Pro Glu Tyr Ser Val 495 500 505 tgc cct ggc atg gat gtc tgt gcg cgg ctg tgg tgt gct gtg gtg cgc 1586 Cys Pro Gly Met Asp Val Cys Ala Arg Leu Trp Cys Ala Val Val Arg 510 515 520 caa ggc caa atg gtg tgt ctg acc aag aag ctg ccg gct gtg gag ggc 1634 Gln Gly Gln Met Val Cys Leu Thr Lys Lys Leu Pro Ala Val Glu Gly 525 530 535 act ccc tgt ggg aag gga aga gtc tgc ctt caa ggc aaa tgt gtg gac 1682 Thr Pro Cys Gly Lys Gly Arg Val Cys Leu Gln Gly Lys Cys Val Asp 540 545 550 555 aaa act aag aaa aaa tat tac tcg aca tca agc cat gga aat tgg ggg 1730 Lys Thr Lys Lys Lys Tyr Tyr Ser Thr Ser Ser His Gly Asn Trp Gly 560 565 570 tcc tgg ggc ccc tgg ggt cag tgt tct cgc tca tgc ggg gga gga gtg 1778 Ser Trp Gly Pro Trp Gly Gln Cys Ser Arg Ser Cys Gly Gly Gly Val 575 580 585 cag ttt gcc tac cgc cat tgt aat aac cct gca cct cga aac agt ggc 1826 Gln Phe Ala Tyr Arg His Cys Asn Asn Pro Ala Pro Arg Asn Ser Gly 590 595 600 cgc tac tgc aca ggg aag agg gcc ata tac cgt tcc tgc agt gtt aca 1874 Arg Tyr Cys Thr Gly Lys Arg Ala Ile Tyr Arg Ser Cys Ser Val Thr 605 610 615 ccc tgc cca ccc aat ggt aaa tct ttt cgc cat gag cag tgt gaa gcc 1922 Pro Cys Pro Pro Asn Gly Lys Ser Phe Arg His Glu Gln Cys Glu Ala 620 625 630 635 aaa aat ggc tat cag tct gat gca aaa gga gtc aaa aca ttt gta gaa 1970 Lys Asn Gly Tyr Gln Ser Asp Ala Lys Gly Val Lys Thr Phe Val Glu 640 645 650 tgg gtt ccc aaa tat gca ggt gtc ctg ccg gca gat gtg tgc aag ctt 2018 Trp Val Pro Lys Tyr Ala Gly Val Leu Pro Ala Asp Val Cys Lys Leu 655 660 665 acc tgc aga gct aag ggc aca ggc tac tat gtg gtc ttt tct cca aag 2066 Thr Cys Arg Ala Lys Gly Thr Gly Tyr Tyr Val Val Phe Ser Pro Lys 670 675 680 gtt acg gat ggg act gaa tgc agg ccg tac agc aac tct gtg tgt gtc 2114 Val Thr Asp Gly Thr Glu Cys Arg Pro Tyr Ser Asn Ser Val Cys Val 685 690 695 cga gga cgg tgt gtg aga act gga tgt gac ggc att att ggc tca aag 2162 Arg Gly Arg Cys Val Arg Thr Gly Cys Asp Gly Ile Ile Gly Ser Lys 700 705 710 715 cta caa tat gac aag tgt gga gtg tgc gga ggg gat aac tcc agt tgt 2210 Leu Gln Tyr Asp Lys Cys Gly Val Cys Gly Gly Asp Asn Ser Ser Cys 720 725 730 aca aag att atc gga acc ttc aat aaa aaa agc aag ggt tat act gac 2258 Thr Lys Ile Ile Gly Thr Phe Asn Lys Lys Ser Lys Gly Tyr Thr Asp 735 740 745 gtt gtg agg atc cct gaa gga gca acc cac ata aaa gtc cga cag ttc 2306 Val Val Arg Ile Pro Glu Gly Ala Thr His Ile Lys Val Arg Gln Phe 750 755 760 aaa gcc aaa gac cag act aga ttc cct gcc tac tta gcc ctg aag aag 2354 Lys Ala Lys Asp Gln Thr Arg Phe Pro Ala Tyr Leu Ala Leu Lys Lys 765 770 775 aaa act ggc gag tac ctt atc aat ggc aag tac atg att tcc act tca 2402 Lys Thr Gly Glu Tyr Leu Ile Asn Gly Lys Tyr Met Ile Ser Thr Ser 780 785 790 795 gag acc atc atc gac atc aat ggt acc gtc atg aac tac agt gga tgg 2450 Glu Thr Ile Ile Asp Ile Asn Gly Thr Val Met Asn Tyr Ser Gly Trp 800 805 810 agc cac aga gat gat ttt tta cat ggg atg ggc tat tca gcc aca aaa 2498 Ser His Arg Asp Asp Phe Leu His Gly Met Gly Tyr Ser Ala Thr Lys 815 820 825 gaa atc ctg atc gtg cag atc ctt gcc aca gac cca act aaa gcg cta 2546 Glu Ile Leu Ile Val Gln Ile Leu Ala Thr Asp Pro Thr Lys Ala Leu 830 835 840 ggc gtc cgt tac agc ttt ttt gtt ccc aag aag acc act caa aaa gta 2594 Gly Val Arg Tyr Ser Phe Phe Val Pro Lys Lys Thr Thr Gln Lys Val 845 850 855 aac tct gtc atc agc cat ggc agc aac aag gtg gga cca cac tct aca 2642 Asn Ser Val Ile Ser His Gly Ser Asn Lys Val Gly Pro His Ser Thr 860 865 870 875 cag ctg cag tgg gtg aca ggt cca tgg ctg gcc tgc tcc agg acc tgt 2690 Gln Leu Gln Trp Val Thr Gly Pro Trp Leu Ala Cys Ser Arg Thr Cys 880 885 890 gac aca ggc tgg cac act agg acc gtg cag tgc cag gat gga aac agg 2738 Asp Thr Gly Trp His Thr Arg Thr Val Gln Cys Gln Asp Gly Asn Arg 895 900 905 aaa tta gct aaa gga tgc ctt ctc tct cag agg cct tct gca ttt aag 2786 Lys Leu Ala Lys Gly Cys Leu Leu Ser Gln Arg Pro Ser Ala Phe Lys 910 915 920 caa tgt ctg ctg aag aaa tgt tag cctgtggttt actctaatgc acaaaaaaac 2840 Gln Cys Leu Leu Lys Lys Cys 925 930 aacaggagga tcatcgcaga tacagctgtg gtgaagacaa ggcctaccca aagcacagaa 2900 agtcatgcct tcatgtcatt gtcaccacga gtcgaattat gggcagaatc tgctctctgc 2960 gaccaaaagg tttactctac ttggtgaatg atggtaccgt ga 3002 <210> SEQ ID NO 2 <211> LENGTH: 930 <212> TYPE: PRT <213> ORGANISM: mus musculus ADAMTS-5 <400> SEQUENCE: 2 Met Arg Leu Glu Trp Ala Ser Leu Leu Leu Leu Leu Leu Leu Leu Ser 1 5 10 15 Ala Ser Cys Leu Ser Leu Ala Ala Asp Ser Pro Ala Ala Ala Pro Ala 20 25 30 Gln Asp Lys Thr Arg Gln Pro Gln Ala Ala Ala Ala Ala Ala Glu Pro 35 40 45 Asp Gln Pro Gln Gly Glu Glu Thr Arg Glu Arg Gly His Leu Gln Pro 50 55 60 Leu Ala Gly Gln Arg Arg Ser Gly Gly Leu Val His Asn Ile Asp Gln 65 70 75 80 Leu Tyr Ser Gly Gly Gly Lys Val Gly Tyr Leu Val Tyr Ala Gly Gly 85 90 95 Arg Arg Phe Leu Leu Asp Leu Glu Arg Asp Asp Thr Val Gly Ala Ala 100 105 110 Gly Ser Ile Val Thr Ala Gly Gly Gly Leu Ser Ala Ser Ser Gly His 115 120 125 Arg Gly His Cys Phe Tyr Arg Gly Thr Val Asp Gly Ser Pro Arg Ser 130 135 140 Leu Ala Val Phe Asp Leu Cys Gly Gly Leu Asp Gly Phe Phe Ala Val 145 150 155 160 Lys His Ala Arg Tyr Thr Leu Lys Pro Leu Leu Arg Gly Ser Trp Ala 165 170 175 Glu Tyr Glu Arg Ile Tyr Gly Asp Gly Ser Ser Arg Ile Leu His Val 180 185 190 Tyr Asn Arg Glu Gly Phe Ser Phe Glu Ala Leu Pro Pro Arg Ala Ser 195 200 205 Cys Glu Thr Pro Ala Ser Pro Ser Gly Pro Gln Glu Ser Pro Ser Val 210 215 220 His Ser Arg Ser Arg Arg Arg Ser Ala Leu Ala Pro Gln Leu Leu Asp 225 230 235 240 His Ser Ala Phe Ser Pro Ser Gly Asn Ala Gly Pro Gln Thr Trp Trp 245 250 255 Arg Arg Arg Arg Arg Ser Ile Ser Arg Ala Arg Gln Val Glu Leu Leu 260 265 270 Leu Val Ala Asp Ser Ser Met Ala Arg Met Tyr Gly Arg Gly Leu Gln 275 280 285 His Tyr Leu Leu Thr Met Ala Ser Ile Ala Asn Arg Leu Tyr Ser His 290 295 300 Ala Ser Ile Glu Asn His Ile Arg Leu Ala Val Val Lys Val Val Val 305 310 315 320 Leu Thr Asp Lys Asp Thr Ser Leu Glu Val Ser Lys Asn Ala Ala Thr 325 330 335 Thr Leu Lys Asn Phe Cys Lys Trp Gln His Gln His Asn Gln Leu Gly 340 345 350 Asp Asp His Glu Glu His Tyr Asp Ala Ala Ile Leu Phe Thr Arg Glu 355 360 365 Asp Leu Cys Gly His His Ser Cys Asp Thr Leu Gly Met Ala Asp Val 370 375 380 Gly Thr Ile Cys Ser Pro Glu Arg Ser Cys Ala Val Ile Glu Asp Asp 385 390 395 400 Gly Leu His Ala Ala Phe Thr Val Ala His Glu Ile Gly His Leu Leu 405 410 415 Gly Leu Ser His Asp Asp Ser Lys Phe Cys Glu Glu Asn Phe Gly Thr 420 425 430 Thr Glu Asp Lys Arg Leu Met Ser Ser Ile Leu Thr Ser Ile Asp Ala 435 440 445 Ser Lys Pro Trp Ser Lys Cys Thr Ser Ala Thr Ile Thr Glu Phe Leu 450 455 460 Asp Asp Gly His Gly Asn Cys Leu Leu Asp Leu Pro Arg Lys Gln Ile 465 470 475 480 Leu Gly Pro Glu Glu Leu Pro Gly Gln Thr Tyr Asp Ala Thr Gln Gln 485 490 495 Cys Asn Leu Thr Phe Gly Pro Glu Tyr Ser Val Cys Pro Gly Met Asp 500 505 510 Val Cys Ala Arg Leu Trp Cys Ala Val Val Arg Gln Gly Gln Met Val 515 520 525 Cys Leu Thr Lys Lys Leu Pro Ala Val Glu Gly Thr Pro Cys Gly Lys 530 535 540 Gly Arg Val Cys Leu Gln Gly Lys Cys Val Asp Lys Thr Lys Lys Lys 545 550 555 560 Tyr Tyr Ser Thr Ser Ser His Gly Asn Trp Gly Ser Trp Gly Pro Trp 565 570 575 Gly Gln Cys Ser Arg Ser Cys Gly Gly Gly Val Gln Phe Ala Tyr Arg 580 585 590 His Cys Asn Asn Pro Ala Pro Arg Asn Ser Gly Arg Tyr Cys Thr Gly 595 600 605 Lys Arg Ala Ile Tyr Arg Ser Cys Ser Val Thr Pro Cys Pro Pro Asn 610 615 620 Gly Lys Ser Phe Arg His Glu Gln Cys Glu Ala Lys Asn Gly Tyr Gln 625 630 635 640 Ser Asp Ala Lys Gly Val Lys Thr Phe Val Glu Trp Val Pro Lys Tyr 645 650 655 Ala Gly Val Leu Pro Ala Asp Val Cys Lys Leu Thr Cys Arg Ala Lys 660 665 670 Gly Thr Gly Tyr Tyr Val Val Phe Ser Pro Lys Val Thr Asp Gly Thr 675 680 685 Glu Cys Arg Pro Tyr Ser Asn Ser Val Cys Val Arg Gly Arg Cys Val 690 695 700 Arg Thr Gly Cys Asp Gly Ile Ile Gly Ser Lys Leu Gln Tyr Asp Lys 705 710 715 720 Cys Gly Val Cys Gly Gly Asp Asn Ser Ser Cys Thr Lys Ile Ile Gly 725 730 735 Thr Phe Asn Lys Lys Ser Lys Gly Tyr Thr Asp Val Val Arg Ile Pro 740 745 750 Glu Gly Ala Thr His Ile Lys Val Arg Gln Phe Lys Ala Lys Asp Gln 755 760 765 Thr Arg Phe Pro Ala Tyr Leu Ala Leu Lys Lys Lys Thr Gly Glu Tyr 770 775 780 Leu Ile Asn Gly Lys Tyr Met Ile Ser Thr Ser Glu Thr Ile Ile Asp 785 790 795 800 Ile Asn Gly Thr Val Met Asn Tyr Ser Gly Trp Ser His Arg Asp Asp 805 810 815 Phe Leu His Gly Met Gly Tyr Ser Ala Thr Lys Glu Ile Leu Ile Val 820 825 830 Gln Ile Leu Ala Thr Asp Pro Thr Lys Ala Leu Gly Val Arg Tyr Ser 835 840 845 Phe Phe Val Pro Lys Lys Thr Thr Gln Lys Val Asn Ser Val Ile Ser 850 855 860 His Gly Ser Asn Lys Val Gly Pro His Ser Thr Gln Leu Gln Trp Val 865 870 875 880 Thr Gly Pro Trp Leu Ala Cys Ser Arg Thr Cys Asp Thr Gly Trp His 885 890 895 Thr Arg Thr Val Gln Cys Gln Asp Gly Asn Arg Lys Leu Ala Lys Gly 900 905 910 Cys Leu Leu Ser Gln Arg Pro Ser Ala Phe Lys Gln Cys Leu Leu Lys 915 920 925 Lys Cys 930 <210> SEQ ID NO 3 <211> LENGTH: 1520 <212> TYPE: DNA <213> ORGANISM: homo sapiens ADAMTS-5 <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (296) <223> OTHER INFORMATION: n=T <221> NAME/KEY: misc_feature <222> LOCATION: (1443) <223> OTHER INFORMATION: n=A <221> NAME/KEY: misc_feature <222> LOCATION: (1457) <223> OTHER INFORMATION: n=G <221> NAME/KEY: misc_feature <222> LOCATION: (1458) <223> OTHER INFORMATION: n =T <400> SEQUENCE: 3 ggacatttac ttggcctctc ccatgacgat tccaaattct gtgaagagac ctttggttcc 60 acagaagata agcgcttaat gtcttccatc cttaccagca ttgatgcatc taagccctgg 120 tccaaatgca cttcagccac catcacagaa ttcctggatg atggccatgg taactgtttg 180 ctggacctac cacgaaagca gatcctgggc cccgaagaac tcccaggaca gacctacgat 240 gccacccagc agtgcaacct gacattcggg cctgagtact ccgtgtgtcc cggcanggat 300 gtctgtgctc gcctgtggtg tgctgtggta cgccagggcc agatggtctg tctgaccaag 360 gagtgcagtt tgcctatcgt cactgtaata accctgctcc cagaaacaac ggacgctact 420 gcacagggaa gagggccatc taccactcct gcagtctcat gccctgccca cccaatggta 480 aatcatttcg tcatgaacag tgtgaggcca aaaatggcta tcagtctgat gcaaaaggag 540 tcaaaacttt tgtggaatgg gttcccaaat atgcaggtgt cctgccagcg gatgtgtgca 600 agctgacctg cagagccaag ggcactggct actatgtggt attttctcca aaggtgaccg 660 atggcactga atgtaggccg tacagtaatt ccgtctgcgt ccgggggaag tgtgtgagaa 720 ctggctgtga cggcatcatt ggctcaaagc tgcagtatga caagtgcgga gtatgtggag 780 gagacaactc cagctgtaca aagattgttg gaacctttaa taagaaaagt aagggttaca 840 ctgacgtggt gaggattcct gaaggggcaa cccacataaa agttcgacag ttcaaagcca 900 aagaccagac tagattcact gcctatttag ccctgaaaaa gaaaaacggt gagtacctta 960 tcaatggaaa gtacatgatc tccacttcag agactatcat tgacatcaat ggaacagtca 1020 tgaactatag cggttggagc cacagggatg acttcctgca tggcatgggc tactctgcca 1080 cgaaggaaat tctaatagtg cagattcttg caacagaccc cactaaacca ttagatgtcc 1140 gttatagctt ttttgttccc aagaagtcca ctccaaaagt aaactctgtc actagtcatg 1200 gcagcaataa agtgggatca cacacttcgc agccgcagtg ggtcacgggc ccatggctcg 1260 cctgctctag gacctgtgac acaggttggc acaccagaac ggtgcagtgc caggatggaa 1320 accggaagtt agcaaaagga tgtcctctct cccaaaggcc ttctgcgttt aagcaatgct 1380 tgttgaagaa atgttagcct gtgggttatg atcttattgc acaaaagata ctggaggatt 1440 cancacccgt gcaatcnngg tgaacaggaa ggctacctta acgcacagaa agtcatgctt 1500 taatgacatt gtcaaccagg 1520 <210> SEQ ID NO 4 <211> LENGTH: 2848 <212> TYPE: DNA <213> ORGANISM: Homo sapiens ADAMTS-6 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (22)..(2601) <221> NAME/KEY: misc_feature <222> LOCATION: (1369) <223> OTHER INFORMATION: n = C <221> NAME/KEY: misc_feature <222> LOCATION: (1620) <223> OTHER INFORMATION: n=C <400> SEQUENCE: 4 aatcatccag ttttctaaat t atg gaa att ttg tgg aag acg ttg acc tgg 51 Met Glu Ile Leu Trp Lys Thr Leu Thr Trp 1 5 10 att ttg agc ctc atc atg gct tca tcg gaa ttt cat agt gac cac agg 99 Ile Leu Ser Leu Ile Met Ala Ser Ser Glu Phe His Ser Asp His Arg 15 20 25 ctt tca tac agt tct caa gag gaa ttc ctg act tat ctt gaa cac tac 147 Leu Ser Tyr Ser Ser Gln Glu Glu Phe Leu Thr Tyr Leu Glu His Tyr 30 35 40 cag cta act att cca ata agg gtt gat caa aat gga gca ttt ctc agc 195 Gln Leu Thr Ile Pro Ile Arg Val Asp Gln Asn Gly Ala Phe Leu Ser 45 50 55 ttt act gtg aaa aat gat aaa cac tca agg aga aga cgg agt atg gac 243 Phe Thr Val Lys Asn Asp Lys His Ser Arg Arg Arg Arg Ser Met Asp 60 65 70 cct att gat cca cag cag gca gta tct aag tta ttt ttt aaa ctt tca 291 Pro Ile Asp Pro Gln Gln Ala Val Ser Lys Leu Phe Phe Lys Leu Ser 75 80 85 90 gcc tat ggc aag cac ttt cat cta aac ttg act ctc aac aca gat ttt 339 Ala Tyr Gly Lys His Phe His Leu Asn Leu Thr Leu Asn Thr Asp Phe 95 100 105 gtg tcc aaa cat ttt aca gta gaa tat tgg ggg aaa gat gga ccc cag 387 Val Ser Lys His Phe Thr Val Glu Tyr Trp Gly Lys Asp Gly Pro Gln 110 115 120 tgg aaa cat gat ttt tta gac aac tgt cat tac aca gga tat ttg caa 435 Trp Lys His Asp Phe Leu Asp Asn Cys His Tyr Thr Gly Tyr Leu Gln 125 130 135 gat caa cgt agt aca act aaa gtg gct tta agc aac tgt gtt ggg ttg 483 Asp Gln Arg Ser Thr Thr Lys Val Ala Leu Ser Asn Cys Val Gly Leu 140 145 150 cat ggt gtt att gct aca gaa gat gaa gag tat ttt atc gaa cct tta 531 His Gly Val Ile Ala Thr Glu Asp Glu Glu Tyr Phe Ile Glu Pro Leu 155 160 165 170 aag aat acc aca gag gat tcc aag cat ttt agt tat gaa aat ggc cac 579 Lys Asn Thr Thr Glu Asp Ser Lys His Phe Ser Tyr Glu Asn Gly His 175 180 185 cct cat gtt att tac aaa aag tct gcc ctt caa caa cga cat ctg tat 627 Pro His Val Ile Tyr Lys Lys Ser Ala Leu Gln Gln Arg His Leu Tyr 190 195 200 gat cac tct cat tgt ggg gtt tcg gat ttc aca aga agt ggc aaa cct 675 Asp His Ser His Cys Gly Val Ser Asp Phe Thr Arg Ser Gly Lys Pro 205 210 215 tgg tgg ctg aat gac act cca ctg ttt ctt att cac tac caa att aac 723 Trp Trp Leu Asn Asp Thr Pro Leu Phe Leu Ile His Tyr Gln Ile Asn 220 225 230 aac aca cat atc cac cac aga cag aag aga tca gtg agc att gaa cgg 771 Asn Thr His Ile His His Arg Gln Lys Arg Ser Val Ser Ile Glu Arg 235 240 245 250 ttt gtg gag aca ttg gta gtg gca gac aaa atg atg gtg ggc tac cat 819 Phe Val Glu Thr Leu Val Val Ala Asp Lys Met Met Val Gly Tyr His 255 260 265 ggc cgc aaa gac att gaa cat tac att ttg agt gtg atg aat att gtt 867 Gly Arg Lys Asp Ile Glu His Tyr Ile Leu Ser Val Met Asn Ile Val 270 275 280 gcc aaa ctt tac cgt gat tcc agc cta gga aac gtt gtg aat att ata 915 Ala Lys Leu Tyr Arg Asp Ser Ser Leu Gly Asn Val Val Asn Ile Ile 285 290 295 gtg gcc cgc tta att gtt ctc aca gaa gat cag cca aac ttg gag ata 963 Val Ala Arg Leu Ile Val Leu Thr Glu Asp Gln Pro Asn Leu Glu Ile 300 305 310 aac cac cat gca gac aag tcc ctc gat agc ttc tgt aaa tgg cag aaa 1011 Asn His His Ala Asp Lys Ser Leu Asp Ser Phe Cys Lys Trp Gln Lys 315 320 325 330 tcc att ctc tcc cac caa agt gat gga aac acc att cca gaa aat ggg 1059 Ser Ile Leu Ser His Gln Ser Asp Gly Asn Thr Ile Pro Glu Asn Gly 335 340 345 att gcc cac cac gat aat gca gtt ctt att act aga tat gat atc tgc 1107 Ile Ala His His Asp Asn Ala Val Leu Ile Thr Arg Tyr Asp Ile Cys 350 355 360 act tat aaa aat aag ccc tgt gga aca ctg ggc ttg gcc tct gtg gct 1155 Thr Tyr Lys Asn Lys Pro Cys Gly Thr Leu Gly Leu Ala Ser Val Ala 365 370 375 gga atg tgt gag cct gaa agg agc tgc agc att aat gaa gac att ggc 1203 Gly Met Cys Glu Pro Glu Arg Ser Cys Ser Ile Asn Glu Asp Ile Gly 380 385 390 ctg ggt tca gct ttt acc att gca cat gag att gtt cac aat ttt ggt 1251 Leu Gly Ser Ala Phe Thr Ile Ala His Glu Ile Val His Asn Phe Gly 395 400 405 410 atg aac cat gat gga att gga aat tct tgt gga cga aag gtc atg aag 1299 Met Asn His Asp Gly Ile Gly Asn Ser Cys Gly Arg Lys Val Met Lys 415 420 425 cag caa aat tat ggc agc tca cat tac tgc gaa tac caa tcc ttt ttc 1347 Gln Gln Asn Tyr Gly Ser Ser His Tyr Cys Glu Tyr Gln Ser Phe Phe 430 435 440 ctg gtc tgc ttg cag tcg aga nta cat cac cag ctt ttt aga gaa gtg 1395 Leu Val Cys Leu Gln Ser Arg Xaa His His Gln Leu Phe Arg Glu Val 445 450 455 tgt aga gag ctc tgg tgt ctc agc aaa agc aac cgc tgt gtc acc aac 1443 Cys Arg Glu Leu Trp Cys Leu Ser Lys Ser Asn Arg Cys Val Thr Asn 460 465 470 agt att cca gca gct gag ggg aca ctg tgt caa act ggg aat att gaa 1491 Ser Ile Pro Ala Ala Glu Gly Thr Leu Cys Gln Thr Gly Asn Ile Glu 475 480 485 490 aaa ggg tgg tgt tat cag gga gat tgt gtt cct ttt ggc act tgg ccc 1539 Lys Gly Trp Cys Tyr Gln Gly Asp Cys Val Pro Phe Gly Thr Trp Pro 495 500 505 cag agc ata gat ggg ggc tgg ggt ccc tgg tca cta tgg gga gag tgc 1587 Gln Ser Ile Asp Gly Gly Trp Gly Pro Trp Ser Leu Trp Gly Glu Cys 510 515 520 agc agg acc tgc ggg gga ggc gtn tcc tca tcc cta aga cac tgt gac 1635 Ser Arg Thr Cys Gly Gly Gly Val Ser Ser Ser Leu Arg His Cys Asp 525 530 535 agt cca gca cct tcg gag gtg gaa aaa tat tgc ctt ggg gaa agg aaa 1683 Ser Pro Ala Pro Ser Glu Val Glu Lys Tyr Cys Leu Gly Glu Arg Lys 540 545 550 cgg tat cgc tcc tgt aac aca gat cca tgc cct ttg ggt tcc cga gat 1731 Arg Tyr Arg Ser Cys Asn Thr Asp Pro Cys Pro Leu Gly Ser Arg Asp 555 560 565 570 ttt cga gag aaa cag tgt gca gac ttt gac aat atg cct ttc cga gga 1779 Phe Arg Glu Lys Gln Cys Ala Asp Phe Asp Asn Met Pro Phe Arg Gly 575 580 585 aag tat tat aac tgg aaa ccc tat act gga ggt ggg gta aaa cct tgt 1827 Lys Tyr Tyr Asn Trp Lys Pro Tyr Thr Gly Gly Gly Val Lys Pro Cys 590 595 600 gca tta aac tgc ttg gct gaa ggt tat aat ttc tac act gaa cgt gct 1875 Ala Leu Asn Cys Leu Ala Glu Gly Tyr Asn Phe Tyr Thr Glu Arg Ala 605 610 615 cct gcg gtg atc gat ggg acc cag tgc aat gcg gat tca ctg gat atc 1923 Pro Ala Val Ile Asp Gly Thr Gln Cys Asn Ala Asp Ser Leu Asp Ile 620 625 630 tgc atc aat gga gaa tgc aag cac gta ggc tgt gat aat att ttg gga 1971 Cys Ile Asn Gly Glu Cys Lys His Val Gly Cys Asp Asn Ile Leu Gly 635 640 645 650 tct gat gct agg gaa gat aga tgt cga gtc tgt gga ggg ggc gga agc 2019 Ser Asp Ala Arg Glu Asp Arg Cys Arg Val Cys Gly Gly Gly Gly Ser 655 660 665 aca tgt gat gcc att gaa ggg ttc ttc aat gat tca ctg ccc agg gga 2067 Thr Cys Asp Ala Ile Glu Gly Phe Phe Asn Asp Ser Leu Pro Arg Gly 670 675 680 ggc tac atg gaa gtg gtg cag ata cca aga ggc tct gtt cac att gaa 2115 Gly Tyr Met Glu Val Val Gln Ile Pro Arg Gly Ser Val His Ile Glu 685 690 695 gtt aga gaa gtt gcc atg tca aag aac tat att gct tta aaa tct gaa 2163 Val Arg Glu Val Ala Met Ser Lys Asn Tyr Ile Ala Leu Lys Ser Glu 700 705 710 gga gat gat tac tat att aat ggt gcc tgg act att gac tgg cct agg 2211 Gly Asp Asp Tyr Tyr Ile Asn Gly Ala Trp Thr Ile Asp Trp Pro Arg 715 720 725 730 aaa ttt gat gtt gct ggg aca gct ttt cat tac aag aga cca act gat 2259 Lys Phe Asp Val Ala Gly Thr Ala Phe His Tyr Lys Arg Pro Thr Asp 735 740 745 gaa cca gaa tcc ttg gaa gct cta ggt cct acc tca gaa aat ctc atc 2307 Glu Pro Glu Ser Leu Glu Ala Leu Gly Pro Thr Ser Glu Asn Leu Ile 750 755 760 gtc atg gtt ctg ctt caa gaa cag aat ttg gga att agg tat aag ttc 2355 Val Met Val Leu Leu Gln Glu Gln Asn Leu Gly Ile Arg Tyr Lys Phe 765 770 775 aat gtt ccc atc act cga act ggc agt gga gat aat gaa gtt ggc ttt 2403 Asn Val Pro Ile Thr Arg Thr Gly Ser Gly Asp Asn Glu Val Gly Phe 780 785 790 aca tgg aat cat cag cct tgg tca gaa tgc tca gct act tgt gct gga 2451 Thr Trp Asn His Gln Pro Trp Ser Glu Cys Ser Ala Thr Cys Ala Gly 795 800 805 810 ggt aag atg ccc act agg cag ccc acc cag agg gca aga tgg aga aca 2499 Gly Lys Met Pro Thr Arg Gln Pro Thr Gln Arg Ala Arg Trp Arg Thr 815 820 825 aaa cac att ctg agc tat gct ttg tgt ttg tta aaa aag cta att gga 2547 Lys His Ile Leu Ser Tyr Ala Leu Cys Leu Leu Lys Lys Leu Ile Gly 830 835 840 aac att tct agg ttt gct tca agc tgt aat tta gca aaa gaa act ttg 2595 Asn Ile Ser Arg Phe Ala Ser Ser Cys Asn Leu Ala Lys Glu Thr Leu 845 850 855 ctt taa ttatattata ttccatttgt tttcaacctc atgtaatttg tgcagatttg 2651 Leu 860 ttggtaaaat acatcttggc acaatgagtg tctctgctgg tgcttctccc aagactatct 2711 tgaaggtggg ctgtttgcct ttcgtgaaca cattcttggt aaagaacatc aaaagtttta 2771 aaaaagaaaa tgagcaagaa tcagacatca cagatgcaac ttcttgtaat gggagatgag 2831 gagaatgtac ggctgtg 2848 <210> SEQ ID NO 5 <211> LENGTH: 859 <212> TYPE: PRT <213> ORGANISM: Homo sapiens ADAMTS-6 <220> FEATURE: <221> NAME/KEY: MOD_RES <222> LOCATION: (450) <223> OTHER INFORMATION: Xaa = Leu <400> SEQUENCE: 5 Met Glu Ile Leu Trp Lys Thr Leu Thr Trp Ile Leu Ser Leu Ile Met 1 5 10 15 Ala Ser Ser Glu Phe His Ser Asp His Arg Leu Ser Tyr Ser Ser Gln 20 25 30 Glu Glu Phe Leu Thr Tyr Leu Glu His Tyr Gln Leu Thr Ile Pro Ile 35 40 45 Arg Val Asp Gln Asn Gly Ala Phe Leu Ser Phe Thr Val Lys Asn Asp 50 55 60 Lys His Ser Arg Arg Arg Arg Ser Met Asp Pro Ile Asp Pro Gln Gln 65 70 75 80 Ala Val Ser Lys Leu Phe Phe Lys Leu Ser Ala Tyr Gly Lys His Phe 85 90 95 His Leu Asn Leu Thr Leu Asn Thr Asp Phe Val Ser Lys His Phe Thr 100 105 110 Val Glu Tyr Trp Gly Lys Asp Gly Pro Gln Trp Lys His Asp Phe Leu 115 120 125 Asp Asn Cys His Tyr Thr Gly Tyr Leu Gln Asp Gln Arg Ser Thr Thr 130 135 140 Lys Val Ala Leu Ser Asn Cys Val Gly Leu His Gly Val Ile Ala Thr 145 150 155 160 Glu Asp Glu Glu Tyr Phe Ile Glu Pro Leu Lys Asn Thr Thr Glu Asp 165 170 175 Ser Lys His Phe Ser Tyr Glu Asn Gly His Pro His Val Ile Tyr Lys 180 185 190 Lys Ser Ala Leu Gln Gln Arg His Leu Tyr Asp His Ser His Cys Gly 195 200 205 Val Ser Asp Phe Thr Arg Ser Gly Lys Pro Trp Trp Leu Asn Asp Thr 210 215 220 Pro Leu Phe Leu Ile His Tyr Gln Ile Asn Asn Thr His Ile His His 225 230 235 240 Arg Gln Lys Arg Ser Val Ser Ile Glu Arg Phe Val Glu Thr Leu Val 245 250 255 Val Ala Asp Lys Met Met Val Gly Tyr His Gly Arg Lys Asp Ile Glu 260 265 270 His Tyr Ile Leu Ser Val Met Asn Ile Val Ala Lys Leu Tyr Arg Asp 275 280 285 Ser Ser Leu Gly Asn Val Val Asn Ile Ile Val Ala Arg Leu Ile Val 290 295 300 Leu Thr Glu Asp Gln Pro Asn Leu Glu Ile Asn His His Ala Asp Lys 305 310 315 320 Ser Leu Asp Ser Phe Cys Lys Trp Gln Lys Ser Ile Leu Ser His Gln 325 330 335 Ser Asp Gly Asn Thr Ile Pro Glu Asn Gly Ile Ala His His Asp Asn 340 345 350 Ala Val Leu Ile Thr Arg Tyr Asp Ile Cys Thr Tyr Lys Asn Lys Pro 355 360 365 Cys Gly Thr Leu Gly Leu Ala Ser Val Ala Gly Met Cys Glu Pro Glu 370 375 380 Arg Ser Cys Ser Ile Asn Glu Asp Ile Gly Leu Gly Ser Ala Phe Thr 385 390 395 400 Ile Ala His Glu Ile Val His Asn Phe Gly Met Asn His Asp Gly Ile 405 410 415 Gly Asn Ser Cys Gly Arg Lys Val Met Lys Gln Gln Asn Tyr Gly Ser 420 425 430 Ser His Tyr Cys Glu Tyr Gln Ser Phe Phe Leu Val Cys Leu Gln Ser 435 440 445 Arg Xaa His His Gln Leu Phe Arg Glu Val Cys Arg Glu Leu Trp Cys 450 455 460 Leu Ser Lys Ser Asn Arg Cys Val Thr Asn Ser Ile Pro Ala Ala Glu 465 470 475 480 Gly Thr Leu Cys Gln Thr Gly Asn Ile Glu Lys Gly Trp Cys Tyr Gln 485 490 495 Gly Asp Cys Val Pro Phe Gly Thr Trp Pro Gln Ser Ile Asp Gly Gly 500 505 510 Trp Gly Pro Trp Ser Leu Trp Gly Glu Cys Ser Arg Thr Cys Gly Gly 515 520 525 Gly Val Ser Ser Ser Leu Arg His Cys Asp Ser Pro Ala Pro Ser Glu 530 535 540 Val Glu Lys Tyr Cys Leu Gly Glu Arg Lys Arg Tyr Arg Ser Cys Asn 545 550 555 560 Thr Asp Pro Cys Pro Leu Gly Ser Arg Asp Phe Arg Glu Lys Gln Cys 565 570 575 Ala Asp Phe Asp Asn Met Pro Phe Arg Gly Lys Tyr Tyr Asn Trp Lys 580 585 590 Pro Tyr Thr Gly Gly Gly Val Lys Pro Cys Ala Leu Asn Cys Leu Ala 595 600 605 Glu Gly Tyr Asn Phe Tyr Thr Glu Arg Ala Pro Ala Val Ile Asp Gly 610 615 620 Thr Gln Cys Asn Ala Asp Ser Leu Asp Ile Cys Ile Asn Gly Glu Cys 625 630 635 640 Lys His Val Gly Cys Asp Asn Ile Leu Gly Ser Asp Ala Arg Glu Asp 645 650 655 Arg Cys Arg Val Cys Gly Gly Gly Gly Ser Thr Cys Asp Ala Ile Glu 660 665 670 Gly Phe Phe Asn Asp Ser Leu Pro Arg Gly Gly Tyr Met Glu Val Val 675 680 685 Gln Ile Pro Arg Gly Ser Val His Ile Glu Val Arg Glu Val Ala Met 690 695 700 Ser Lys Asn Tyr Ile Ala Leu Lys Ser Glu Gly Asp Asp Tyr Tyr Ile 705 710 715 720 Asn Gly Ala Trp Thr Ile Asp Trp Pro Arg Lys Phe Asp Val Ala Gly 725 730 735 Thr Ala Phe His Tyr Lys Arg Pro Thr Asp Glu Pro Glu Ser Leu Glu 740 745 750 Ala Leu Gly Pro Thr Ser Glu Asn Leu Ile Val Met Val Leu Leu Gln 755 760 765 Glu Gln Asn Leu Gly Ile Arg Tyr Lys Phe Asn Val Pro Ile Thr Arg 770 775 780 Thr Gly Ser Gly Asp Asn Glu Val Gly Phe Thr Trp Asn His Gln Pro 785 790 795 800 Trp Ser Glu Cys Ser Ala Thr Cys Ala Gly Gly Lys Met Pro Thr Arg 805 810 815 Gln Pro Thr Gln Arg Ala Arg Trp Arg Thr Lys His Ile Leu Ser Tyr 820 825 830 Ala Leu Cys Leu Leu Lys Lys Leu Ile Gly Asn Ile Ser Arg Phe Ala 835 840 845 Ser Ser Cys Asn Leu Ala Lys Glu Thr Leu Leu 850 855 <210> SEQ ID NO 6 <211> LENGTH: 3218 <212> TYPE: DNA <213> ORGANISM: Homo sapiens ADAMTS-7 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (13)..(3003) <400> SEQUENCE: 6 ccggttcctg cc atg ccc ggc ggc ccc agt ccc cgc agc ccc gcg cct ttg 51 Met Pro Gly Gly Pro Ser Pro Arg Ser Pro Ala Pro Leu 1 5 10 ctg cgc ccc ctc ctc ctg ctc ctc tgc gct ctg gct ccc ggc gcc ccc 99 Leu Arg Pro Leu Leu Leu Leu Leu Cys Ala Leu Ala Pro Gly Ala Pro 15 20 25 gga ccc gca cca gga cgt gca acc gag ggc cgg gcg gca ctg gac atc 147 Gly Pro Ala Pro Gly Arg Ala Thr Glu Gly Arg Ala Ala Leu Asp Ile 30 35 40 45 gtg cac ccg gtt cga gtc gac gcg ggg ggc tcc ttc ctg tcc tac gag 195 Val His Pro Val Arg Val Asp Ala Gly Gly Ser Phe Leu Ser Tyr Glu 50 55 60 ctg tgg ccc cgc gca ctg cgc aag cgg gat gta tct gtg cgc cga gac 243 Leu Trp Pro Arg Ala Leu Arg Lys Arg Asp Val Ser Val Arg Arg Asp 65 70 75 gcg ccc gcc ttc tac gag cta caa tac cgc ggg cgc gag ctg cgc ttc 291 Ala Pro Ala Phe Tyr Glu Leu Gln Tyr Arg Gly Arg Glu Leu Arg Phe 80 85 90 aac ctg acc gcc aat cag cac ctg ctg gcg ccc ggc ttt gtg agc gag 339 Asn Leu Thr Ala Asn Gln His Leu Leu Ala Pro Gly Phe Val Ser Glu 95 100 105 acg cgg cgg cgc ggc ggc ctg ggc cgc gcg cac atc cgg gcc cac acc 387 Thr Arg Arg Arg Gly Gly Leu Gly Arg Ala His Ile Arg Ala His Thr 110 115 120 125 ccg gcc tgc cac ctg ctt ggc gag gtg cag gac cct gag ctc gag ggt 435 Pro Ala Cys His Leu Leu Gly Glu Val Gln Asp Pro Glu Leu Glu Gly 130 135 140 ggc ctg gcg gcc atc agc gcc tgc gac ggc ctg aaa ggt gtg ttc cag 483 Gly Leu Ala Ala Ile Ser Ala Cys Asp Gly Leu Lys Gly Val Phe Gln 145 150 155 ctc tcc aac gag gac tac ttc att gag ccc ctg gac agt gcc ccg gcc 531 Leu Ser Asn Glu Asp Tyr Phe Ile Glu Pro Leu Asp Ser Ala Pro Ala 160 165 170 cgg cct ggc cac gcc cag ccc cat gtg gtg tac aag cgt cag gcc ccg 579 Arg Pro Gly His Ala Gln Pro His Val Val Tyr Lys Arg Gln Ala Pro 175 180 185 gag agg ctg gca cag cgg ggt gat tcc agt gct cca agc acc tgt gga 627 Glu Arg Leu Ala Gln Arg Gly Asp Ser Ser Ala Pro Ser Thr Cys Gly 190 195 200 205 gtg caa gtg tac cca gag ctg gag tct cga cgg gag cgt tgg gag cag 675 Val Gln Val Tyr Pro Glu Leu Glu Ser Arg Arg Glu Arg Trp Glu Gln 210 215 220 cgg cag cag tgg cgg cgg cca cgg ctg agg cgt cta cac cag cgg tcg 723 Arg Gln Gln Trp Arg Arg Pro Arg Leu Arg Arg Leu His Gln Arg Ser 225 230 235 gtc agc aaa gag aag tgg tgt gag acc ctg gta gta gct gat gcc aaa 771 Val Ser Lys Glu Lys Trp Cys Glu Thr Leu Val Val Ala Asp Ala Lys 240 245 250 atg gtg gag tac cac gga cag ccg cag gtt gag agc tat gtg ctg acc 819 Met Val Glu Tyr His Gly Gln Pro Gln Val Glu Ser Tyr Val Leu Thr 255 260 265 atc atg aac atg gtg gct ggc ctg ttt cat gac ccc agc att ggg aac 867 Ile Met Asn Met Val Ala Gly Leu Phe His Asp Pro Ser Ile Gly Asn 270 275 280 285 ccc atc cac atc acc att gtg cgc ctg gtc ctg ctg gaa gat gag gag 915 Pro Ile His Ile Thr Ile Val Arg Leu Val Leu Leu Glu Asp Glu Glu 290 295 300 gag gac cta aag atc acg cac cat gca gac aac acc ctg aag agc ttc 963 Glu Asp Leu Lys Ile Thr His His Ala Asp Asn Thr Leu Lys Ser Phe 305 310 315 tgc aag tgg cag aaa agc atc aac atg aag ggg gat gcc cat ccc ctg 1011 Cys Lys Trp Gln Lys Ser Ile Asn Met Lys Gly Asp Ala His Pro Leu 320 325 330 cac cat gac act gcc atc ctg ctc acc aga aag gac ctg tgt gca gcc 1059 His His Asp Thr Ala Ile Leu Leu Thr Arg Lys Asp Leu Cys Ala Ala 335 340 345 atg aac cgg ccc tgt gag acc ctg gga ctg tcc cat gtg gcg ggc atg 1107 Met Asn Arg Pro Cys Glu Thr Leu Gly Leu Ser His Val Ala Gly Met 350 355 360 365 tgc cag ccg cac cgc agc tgc agc atc aac gag gac acg ggc ctg ccg 1155 Cys Gln Pro His Arg Ser Cys Ser Ile Asn Glu Asp Thr Gly Leu Pro 370 375 380 ctg gcc ttc act gta gcc cac gag ctc ggg cac agt ttt ggc att cag 1203 Leu Ala Phe Thr Val Ala His Glu Leu Gly His Ser Phe Gly Ile Gln 385 390 395 cat gac gga agc ggc aat gac tgt gag ccc gtt ggg aaa cga cct ttc 1251 His Asp Gly Ser Gly Asn Asp Cys Glu Pro Val Gly Lys Arg Pro Phe 400 405 410 atc atg tct cca cag ctc ctg tac gac gcc gct ccc ctc acc tgg tcc 1299 Ile Met Ser Pro Gln Leu Leu Tyr Asp Ala Ala Pro Leu Thr Trp Ser 415 420 425 cgc tgc agc cgc cag tat atc acc agg ttc ctt gac cgt ggg tgg ggc 1347 Arg Cys Ser Arg Gln Tyr Ile Thr Arg Phe Leu Asp Arg Gly Trp Gly 430 435 440 445 ctg tgc ctg gac gac cct cct gcc aag gac att atc gac ttc ccc tcg 1395 Leu Cys Leu Asp Asp Pro Pro Ala Lys Asp Ile Ile Asp Phe Pro Ser 450 455 460 gtg cca cct ggc gtc ctc tat gat gta agc cac cag tgc cgc ctc cag 1443 Val Pro Pro Gly Val Leu Tyr Asp Val Ser His Gln Cys Arg Leu Gln 465 470 475 tac ggg gcc tac tct gcc ttc tgc gag gac atg gat aat gtc tgc cac 1491 Tyr Gly Ala Tyr Ser Ala Phe Cys Glu Asp Met Asp Asn Val Cys His 480 485 490 aca ctc tgg tgc tct gtg ggg acc acc tgt cac tcc aag ctg gat gca 1539 Thr Leu Trp Cys Ser Val Gly Thr Thr Cys His Ser Lys Leu Asp Ala 495 500 505 gct gtg gac ggc acc cgg tgt ggg gag aat aag tgg tgt ctc agt ggg 1587 Ala Val Asp Gly Thr Arg Cys Gly Glu Asn Lys Trp Cys Leu Ser Gly 510 515 520 525 gag tgc gta ccc gtg ggc ttc cgg ccc gag gcc gtg gat ggt ggc tgg 1635 Glu Cys Val Pro Val Gly Phe Arg Pro Glu Ala Val Asp Gly Gly Trp 530 535 540 tct ggc tgg agc gcc tgg tcc atc tgc tca cgg agc tgt ggc atg ggc 1683 Ser Gly Trp Ser Ala Trp Ser Ile Cys Ser Arg Ser Cys Gly Met Gly 545 550 555 gta cag agc gcc gag cgg cag tgc acg cag cct acg ccc aaa tac aaa 1731 Val Gln Ser Ala Glu Arg Gln Cys Thr Gln Pro Thr Pro Lys Tyr Lys 560 565 570 ggc aga tac tgt gtg ggt gag cgc aag cgc ttc cgc ctc tgc aac ctg 1779 Gly Arg Tyr Cys Val Gly Glu Arg Lys Arg Phe Arg Leu Cys Asn Leu 575 580 585 cag gcc tgc cct gct ggc cgc ccc tcc ttc cgc cac gtc cag tgc agc 1827 Gln Ala Cys Pro Ala Gly Arg Pro Ser Phe Arg His Val Gln Cys Ser 590 595 600 605 cac ttt gac gct atg ctc tac aag ggc cag ctg cac aca tgg gtg ccc 1875 His Phe Asp Ala Met Leu Tyr Lys Gly Gln Leu His Thr Trp Val Pro 610 615 620 gtg gtc aat gac gtg aac ccc tgc gag ctg cac tgc cgg ccc gcg aat 1923 Val Val Asn Asp Val Asn Pro Cys Glu Leu His Cys Arg Pro Ala Asn 625 630 635 gag tac ttt gcc aag aag ctg cgg gac gcc tgt gtc gat ggc acc ccc 1971 Glu Tyr Phe Ala Lys Lys Leu Arg Asp Ala Cys Val Asp Gly Thr Pro 640 645 650 tgc tac cag gtc cga gcc agc cgg gac ctc tgc atc aac ggc atc tgt 2019 Cys Tyr Gln Val Arg Ala Ser Arg Asp Leu Cys Ile Asn Gly Ile Cys 655 660 665 aag aac gtg ggc tgt gac ttc gag att gac tcc ggt gct atg gag gac 2067 Lys Asn Val Gly Cys Asp Phe Glu Ile Asp Ser Gly Ala Met Glu Asp 670 675 680 685 cgc tgt ggt gtg tgc cac ggc aac ggc tcc acc tgc cac acc gtg agc 2115 Arg Cys Gly Val Cys His Gly Asn Gly Ser Thr Cys His Thr Val Ser 690 695 700 ggg acc ttc gag gag gcc gag ggt ctg ggg tat gtg gat gtg ggg ctg 2163 Gly Thr Phe Glu Glu Ala Glu Gly Leu Gly Tyr Val Asp Val Gly Leu 705 710 715 atc cca gcg ggc gca cgc gag atc cgc atc caa gag gtt gcc gag gct 2211 Ile Pro Ala Gly Ala Arg Glu Ile Arg Ile Gln Glu Val Ala Glu Ala 720 725 730 gcc aac ttc ctg gca ctg cgg agc gag gac ccg gag aag tac ttc ctc 2259 Ala Asn Phe Leu Ala Leu Arg Ser Glu Asp Pro Glu Lys Tyr Phe Leu 735 740 745 aat ggt ggc tgg acc atc cag tgg aac ggg gac tac cag gtg gca ggg 2307 Asn Gly Gly Trp Thr Ile Gln Trp Asn Gly Asp Tyr Gln Val Ala Gly 750 755 760 765 acc acc ttc aca tac gca cgc agg ggc aac tgg gag aac ctc acg tcc 2355 Thr Thr Phe Thr Tyr Ala Arg Arg Gly Asn Trp Glu Asn Leu Thr Ser 770 775 780 ccg ggt ccc acc aag gag cct gtc tgg atc cag gtg cct gcc tcc cgt 2403 Pro Gly Pro Thr Lys Glu Pro Val Trp Ile Gln Val Pro Ala Ser Arg 785 790 795 ggc cca ggc ggg ggg agc aga ggc gga gtc ccc agg ccc agc acc ctc 2451 Gly Pro Gly Gly Gly Ser Arg Gly Gly Val Pro Arg Pro Ser Thr Leu 800 805 810 cat ggc agg tct cgt cct gga gga gtg agc cct ggt tca gtc aca gag 2499 His Gly Arg Ser Arg Pro Gly Gly Val Ser Pro Gly Ser Val Thr Glu 815 820 825 cct ggc tct gag cca ggc cct cct gct gcg gcc tct acc tca gtt tcc 2547 Pro Gly Ser Glu Pro Gly Pro Pro Ala Ala Ala Ser Thr Ser Val Ser 830 835 840 845 cca tct tta aaa tgg ccc aat ctt gta gct gca gtt cac aga ggt ggc 2595 Pro Ser Leu Lys Trp Pro Asn Leu Val Ala Ala Val His Arg Gly Gly 850 855 860 tgg ggt caa gct cct tta gga ctg ggt gga tgg aga aga cac ctt gtg 2643 Trp Gly Gln Ala Pro Leu Gly Leu Gly Gly Trp Arg Arg His Leu Val 865 870 875 ctc atg ggc ccc cgc ctg ccc acc cag ctg ctg ttc cag gag agc aac 2691 Leu Met Gly Pro Arg Leu Pro Thr Gln Leu Leu Phe Gln Glu Ser Asn 880 885 890 cct ggg gtg cac tac gag tac acc atc cac agg gag gca ggt ggc cac 2739 Pro Gly Val His Tyr Glu Tyr Thr Ile His Arg Glu Ala Gly Gly His 895 900 905 gac gag gtc ccg ccg ccc gtg ttc tcc tgg cat tat ggg ccc tgg acc 2787 Asp Glu Val Pro Pro Pro Val Phe Ser Trp His Tyr Gly Pro Trp Thr 910 915 920 925 aag tgc aca gtc acc tgc ggc aga ggt gag aag tgg ggc agg cac agc 2835 Lys Cys Thr Val Thr Cys Gly Arg Gly Glu Lys Trp Gly Arg His Ser 930 935 940 ccc acc tgc agg ggc tta gtg tct gga cag gga cac tgg ctt cag ctc 2883 Pro Thr Cys Arg Gly Leu Val Ser Gly Gln Gly His Trp Leu Gln Leu 945 950 955 cca gct cac tgc tgg gcc acc acg ggt ttg gaa gtt tgc ttc tct gag 2931 Pro Ala His Cys Trp Ala Thr Thr Gly Leu Glu Val Cys Phe Ser Glu 960 965 970 cct cag ttc tcc atc tgt gag atg agg cta gcg att gcc ctg tgt ccc 2979 Pro Gln Phe Ser Ile Cys Glu Met Arg Leu Ala Ile Ala Leu Cys Pro 975 980 985 agg ccc gct ggg agg gta cat gga tgaggcaggt gggtgctggc tcgcggcgca 3033 Arg Pro Ala Gly Arg Val His Gly 990 995 tgttcagtgt gctccagctc ttggcgttct ccctccaggg gacacagctc cccctcgata 3093 gaccagtcca gtggcccctc accacactga cttatttccc taaactattt ataaaaagta 3153 gggcaatttc attaactctg actcttacct gcccgggcgg ccgctcgagc cgagtaatca 3213 ctagt 3218 <210> SEQ ID NO 7 <211> LENGTH: 997 <212> TYPE: PRT <213> ORGANISM: Homo sapiens ADAMTS-7 <400> SEQUENCE: 7 Met Pro Gly Gly Pro Ser Pro Arg Ser Pro Ala Pro Leu Leu Arg Pro 1 5 10 15 Leu Leu Leu Leu Leu Cys Ala Leu Ala Pro Gly Ala Pro Gly Pro Ala 20 25 30 Pro Gly Arg Ala Thr Glu Gly Arg Ala Ala Leu Asp Ile Val His Pro 35 40 45 Val Arg Val Asp Ala Gly Gly Ser Phe Leu Ser Tyr Glu Leu Trp Pro 50 55 60 Arg Ala Leu Arg Lys Arg Asp Val Ser Val Arg Arg Asp Ala Pro Ala 65 70 75 80 Phe Tyr Glu Leu Gln Tyr Arg Gly Arg Glu Leu Arg Phe Asn Leu Thr 85 90 95 Ala Asn Gln His Leu Leu Ala Pro Gly Phe Val Ser Glu Thr Arg Arg 100 105 110 Arg Gly Gly Leu Gly Arg Ala His Ile Arg Ala His Thr Pro Ala Cys 115 120 125 His Leu Leu Gly Glu Val Gln Asp Pro Glu Leu Glu Gly Gly Leu Ala 130 135 140 Ala Ile Ser Ala Cys Asp Gly Leu Lys Gly Val Phe Gln Leu Ser Asn 145 150 155 160 Glu Asp Tyr Phe Ile Glu Pro Leu Asp Ser Ala Pro Ala Arg Pro Gly 165 170 175 His Ala Gln Pro His Val Val Tyr Lys Arg Gln Ala Pro Glu Arg Leu 180 185 190 Ala Gln Arg Gly Asp Ser Ser Ala Pro Ser Thr Cys Gly Val Gln Val 195 200 205 Tyr Pro Glu Leu Glu Ser Arg Arg Glu Arg Trp Glu Gln Arg Gln Gln 210 215 220 Trp Arg Arg Pro Arg Leu Arg Arg Leu His Gln Arg Ser Val Ser Lys 225 230 235 240 Glu Lys Trp Cys Glu Thr Leu Val Val Ala Asp Ala Lys Met Val Glu 245 250 255 Tyr His Gly Gln Pro Gln Val Glu Ser Tyr Val Leu Thr Ile Met Asn 260 265 270 Met Val Ala Gly Leu Phe His Asp Pro Ser Ile Gly Asn Pro Ile His 275 280 285 Ile Thr Ile Val Arg Leu Val Leu Leu Glu Asp Glu Glu Glu Asp Leu 290 295 300 Lys Ile Thr His His Ala Asp Asn Thr Leu Lys Ser Phe Cys Lys Trp 305 310 315 320 Gln Lys Ser Ile Asn Met Lys Gly Asp Ala His Pro Leu His His Asp 325 330 335 Thr Ala Ile Leu Leu Thr Arg Lys Asp Leu Cys Ala Ala Met Asn Arg 340 345 350 Pro Cys Glu Thr Leu Gly Leu Ser His Val Ala Gly Met Cys Gln Pro 355 360 365 His Arg Ser Cys Ser Ile Asn Glu Asp Thr Gly Leu Pro Leu Ala Phe 370 375 380 Thr Val Ala His Glu Leu Gly His Ser Phe Gly Ile Gln His Asp Gly 385 390 395 400 Ser Gly Asn Asp Cys Glu Pro Val Gly Lys Arg Pro Phe Ile Met Ser 405 410 415 Pro Gln Leu Leu Tyr Asp Ala Ala Pro Leu Thr Trp Ser Arg Cys Ser 420 425 430 Arg Gln Tyr Ile Thr Arg Phe Leu Asp Arg Gly Trp Gly Leu Cys Leu 435 440 445 Asp Asp Pro Pro Ala Lys Asp Ile Ile Asp Phe Pro Ser Val Pro Pro 450 455 460 Gly Val Leu Tyr Asp Val Ser His Gln Cys Arg Leu Gln Tyr Gly Ala 465 470 475 480 Tyr Ser Ala Phe Cys Glu Asp Met Asp Asn Val Cys His Thr Leu Trp 485 490 495 Cys Ser Val Gly Thr Thr Cys His Ser Lys Leu Asp Ala Ala Val Asp 500 505 510 Gly Thr Arg Cys Gly Glu Asn Lys Trp Cys Leu Ser Gly Glu Cys Val 515 520 525 Pro Val Gly Phe Arg Pro Glu Ala Val Asp Gly Gly Trp Ser Gly Trp 530 535 540 Ser Ala Trp Ser Ile Cys Ser Arg Ser Cys Gly Met Gly Val Gln Ser 545 550 555 560 Ala Glu Arg Gln Cys Thr Gln Pro Thr Pro Lys Tyr Lys Gly Arg Tyr 565 570 575 Cys Val Gly Glu Arg Lys Arg Phe Arg Leu Cys Asn Leu Gln Ala Cys 580 585 590 Pro Ala Gly Arg Pro Ser Phe Arg His Val Gln Cys Ser His Phe Asp 595 600 605 Ala Met Leu Tyr Lys Gly Gln Leu His Thr Trp Val Pro Val Val Asn 610 615 620 Asp Val Asn Pro Cys Glu Leu His Cys Arg Pro Ala Asn Glu Tyr Phe 625 630 635 640 Ala Lys Lys Leu Arg Asp Ala Cys Val Asp Gly Thr Pro Cys Tyr Gln 645 650 655 Val Arg Ala Ser Arg Asp Leu Cys Ile Asn Gly Ile Cys Lys Asn Val 660 665 670 Gly Cys Asp Phe Glu Ile Asp Ser Gly Ala Met Glu Asp Arg Cys Gly 675 680 685 Val Cys His Gly Asn Gly Ser Thr Cys His Thr Val Ser Gly Thr Phe 690 695 700 Glu Glu Ala Glu Gly Leu Gly Tyr Val Asp Val Gly Leu Ile Pro Ala 705 710 715 720 Gly Ala Arg Glu Ile Arg Ile Gln Glu Val Ala Glu Ala Ala Asn Phe 725 730 735 Leu Ala Leu Arg Ser Glu Asp Pro Glu Lys Tyr Phe Leu Asn Gly Gly 740 745 750 Trp Thr Ile Gln Trp Asn Gly Asp Tyr Gln Val Ala Gly Thr Thr Phe 755 760 765 Thr Tyr Ala Arg Arg Gly Asn Trp Glu Asn Leu Thr Ser Pro Gly Pro 770 775 780 Thr Lys Glu Pro Val Trp Ile Gln Val Pro Ala Ser Arg Gly Pro Gly 785 790 795 800 Gly Gly Ser Arg Gly Gly Val Pro Arg Pro Ser Thr Leu His Gly Arg 805 810 815 Ser Arg Pro Gly Gly Val Ser Pro Gly Ser Val Thr Glu Pro Gly Ser 820 825 830 Glu Pro Gly Pro Pro Ala Ala Ala Ser Thr Ser Val Ser Pro Ser Leu 835 840 845 Lys Trp Pro Asn Leu Val Ala Ala Val His Arg Gly Gly Trp Gly Gln 850 855 860 Ala Pro Leu Gly Leu Gly Gly Trp Arg Arg His Leu Val Leu Met Gly 865 870 875 880 Pro Arg Leu Pro Thr Gln Leu Leu Phe Gln Glu Ser Asn Pro Gly Val 885 890 895 His Tyr Glu Tyr Thr Ile His Arg Glu Ala Gly Gly His Asp Glu Val 900 905 910 Pro Pro Pro Val Phe Ser Trp His Tyr Gly Pro Trp Thr Lys Cys Thr 915 920 925 Val Thr Cys Gly Arg Gly Glu Lys Trp Gly Arg His Ser Pro Thr Cys 930 935 940 Arg Gly Leu Val Ser Gly Gln Gly His Trp Leu Gln Leu Pro Ala His 945 950 955 960 Cys Trp Ala Thr Thr Gly Leu Glu Val Cys Phe Ser Glu Pro Gln Phe 965 970 975 Ser Ile Cys Glu Met Arg Leu Ala Ile Ala Leu Cys Pro Arg Pro Ala 980 985 990 Gly Arg Val His Gly 995 <210> SEQ ID NO 8 <211> LENGTH: 3638 <212> TYPE: DNA <213> ORGANISM: Mus musculus ADAMTS-8 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (278)..(2992) <221> NAME/KEY: misc_feature <222> LOCATION: (3636) <223> OTHER INFORMATION: n = T <400> SEQUENCE: 8 tagggcgact gcacgggacg ccgcggagga cgcgcgctcg cggcccgggg cgccacgtgc 60 tcgagttctg ctaggttggc tggcgcagga ggagcgggct gcgcgatcca gaggggccgc 120 cagggaccgc cgcgccacgt gccgctagcc gagtcggcct ccccatccga ttgatcattt 180 ttcctggaca gagcgacccg gccgcctcgg gccaccagca cctgcccgcg cgcggcgatc 240 ttcttccctc tcccgcgctc cgcagcactc tgccccc atg ctc cgc gac ccc acc 295 Met Leu Arg Asp Pro Thr 1 5 acc acc ggg tgg ccg ccc ctc ctg ctg ctg cta ttg cag ctg ccg ccg 343 Thr Thr Gly Trp Pro Pro Leu Leu Leu Leu Leu Leu Gln Leu Pro Pro 10 15 20 ccg cca ctc gtc tgc gga gcc ccg gcg ggg ccg gga acc ggg gcg cag 391 Pro Pro Leu Val Cys Gly Ala Pro Ala Gly Pro Gly Thr Gly Ala Gln 25 30 35 gcc tcg gag cta gtg gtg ccc acg cgg ttg ccc ggc agc gcg agc gag 439 Ala Ser Glu Leu Val Val Pro Thr Arg Leu Pro Gly Ser Ala Ser Glu 40 45 50 ctc gcc ttc cac ctg tcc gcc ttc ggc cag ggc ttc gtg ctg cgc ctg 487 Leu Ala Phe His Leu Ser Ala Phe Gly Gln Gly Phe Val Leu Arg Leu 55 60 65 70 gcg cct gac gcc agc ttc ctg gcg ccg gaa ttc aag atc gag cgc ctc 535 Ala Pro Asp Ala Ser Phe Leu Ala Pro Glu Phe Lys Ile Glu Arg Leu 75 80 85 ggg ggc tcg agc gcg gcg gcc ggg ggc gag ccg gga ctg cgt ggc tgc 583 Gly Gly Ser Ser Ala Ala Ala Gly Gly Glu Pro Gly Leu Arg Gly Cys 90 95 100 ttc ttc tct ggc aca gtg aat gga gaa cgg gag tcg ctg gcg gcg atg 631 Phe Phe Ser Gly Thr Val Asn Gly Glu Arg Glu Ser Leu Ala Ala Met 105 110 115 agc tgt gtc gcg ggc tgg agc ggc tcg ttc ttg ctg gca ggc gag gag 679 Ser Cys Val Ala Gly Trp Ser Gly Ser Phe Leu Leu Ala Gly Glu Glu 120 125 130 ttc acc atc cag cca cag ggc gct ggg gac tcc ctg gac cag cct cat 727 Phe Thr Ile Gln Pro Gln Gly Ala Gly Asp Ser Leu Asp Gln Pro His 135 140 145 150 cgc ctg cag cgc tgg ggg ccg gga cag cgc cgc gaa gac ccc ggg ctc 775 Arg Leu Gln Arg Trp Gly Pro Gly Gln Arg Arg Glu Asp Pro Gly Leu 155 160 165 gct gcc gcc gaa gtt ttc ccc ctc cct caa gga ctg gag tgg gag gtg 823 Ala Ala Ala Glu Val Phe Pro Leu Pro Gln Gly Leu Glu Trp Glu Val 170 175 180 gag atg ggt aat ggg cag gga cag gag aga agt gac aac gaa gag gac 871 Glu Met Gly Asn Gly Gln Gly Gln Glu Arg Ser Asp Asn Glu Glu Asp 185 190 195 aag aag cag gac aag gag ggg ttg ctc aaa gag aca gaa gac tcc cgc 919 Lys Lys Gln Asp Lys Glu Gly Leu Leu Lys Glu Thr Glu Asp Ser Arg 200 205 210 aaa gtg cca cca ccc ttc gga tcc aaa act aga agc aag agg ttt gtg 967 Lys Val Pro Pro Pro Phe Gly Ser Lys Thr Arg Ser Lys Arg Phe Val 215 220 225 230 tcc gag gct cgc ttc gtg gaa aca ctt ctg gtg gct gat gcg tcc atg 1015 Ser Glu Ala Arg Phe Val Glu Thr Leu Leu Val Ala Asp Ala Ser Met 235 240 245 gct gcc ttc tat ggg acc gac ctg cag aac cac atc ctc acg gtg atg 1063 Ala Ala Phe Tyr Gly Thr Asp Leu Gln Asn His Ile Leu Thr Val Met 250 255 260 tca atg gca gcc cga atc tac aag cac ccg agc atc agg aac tcc gtc 1111 Ser Met Ala Ala Arg Ile Tyr Lys His Pro Ser Ile Arg Asn Ser Val 265 270 275 aac ctt gtg gtg gtg aaa gtg cta ata gtg gaa aaa gaa aga tgg ggc 1159 Asn Leu Val Val Val Lys Val Leu Ile Val Glu Lys Glu Arg Trp Gly 280 285 290 ccg gaa gtg tcc gac aac ggg ggg ctc aca ctg cgc aac ttc tgc agc 1207 Pro Glu Val Ser Asp Asn Gly Gly Leu Thr Leu Arg Asn Phe Cys Ser 295 300 305 310 tgg caa cgg cgt ttc aac aag ccc agt gac cgc cac ccg gag cac tat 1255 Trp Gln Arg Arg Phe Asn Lys Pro Ser Asp Arg His Pro Glu His Tyr 315 320 325 gac act gcc atc ttg ttc acc aga cag aac ttc tgt ggg aag gga gag 1303 Asp Thr Ala Ile Leu Phe Thr Arg Gln Asn Phe Cys Gly Lys Gly Glu 330 335 340 cag tgt gac acc ctg ggg atg gca gac gtt ggc acc atc tgt gac ccc 1351 Gln Cys Asp Thr Leu Gly Met Ala Asp Val Gly Thr Ile Cys Asp Pro 345 350 355 gac aag agc tgc tca gtg atc aag gat gag gga ctg cag gca gcc tac 1399 Asp Lys Ser Cys Ser Val Ile Lys Asp Glu Gly Leu Gln Ala Ala Tyr 360 365 370 acc ctg gcc cat gag cta ggg cac gtt ctc agc atg ccc cat gat gat 1447 Thr Leu Ala His Glu Leu Gly His Val Leu Ser Met Pro His Asp Asp 375 380 385 390 tct aag ccc tgt gtg aga ttg ttt ggg ccc atg ggc aag tac cac atg 1495 Ser Lys Pro Cys Val Arg Leu Phe Gly Pro Met Gly Lys Tyr His Met 395 400 405 atg gcg cca ttc ttc atc cac gtg aac aag acg ctg ccc tgg tct ccc 1543 Met Ala Pro Phe Phe Ile His Val Asn Lys Thr Leu Pro Trp Ser Pro 410 415 420 tgc agt gct gtc tac ctc aca gag ctc ctg gat gat ggt cac gga gat 1591 Cys Ser Ala Val Tyr Leu Thr Glu Leu Leu Asp Asp Gly His Gly Asp 425 430 435 tgt ctt ctg gat gcc ccc acc tcg gtt ctg ccc ctc ccc aca ggc ctc 1639 Cys Leu Leu Asp Ala Pro Thr Ser Val Leu Pro Leu Pro Thr Gly Leu 440 445 450 ccg ggc cac agc acc ctc tac gag ctg gac cag cag tgc aag cag atc 1687 Pro Gly His Ser Thr Leu Tyr Glu Leu Asp Gln Gln Cys Lys Gln Ile 455 460 465 470 ttt ggg cct gat ttc cga cac tgc ccc aac acc tct gtg gag gac atc 1735 Phe Gly Pro Asp Phe Arg His Cys Pro Asn Thr Ser Val Glu Asp Ile 475 480 485 tgt gtc cag ctc tgt gcc cgt cat cgg gat agt gat gag ccc att tgc 1783 Cys Val Gln Leu Cys Ala Arg His Arg Asp Ser Asp Glu Pro Ile Cys 490 495 500 cac aca aag aat ggt agc ctg ctc tgg gct gat ggt aca ccc tgt ggc 1831 His Thr Lys Asn Gly Ser Leu Leu Trp Ala Asp Gly Thr Pro Cys Gly 505 510 515 cct ggg cac ctg tgc ctg gat ggt agc tgt gta ctc aag gag gat gtg 1879 Pro Gly His Leu Cys Leu Asp Gly Ser Cys Val Leu Lys Glu Asp Val 520 525 530 gag aat ccc aag gct gtg gta gat gga gac tgg ggt ccc tgg aga ccc 1927 Glu Asn Pro Lys Ala Val Val Asp Gly Asp Trp Gly Pro Trp Arg Pro 535 540 545 550 tgg gga caa tgt tct cgc acc tgt ggt gga ggg ata caa ttc tcg aac 1975 Trp Gly Gln Cys Ser Arg Thr Cys Gly Gly Gly Ile Gln Phe Ser Asn 555 560 565 cgt gaa tgt gat aat cca atg cct cag aat gga gga aga ttt tgc ctg 2023 Arg Glu Cys Asp Asn Pro Met Pro Gln Asn Gly Gly Arg Phe Cys Leu 570 575 580 ggt gaa aga gtc aag tac caa tca tgc aac aca gag gaa tgt cca cca 2071 Gly Glu Arg Val Lys Tyr Gln Ser Cys Asn Thr Glu Glu Cys Pro Pro 585 590 595 aac gga aaa agc ttc cgg gag cag cag tgt gag aaa tat aat gcc tac 2119 Asn Gly Lys Ser Phe Arg Glu Gln Gln Cys Glu Lys Tyr Asn Ala Tyr 600 605 610 aac cac act gac ctg gat ggg aat ttc ctg cag tgg gtc ccc aag tat 2167 Asn His Thr Asp Leu Asp Gly Asn Phe Leu Gln Trp Val Pro Lys Tyr 615 620 625 630 tca gga gtg tcc ccc cga gac cga tgc aag ctg ttt tgc aga gcc cgt 2215 Ser Gly Val Ser Pro Arg Asp Arg Cys Lys Leu Phe Cys Arg Ala Arg 635 640 645 ggg agg agt gag ttc aaa gtg ttt gaa gct aag gtg atc gat ggc act 2263 Gly Arg Ser Glu Phe Lys Val Phe Glu Ala Lys Val Ile Asp Gly Thr 650 655 660 ctg tgt gga ccg gat act ctg tcc atc tgc gtc cgg ggg caa tgt gtt 2311 Leu Cys Gly Pro Asp Thr Leu Ser Ile Cys Val Arg Gly Gln Cys Val 665 670 675 aag gct ggc tgt gac cat gtg gtg aac tca cct aag aag ctg gac aaa 2359 Lys Ala Gly Cys Asp His Val Val Asn Ser Pro Lys Lys Leu Asp Lys 680 685 690 tgt ggg gtg tgt ggg ggc aaa ggc act gcc tgt agg aag atc tcc ggt 2407 Cys Gly Val Cys Gly Gly Lys Gly Thr Ala Cys Arg Lys Ile Ser Gly 695 700 705 710 tct ttc acc ccc ttc agt tat ggc tac aat gac att gtc acc atc cca 2455 Ser Phe Thr Pro Phe Ser Tyr Gly Tyr Asn Asp Ile Val Thr Ile Pro 715 720 725 gct ggt gcc aca aac att gat gtg aaa cag cgg agt cac cca ggg gtc 2503 Ala Gly Ala Thr Asn Ile Asp Val Lys Gln Arg Ser His Pro Gly Val 730 735 740 agg aac gac ggc agc tac ctg gcg ctg aag aca gcc aat ggg cag tac 2551 Arg Asn Asp Gly Ser Tyr Leu Ala Leu Lys Thr Ala Asn Gly Gln Tyr 745 750 755 ctg ctc aat ggt aac ctg gcc atc tct gcc ata gag caa gac atc ttg 2599 Leu Leu Asn Gly Asn Leu Ala Ile Ser Ala Ile Glu Gln Asp Ile Leu 760 765 770 gtg aag ggg acc atc ctg aag tac agt ggc tcc atg gct acc ctg gag 2647 Val Lys Gly Thr Ile Leu Lys Tyr Ser Gly Ser Met Ala Thr Leu Glu 775 780 785 790 cgg ctg cag agc ttc cag gcc ctg cct gag cct ctt aca gta cag ctc 2695 Arg Leu Gln Ser Phe Gln Ala Leu Pro Glu Pro Leu Thr Val Gln Leu 795 800 805 ctg act gtg tct ggt gag gtc ttc cct cca aaa gtc aga tat acc ttc 2743 Leu Thr Val Ser Gly Glu Val Phe Pro Pro Lys Val Arg Tyr Thr Phe 810 815 820 ttt gtc ccc aat gac atg gac ttc agc gtg cag aat agc aag gaa aga 2791 Phe Val Pro Asn Asp Met Asp Phe Ser Val Gln Asn Ser Lys Glu Arg 825 830 835 gca acc acc aac atc att cag tca ctg ccc tct gcg gag tgg gtt ctg 2839 Ala Thr Thr Asn Ile Ile Gln Ser Leu Pro Ser Ala Glu Trp Val Leu 840 845 850 gga gac tgg tct gaa tgt ccg agc acg tgc aga ggt agc tgg cag cgg 2887 Gly Asp Trp Ser Glu Cys Pro Ser Thr Cys Arg Gly Ser Trp Gln Arg 855 860 865 870 cgg act gtg gaa tgc agg gac ccc tca ggt cag gcc tct gac acc tgt 2935 Arg Thr Val Glu Cys Arg Asp Pro Ser Gly Gln Ala Ser Asp Thr Cys 875 880 885 gat gag gct ctg aaa cct gag gat gcc aag ccc tgt gga agc cag ccg 2983 Asp Glu Ala Leu Lys Pro Glu Asp Ala Lys Pro Cys Gly Ser Gln Pro 890 895 900 tgt ccc ctc tgatcccctt ggtggaaatc tcttaggctt atggatttgg 3032 Cys Pro Leu 905 gctactggtg taacagacaa aggtcccctc caaggtgata ctacatatca agatggcacg 3092 gccctttcag gccttctatt actacaaccc cttgggtact acctaattca taaggaagag 3152 agaagagggt ataagggtaa cagattgtaa agttgactgt ctggtggact ggaccttgct 3212 tatgaccaag aagtcgggat aggttaaaag gtagaagtgc acttattgat ccaaatggga 3272 gatttcagag ccagtctctt tgcaaaggac tagcaaagct aaatgaaaaa gaagaatttt 3332 ttttttctat ttggtttccc caataatcaa tctacctcac agcggggaaa aatcagtata 3392 caagaggtat aaggccaggt gttggcagtg aacgccaaag caagctccat aggtatctcc 3452 aagctatctt cagaaatgtc cgtggctgtt ttcagtatta aaatctgttg tctaaaaggg 3512 cagcagtgtc catcacaggg ttatagaaag ccacttttct caggctgcca cctgctgggg 3572 cggacccatt tcaagtattt atgcaaatat gtctccgaac taaagtgtgt cttacaccaa 3632 aagngc 3638 <210> SEQ ID NO 9 <211> LENGTH: 905 <212> TYPE: PRT <213> ORGANISM: Mus musculus ADAMTS-8 <400> SEQUENCE: 9 Met Leu Arg Asp Pro Thr Thr Thr Gly Trp Pro Pro Leu Leu Leu Leu 1 5 10 15 Leu Leu Gln Leu Pro Pro Pro Pro Leu Val Cys Gly Ala Pro Ala Gly 20 25 30 Pro Gly Thr Gly Ala Gln Ala Ser Glu Leu Val Val Pro Thr Arg Leu 35 40 45 Pro Gly Ser Ala Ser Glu Leu Ala Phe His Leu Ser Ala Phe Gly Gln 50 55 60 Gly Phe Val Leu Arg Leu Ala Pro Asp Ala Ser Phe Leu Ala Pro Glu 65 70 75 80 Phe Lys Ile Glu Arg Leu Gly Gly Ser Ser Ala Ala Ala Gly Gly Glu 85 90 95 Pro Gly Leu Arg Gly Cys Phe Phe Ser Gly Thr Val Asn Gly Glu Arg 100 105 110 Glu Ser Leu Ala Ala Met Ser Cys Val Ala Gly Trp Ser Gly Ser Phe 115 120 125 Leu Leu Ala Gly Glu Glu Phe Thr Ile Gln Pro Gln Gly Ala Gly Asp 130 135 140 Ser Leu Asp Gln Pro His Arg Leu Gln Arg Trp Gly Pro Gly Gln Arg 145 150 155 160 Arg Glu Asp Pro Gly Leu Ala Ala Ala Glu Val Phe Pro Leu Pro Gln 165 170 175 Gly Leu Glu Trp Glu Val Glu Met Gly Asn Gly Gln Gly Gln Glu Arg 180 185 190 Ser Asp Asn Glu Glu Asp Lys Lys Gln Asp Lys Glu Gly Leu Leu Lys 195 200 205 Glu Thr Glu Asp Ser Arg Lys Val Pro Pro Pro Phe Gly Ser Lys Thr 210 215 220 Arg Ser Lys Arg Phe Val Ser Glu Ala Arg Phe Val Glu Thr Leu Leu 225 230 235 240 Val Ala Asp Ala Ser Met Ala Ala Phe Tyr Gly Thr Asp Leu Gln Asn 245 250 255 His Ile Leu Thr Val Met Ser Met Ala Ala Arg Ile Tyr Lys His Pro 260 265 270 Ser Ile Arg Asn Ser Val Asn Leu Val Val Val Lys Val Leu Ile Val 275 280 285 Glu Lys Glu Arg Trp Gly Pro Glu Val Ser Asp Asn Gly Gly Leu Thr 290 295 300 Leu Arg Asn Phe Cys Ser Trp Gln Arg Arg Phe Asn Lys Pro Ser Asp 305 310 315 320 Arg His Pro Glu His Tyr Asp Thr Ala Ile Leu Phe Thr Arg Gln Asn 325 330 335 Phe Cys Gly Lys Gly Glu Gln Cys Asp Thr Leu Gly Met Ala Asp Val 340 345 350 Gly Thr Ile Cys Asp Pro Asp Lys Ser Cys Ser Val Ile Lys Asp Glu 355 360 365 Gly Leu Gln Ala Ala Tyr Thr Leu Ala His Glu Leu Gly His Val Leu 370 375 380 Ser Met Pro His Asp Asp Ser Lys Pro Cys Val Arg Leu Phe Gly Pro 385 390 395 400 Met Gly Lys Tyr His Met Met Ala Pro Phe Phe Ile His Val Asn Lys 405 410 415 Thr Leu Pro Trp Ser Pro Cys Ser Ala Val Tyr Leu Thr Glu Leu Leu 420 425 430 Asp Asp Gly His Gly Asp Cys Leu Leu Asp Ala Pro Thr Ser Val Leu 435 440 445 Pro Leu Pro Thr Gly Leu Pro Gly His Ser Thr Leu Tyr Glu Leu Asp 450 455 460 Gln Gln Cys Lys Gln Ile Phe Gly Pro Asp Phe Arg His Cys Pro Asn 465 470 475 480 Thr Ser Val Glu Asp Ile Cys Val Gln Leu Cys Ala Arg His Arg Asp 485 490 495 Ser Asp Glu Pro Ile Cys His Thr Lys Asn Gly Ser Leu Leu Trp Ala 500 505 510 Asp Gly Thr Pro Cys Gly Pro Gly His Leu Cys Leu Asp Gly Ser Cys 515 520 525 Val Leu Lys Glu Asp Val Glu Asn Pro Lys Ala Val Val Asp Gly Asp 530 535 540 Trp Gly Pro Trp Arg Pro Trp Gly Gln Cys Ser Arg Thr Cys Gly Gly 545 550 555 560 Gly Ile Gln Phe Ser Asn Arg Glu Cys Asp Asn Pro Met Pro Gln Asn 565 570 575 Gly Gly Arg Phe Cys Leu Gly Glu Arg Val Lys Tyr Gln Ser Cys Asn 580 585 590 Thr Glu Glu Cys Pro Pro Asn Gly Lys Ser Phe Arg Glu Gln Gln Cys 595 600 605 Glu Lys Tyr Asn Ala Tyr Asn His Thr Asp Leu Asp Gly Asn Phe Leu 610 615 620 Gln Trp Val Pro Lys Tyr Ser Gly Val Ser Pro Arg Asp Arg Cys Lys 625 630 635 640 Leu Phe Cys Arg Ala Arg Gly Arg Ser Glu Phe Lys Val Phe Glu Ala 645 650 655 Lys Val Ile Asp Gly Thr Leu Cys Gly Pro Asp Thr Leu Ser Ile Cys 660 665 670 Val Arg Gly Gln Cys Val Lys Ala Gly Cys Asp His Val Val Asn Ser 675 680 685 Pro Lys Lys Leu Asp Lys Cys Gly Val Cys Gly Gly Lys Gly Thr Ala 690 695 700 Cys Arg Lys Ile Ser Gly Ser Phe Thr Pro Phe Ser Tyr Gly Tyr Asn 705 710 715 720 Asp Ile Val Thr Ile Pro Ala Gly Ala Thr Asn Ile Asp Val Lys Gln 725 730 735 Arg Ser His Pro Gly Val Arg Asn Asp Gly Ser Tyr Leu Ala Leu Lys 740 745 750 Thr Ala Asn Gly Gln Tyr Leu Leu Asn Gly Asn Leu Ala Ile Ser Ala 755 760 765 Ile Glu Gln Asp Ile Leu Val Lys Gly Thr Ile Leu Lys Tyr Ser Gly 770 775 780 Ser Met Ala Thr Leu Glu Arg Leu Gln Ser Phe Gln Ala Leu Pro Glu 785 790 795 800 Pro Leu Thr Val Gln Leu Leu Thr Val Ser Gly Glu Val Phe Pro Pro 805 810 815 Lys Val Arg Tyr Thr Phe Phe Val Pro Asn Asp Met Asp Phe Ser Val 820 825 830 Gln Asn Ser Lys Glu Arg Ala Thr Thr Asn Ile Ile Gln Ser Leu Pro 835 840 845 Ser Ala Glu Trp Val Leu Gly Asp Trp Ser Glu Cys Pro Ser Thr Cys 850 855 860 Arg Gly Ser Trp Gln Arg Arg Thr Val Glu Cys Arg Asp Pro Ser Gly 865 870 875 880 Gln Ala Ser Asp Thr Cys Asp Glu Ala Leu Lys Pro Glu Asp Ala Lys 885 890 895 Pro Cys Gly Ser Gln Pro Cys Pro Leu 900 905 <210> SEQ ID NO 10 <211> LENGTH: 739 <212> TYPE: DNA <213> ORGANISM: Homo sapiens ADAMTS-8 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (3)..(737) <400> SEQUENCE: 10 cg agg gca gaa ggc gct agc gag ccg cca ccg ccc ctg ggg gcc acg 47 Arg Ala Glu Gly Ala Ser Glu Pro Pro Pro Pro Leu Gly Ala Thr 1 5 10 15 agt agg acc aag cgg ttt gtg tct gag gcg cgc ttc gtg gag acg ctg 95 Ser Arg Thr Lys Arg Phe Val Ser Glu Ala Arg Phe Val Glu Thr Leu 20 25 30 ctg gtg gcc gat gcg tcc atg gct gcc ttc tac ggg gcc gac ctg cag 143 Leu Val Ala Asp Ala Ser Met Ala Ala Phe Tyr Gly Ala Asp Leu Gln 35 40 45 aac cac atc ctg acg tta atg tct gtg gca gcc cga atc tac aag cac 191 Asn His Ile Leu Thr Leu Met Ser Val Ala Ala Arg Ile Tyr Lys His 50 55 60 ccc agc atc aag aat tcc atc aac ctg atg gtg gta aaa gtg ctg atc 239 Pro Ser Ile Lys Asn Ser Ile Asn Leu Met Val Val Lys Val Leu Ile 65 70 75 gta gaa gat gaa aaa tgg ggc cca gag gtg tcc gac aat ggg ggg ctt 287 Val Glu Asp Glu Lys Trp Gly Pro Glu Val Ser Asp Asn Gly Gly Leu 80 85 90 95 aca ctg cgt aac ttc tgc aac tgg cag cgg cgt ttc aac cag ccc agc 335 Thr Leu Arg Asn Phe Cys Asn Trp Gln Arg Arg Phe Asn Gln Pro Ser 100 105 110 gac cgc cac cca gag cac tac gac acg gcc atc ctg ctc acc aga cag 383 Asp Arg His Pro Glu His Tyr Asp Thr Ala Ile Leu Leu Thr Arg Gln 115 120 125 aac ttc tgt ggg cag gag ggg ctg tgt gac acc ctg ggt gtg gca gac 431 Asn Phe Cys Gly Gln Glu Gly Leu Cys Asp Thr Leu Gly Val Ala Asp 130 135 140 atc ggg acc att tgt gac ccc aac aaa agc tgc tcc gtg atc gag gat 479 Ile Gly Thr Ile Cys Asp Pro Asn Lys Ser Cys Ser Val Ile Glu Asp 145 150 155 gag ggg ctc cag gcg gcc cac acc ctg gcc cat gaa cta ggg cac gtc 527 Glu Gly Leu Gln Ala Ala His Thr Leu Ala His Glu Leu Gly His Val 160 165 170 175 ctc agc atg ccc cac gac gac tcc aag ccc tgc aca cgg ctc ttc ggg 575 Leu Ser Met Pro His Asp Asp Ser Lys Pro Cys Thr Arg Leu Phe Gly 180 185 190 ccc atg ggc aag cac cac gtg atg gca ccg ctg ttc gtc cac ctg aac 623 Pro Met Gly Lys His His Val Met Ala Pro Leu Phe Val His Leu Asn 195 200 205 cag acg ctg ccc tgg tcc ccc tgc agc gcc atg ttc tca ggc tgc cac 671 Gln Thr Leu Pro Trp Ser Pro Cys Ser Ala Met Phe Ser Gly Cys His 210 215 220 ctg cag ggg tgg atc cat ttc aag tat tta tgc aaa tgt gtc tct gaa 719 Leu Gln Gly Trp Ile His Phe Lys Tyr Leu Cys Lys Cys Val Ser Glu 225 230 235 cta aag tgt gat ctt atg cc 739 Leu Lys Cys Asp Leu Met 240 245 <210> SEQ ID NO 11 <211> LENGTH: 245 <212> TYPE: PRT <213> ORGANISM: Homo sapiens ADAMTS-8 <400> SEQUENCE: 11 Arg Ala Glu Gly Ala Ser Glu Pro Pro Pro Pro Leu Gly Ala Thr Ser 1 5 10 15 Arg Thr Lys Arg Phe Val Ser Glu Ala Arg Phe Val Glu Thr Leu Leu 20 25 30 Val Ala Asp Ala Ser Met Ala Ala Phe Tyr Gly Ala Asp Leu Gln Asn 35 40 45 His Ile Leu Thr Leu Met Ser Val Ala Ala Arg Ile Tyr Lys His Pro 50 55 60 Ser Ile Lys Asn Ser Ile Asn Leu Met Val Val Lys Val Leu Ile Val 65 70 75 80 Glu Asp Glu Lys Trp Gly Pro Glu Val Ser Asp Asn Gly Gly Leu Thr 85 90 95 Leu Arg Asn Phe Cys Asn Trp Gln Arg Arg Phe Asn Gln Pro Ser Asp 100 105 110 Arg His Pro Glu His Tyr Asp Thr Ala Ile Leu Leu Thr Arg Gln Asn 115 120 125 Phe Cys Gly Gln Glu Gly Leu Cys Asp Thr Leu Gly Val Ala Asp Ile 130 135 140 Gly Thr Ile Cys Asp Pro Asn Lys Ser Cys Ser Val Ile Glu Asp Glu 145 150 155 160 Gly Leu Gln Ala Ala His Thr Leu Ala His Glu Leu Gly His Val Leu 165 170 175 Ser Met Pro His Asp Asp Ser Lys Pro Cys Thr Arg Leu Phe Gly Pro 180 185 190 Met Gly Lys His His Val Met Ala Pro Leu Phe Val His Leu Asn Gln 195 200 205 Thr Leu Pro Trp Ser Pro Cys Ser Ala Met Phe Ser Gly Cys His Leu 210 215 220 Gln Gly Trp Ile His Phe Lys Tyr Leu Cys Lys Cys Val Ser Glu Leu 225 230 235 240 Lys Cys Asp Leu Met 245 <210> SEQ ID NO 12 <211> LENGTH: 5804 <212> TYPE: DNA <213> ORGANISM: Homo sapiens ADAMTS-9 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (3)..(5648) <221> NAME/KEY: misc_feature <222> LOCATION: (1406) <223> OTHER INFORMATION: n=T <221> NAME/KEY: misc_feature <222> LOCATION: (1563) <223> OTHER INFORMATION: n=T <400> SEQUENCE: 12 ga agc acc atg cag ttt gta tcc tgg gcc aca ctg cta acg ctc ctg 47 Ser Thr Met Gln Phe Val Ser Trp Ala Thr Leu Leu Thr Leu Leu 1 5 10 15 gtg cgg gac ctg gcc gag atg ggg agc cca gac gcc gcg gcg gcc gtg 95 Val Arg Asp Leu Ala Glu Met Gly Ser Pro Asp Ala Ala Ala Ala Val 20 25 30 cgc aag gac agg ctg cac ccg agg caa gtg aaa tta tta gag acc ctg 143 Arg Lys Asp Arg Leu His Pro Arg Gln Val Lys Leu Leu Glu Thr Leu 35 40 45 agc gaa tac gaa atc gtg tct ccc atc cga gtg aac gct ctc gga gaa 191 Ser Glu Tyr Glu Ile Val Ser Pro Ile Arg Val Asn Ala Leu Gly Glu 50 55 60 ccc ttt ccc acg aac gtc cac ttc aaa aga acg cga cgg agc att aac 239 Pro Phe Pro Thr Asn Val His Phe Lys Arg Thr Arg Arg Ser Ile Asn 65 70 75 tct gcc act gac ccc tgg cct gcc ttc gcc tcc tcc tct tcc tcc tct 287 Ser Ala Thr Asp Pro Trp Pro Ala Phe Ala Ser Ser Ser Ser Ser Ser 80 85 90 95 acc tcc tcc cag gcg cat tac cgc ctc tct gcc ttc ggc cag cag ttt 335 Thr Ser Ser Gln Ala His Tyr Arg Leu Ser Ala Phe Gly Gln Gln Phe 100 105 110 cta ttt aat ctc acc gcc aat gcc gga ttt atc gct cca ctg ttc act 383 Leu Phe Asn Leu Thr Ala Asn Ala Gly Phe Ile Ala Pro Leu Phe Thr 115 120 125 gtc acc ctc ctt ggg acg ccc ggg gtg aat cag acc aag ttt tat tcc 431 Val Thr Leu Leu Gly Thr Pro Gly Val Asn Gln Thr Lys Phe Tyr Ser 130 135 140 gaa gag gaa gcg gaa cta aag cac tgt ttc tac aaa agg cta tgt caa 479 Glu Glu Glu Ala Glu Leu Lys His Cys Phe Tyr Lys Arg Leu Cys Gln 145 150 155 tac caa ctc cga gca cac ggc cgt cat cag cct ctg ctc agg aat gaa 527 Tyr Gln Leu Arg Ala His Gly Arg His Gln Pro Leu Leu Arg Asn Glu 160 165 170 175 cac aaa aat agg cac agt aaa gac aag aag aaa acc aga gca aga aaa 575 His Lys Asn Arg His Ser Lys Asp Lys Lys Lys Thr Arg Ala Arg Lys 180 185 190 tgg gga gaa agg att aac ctg gct ggt gac gta gca gca tta aac agc 623 Trp Gly Glu Arg Ile Asn Leu Ala Gly Asp Val Ala Ala Leu Asn Ser 195 200 205 ggc tta gca aca gag gca ttt tct gct tat ggt aat aag acg gac aac 671 Gly Leu Ala Thr Glu Ala Phe Ser Ala Tyr Gly Asn Lys Thr Asp Asn 210 215 220 aca aga gaa aag agg acc cac aga agg aca aaa cgt ttt tta tcc tat 719 Thr Arg Glu Lys Arg Thr His Arg Arg Thr Lys Arg Phe Leu Ser Tyr 225 230 235 cca cgg ttt gta gaa gtc ttg gtg gtg gca gac aac aga atg gtt tca 767 Pro Arg Phe Val Glu Val Leu Val Val Ala Asp Asn Arg Met Val Ser 240 245 250 255 tac cat gga gaa aac ctt caa cac tat att tta act tta atg tca att 815 Tyr His Gly Glu Asn Leu Gln His Tyr Ile Leu Thr Leu Met Ser Ile 260 265 270 gta gcc tct atc tat aaa gac cca agt att gga aat tta att aat att 863 Val Ala Ser Ile Tyr Lys Asp Pro Ser Ile Gly Asn Leu Ile Asn Ile 275 280 285 gtt att gtg aac tta att gtg att cat aat gaa cag gat ggg cct tcc 911 Val Ile Val Asn Leu Ile Val Ile His Asn Glu Gln Asp Gly Pro Ser 290 295 300 ata tct ttt aat gct cag aca aca tta aaa aac ttt tgc cag tgg cag 959 Ile Ser Phe Asn Ala Gln Thr Thr Leu Lys Asn Phe Cys Gln Trp Gln 305 310 315 cat tcg aac agt cca ggt gga atc cat cat gat act gct gtt ctc tta 1007 His Ser Asn Ser Pro Gly Gly Ile His His Asp Thr Ala Val Leu Leu 320 325 330 335 aca aga cag gat atc tgc aga gct cac gac aaa tgt gat acc tta ggc 1055 Thr Arg Gln Asp Ile Cys Arg Ala His Asp Lys Cys Asp Thr Leu Gly 340 345 350 ctg gct gaa ctg gga acc att tgt gat ccc tat aga agc tgt tct att 1103 Leu Ala Glu Leu Gly Thr Ile Cys Asp Pro Tyr Arg Ser Cys Ser Ile 355 360 365 agt gaa gat agt gga ttg agt aca gct ttt acg atc gcc cat gag ctg 1151 Ser Glu Asp Ser Gly Leu Ser Thr Ala Phe Thr Ile Ala His Glu Leu 370 375 380 ggc cat gtg ttt aac atg cct cat gat gac aac aac aaa tgt aaa gaa 1199 Gly His Val Phe Asn Met Pro His Asp Asp Asn Asn Lys Cys Lys Glu 385 390 395 gaa gga gtt aag agt ccc cag cat gtc atg gct cca aca ctg aac ttc 1247 Glu Gly Val Lys Ser Pro Gln His Val Met Ala Pro Thr Leu Asn Phe 400 405 410 415 tac acc aac ccc tgg atg tgg tca aag tgt agt cga aaa tat atc act 1295 Tyr Thr Asn Pro Trp Met Trp Ser Lys Cys Ser Arg Lys Tyr Ile Thr 420 425 430 gag ttt tta gac act ggt tat ggc gag tgt ttg ctt aac gaa cct gaa 1343 Glu Phe Leu Asp Thr Gly Tyr Gly Glu Cys Leu Leu Asn Glu Pro Glu 435 440 445 tcc aga ccc tac cct ttg cct gtc caa ctg cca ggc atc ctt tac aac 1391 Ser Arg Pro Tyr Pro Leu Pro Val Gln Leu Pro Gly Ile Leu Tyr Asn 450 455 460 gtg aat aaa caa tgn gaa ttg att ttt gga cca ggt tct cag gtg tgc 1439 Val Asn Lys Gln Xaa Glu Leu Ile Phe Gly Pro Gly Ser Gln Val Cys 465 470 475 cca tat atg atg cag tgc aga cgg ctc tgg tgc aat aac gtc aat gga 1487 Pro Tyr Met Met Gln Cys Arg Arg Leu Trp Cys Asn Asn Val Asn Gly 480 485 490 495 gta cac aaa ggc tgc cgg act cag cac aca ccc tgg gcc gat ggg acg 1535 Val His Lys Gly Cys Arg Thr Gln His Thr Pro Trp Ala Asp Gly Thr 500 505 510 gag tgc gag cct gga aag cac tgc aag nat gga ttt tgt gtt ccc aaa 1583 Glu Cys Glu Pro Gly Lys His Cys Lys Xaa Gly Phe Cys Val Pro Lys 515 520 525 gaa atg gat gtc ccc gtg aca gat gga tcc tgg gga agt tgg agt ccc 1631 Glu Met Asp Val Pro Val Thr Asp Gly Ser Trp Gly Ser Trp Ser Pro 530 535 540 ttt gga acc tgc tcc aga aca tgt gga ggg ggc atc aaa aca gcc att 1679 Phe Gly Thr Cys Ser Arg Thr Cys Gly Gly Gly Ile Lys Thr Ala Ile 545 550 555 cga gag tgc aac aga cca gaa cca aaa aat ggt gga aaa tac tgt gta 1727 Arg Glu Cys Asn Arg Pro Glu Pro Lys Asn Gly Gly Lys Tyr Cys Val 560 565 570 575 gga cgt aga atg aaa ttt aag tcc tgc aac acg gag cca tgt ctc aag 1775 Gly Arg Arg Met Lys Phe Lys Ser Cys Asn Thr Glu Pro Cys Leu Lys 580 585 590 cag aag cga gac ttc cga gat gaa cag tgt gct cac ttt gac ggg aag 1823 Gln Lys Arg Asp Phe Arg Asp Glu Gln Cys Ala His Phe Asp Gly Lys 595 600 605 cat ttt aac atc aac ggt ctg ctt ccc aat gtg cgc tgg gtc cct aaa 1871 His Phe Asn Ile Asn Gly Leu Leu Pro Asn Val Arg Trp Val Pro Lys 610 615 620 tac agt gga att ctg atg aag gac cgg tgc aag ttg ttc tgc aga gtg 1919 Tyr Ser Gly Ile Leu Met Lys Asp Arg Cys Lys Leu Phe Cys Arg Val 625 630 635 gca ggg aac aca gcc tac tat cag ctt cga gac aga gtg ata gat gga 1967 Ala Gly Asn Thr Ala Tyr Tyr Gln Leu Arg Asp Arg Val Ile Asp Gly 640 645 650 655 act cct tgt ggc cag gac aca aat gat atc tgt gtc cag ggc ctt tgc 2015 Thr Pro Cys Gly Gln Asp Thr Asn Asp Ile Cys Val Gln Gly Leu Cys 660 665 670 cgg caa gct gga tgc gat cat gtt tta aac tca aaa gcc cgg aga gat 2063 Arg Gln Ala Gly Cys Asp His Val Leu Asn Ser Lys Ala Arg Arg Asp 675 680 685 aaa tgc ggg gtt tgt ggt ggc gat aat tct tca tgc aaa aca gtg gca 2111 Lys Cys Gly Val Cys Gly Gly Asp Asn Ser Ser Cys Lys Thr Val Ala 690 695 700 gga aca ttt aat aca gta cat tat ggt tac aat act gtg gtc cga att 2159 Gly Thr Phe Asn Thr Val His Tyr Gly Tyr Asn Thr Val Val Arg Ile 705 710 715 cca gct ggt gct acc aat att gat gtg cgg cag cac agt ttc tca ggg 2207 Pro Ala Gly Ala Thr Asn Ile Asp Val Arg Gln His Ser Phe Ser Gly 720 725 730 735 gaa aca gac gat gac aac tac tta gct tta tca agc agt aaa ggt gaa 2255 Glu Thr Asp Asp Asp Asn Tyr Leu Ala Leu Ser Ser Ser Lys Gly Glu 740 745 750 ttc ttg cta aat gga aac ttt gtt gtc aca atg gcc aaa agg gaa att 2303 Phe Leu Leu Asn Gly Asn Phe Val Val Thr Met Ala Lys Arg Glu Ile 755 760 765 cgc att ggg aat gct gtg gta gag tac agt ggg tcc gag act gcc gta 2351 Arg Ile Gly Asn Ala Val Val Glu Tyr Ser Gly Ser Glu Thr Ala Val 770 775 780 gaa aga att aac tca aca gat cgc att gag caa gaa ctt ttg ctt cag 2399 Glu Arg Ile Asn Ser Thr Asp Arg Ile Glu Gln Glu Leu Leu Leu Gln 785 790 795 gtt ttg tcg gtg gga aag ttg tac aac ccc gat gta cgc tat tct ttc 2447 Val Leu Ser Val Gly Lys Leu Tyr Asn Pro Asp Val Arg Tyr Ser Phe 800 805 810 815 aat att cca att gaa gat aaa cct cag cag ttt tac tgg aac agt cat 2495 Asn Ile Pro Ile Glu Asp Lys Pro Gln Gln Phe Tyr Trp Asn Ser His 820 825 830 ggg cca tgg caa gca tgc agt aaa ccc tgc caa ggg gaa cgg aaa cga 2543 Gly Pro Trp Gln Ala Cys Ser Lys Pro Cys Gln Gly Glu Arg Lys Arg 835 840 845 aaa ctt gtt tgc acc agg gaa tct gat cag ctt act gtt tct gat caa 2591 Lys Leu Val Cys Thr Arg Glu Ser Asp Gln Leu Thr Val Ser Asp Gln 850 855 860 aga tgc gat cgg ctg ccc cag cct gga cac att act gaa ccc tgt ggt 2639 Arg Cys Asp Arg Leu Pro Gln Pro Gly His Ile Thr Glu Pro Cys Gly 865 870 875 aca ggc tgt gac ctg agg tgg cat gtt gcc agc agg agt gaa tgt agt 2687 Thr Gly Cys Asp Leu Arg Trp His Val Ala Ser Arg Ser Glu Cys Ser 880 885 890 895 gcc cag tgt ggc ttg ggt tac cgc aca ttg gac atc tac tgt gcc aaa 2735 Ala Gln Cys Gly Leu Gly Tyr Arg Thr Leu Asp Ile Tyr Cys Ala Lys 900 905 910 tat agc agg ctg gat ggg aag act gag aag gtt gat gat ggt ttt tgc 2783 Tyr Ser Arg Leu Asp Gly Lys Thr Glu Lys Val Asp Asp Gly Phe Cys 915 920 925 agc agc cat ccc aaa cca agc aac cgt gaa aaa tgc tca ggg gaa tgt 2831 Ser Ser His Pro Lys Pro Ser Asn Arg Glu Lys Cys Ser Gly Glu Cys 930 935 940 aac acg ggt ggc tgg cgc tat tct gcc tgg act gaa tgt tca aaa agc 2879 Asn Thr Gly Gly Trp Arg Tyr Ser Ala Trp Thr Glu Cys Ser Lys Ser 945 950 955 tgt gac ggt ggg acc cag agg aga agg gct att tgt gtc aat acc cga 2927 Cys Asp Gly Gly Thr Gln Arg Arg Arg Ala Ile Cys Val Asn Thr Arg 960 965 970 975 aat gat gta ctg gat gac agc aaa tgc aca cat caa gag aaa gtt acc 2975 Asn Asp Val Leu Asp Asp Ser Lys Cys Thr His Gln Glu Lys Val Thr 980 985 990 att cag agg tgc agt gag ttc cct tgt cca cag tgg aaa tct gga gac 3023 Ile Gln Arg Cys Ser Glu Phe Pro Cys Pro Gln Trp Lys Ser Gly Asp 995 1000 1005 tgg tca gag tgc ttg gtc acc tgt gga aaa ggg cat aag cac agc cag 3071 Trp Ser Glu Cys Leu Val Thr Cys Gly Lys Gly His Lys His Ser Gln 1010 1015 1020 gtc tgg tgt cag ttt ggt gaa gat cga tta aat gat aga atg tgt gac 3119 Val Trp Cys Gln Phe Gly Glu Asp Arg Leu Asn Asp Arg Met Cys Asp 1025 1030 1035 cct gag acc aag cca aca tct atg cag act tgt cag cag ccg gaa tgt 3167 Pro Glu Thr Lys Pro Thr Ser Met Gln Thr Cys Gln Gln Pro Glu Cys 1040 1045 1050 1055 gca tcc tgg cag gcg ggt ccc tgg gta cag tgc agt gtc act tgt gga 3215 Ala Ser Trp Gln Ala Gly Pro Trp Val Gln Cys Ser Val Thr Cys Gly 1060 1065 1070 cag gga tac cag cta aga gca gtg aaa tgc atc att ggg act tat atg 3263 Gln Gly Tyr Gln Leu Arg Ala Val Lys Cys Ile Ile Gly Thr Tyr Met 1075 1080 1085 tca gtg gta gat gac aat gac tgt aat gca gca act aga cca act gat 3311 Ser Val Val Asp Asp Asn Asp Cys Asn Ala Ala Thr Arg Pro Thr Asp 1090 1095 1100 acc cag gac tgt gaa tta cca tca tgt cat cct ccc cca gct gcc ccg 3359 Thr Gln Asp Cys Glu Leu Pro Ser Cys His Pro Pro Pro Ala Ala Pro 1105 1110 1115 gaa acg agg aga agc aca tac agt gca cca aga acc cag tgg cga ttt 3407 Glu Thr Arg Arg Ser Thr Tyr Ser Ala Pro Arg Thr Gln Trp Arg Phe 1120 1125 1130 1135 ggg tct tgg acc cca tgc tca gcc act tgt ggg aaa ggt acc cgg atg 3455 Gly Ser Trp Thr Pro Cys Ser Ala Thr Cys Gly Lys Gly Thr Arg Met 1140 1145 1150 aga tac gtc agc tgc cga gat gag aat ggc tct gtg gct gac gag agt 3503 Arg Tyr Val Ser Cys Arg Asp Glu Asn Gly Ser Val Ala Asp Glu Ser 1155 1160 1165 gcc tgt gct acc ctg cct aga cca gtg gca aag gaa gaa tgt tct gtg 3551 Ala Cys Ala Thr Leu Pro Arg Pro Val Ala Lys Glu Glu Cys Ser Val 1170 1175 1180 aca ccc tgt ggg caa tgg aag gcc ttg gac tgg agc tct tgc tct gtg 3599 Thr Pro Cys Gly Gln Trp Lys Ala Leu Asp Trp Ser Ser Cys Ser Val 1185 1190 1195 acc tgt ggg caa ggt agg gca acc cgg caa gtg atg tgt gtc aac tac 3647 Thr Cys Gly Gln Gly Arg Ala Thr Arg Gln Val Met Cys Val Asn Tyr 1200 1205 1210 1215 agt gac cac gtg atc gat cgg agt gag tgt gac cag gat tat atc cca 3695 Ser Asp His Val Ile Asp Arg Ser Glu Cys Asp Gln Asp Tyr Ile Pro 1220 1225 1230 gaa act gac cag gac tgt tcc atg tca cca tgc cct caa agg acc cca 3743 Glu Thr Asp Gln Asp Cys Ser Met Ser Pro Cys Pro Gln Arg Thr Pro 1235 1240 1245 gac agt ggc tta gct cag cac ccc ttc caa aat gag gac tat cgt ccc 3791 Asp Ser Gly Leu Ala Gln His Pro Phe Gln Asn Glu Asp Tyr Arg Pro 1250 1255 1260 cgg agc gcc agc ccc agc cgc acc cat gtg ctc ggt gga aac cag tgg 3839 Arg Ser Ala Ser Pro Ser Arg Thr His Val Leu Gly Gly Asn Gln Trp 1265 1270 1275 aga act ggc ccc tgg gga gca tgt tcc agt acc tgt gct ggc gga tcc 3887 Arg Thr Gly Pro Trp Gly Ala Cys Ser Ser Thr Cys Ala Gly Gly Ser 1280 1285 1290 1295 cag cgg cgt gtt gtt gta tgt cag gat gaa aat gga tac acc gca aac 3935 Gln Arg Arg Val Val Val Cys Gln Asp Glu Asn Gly Tyr Thr Ala Asn 1300 1305 1310 gac tgt gtg gag aga ata aaa cct gat gag caa aga gcc tgt gaa tcc 3983 Asp Cys Val Glu Arg Ile Lys Pro Asp Glu Gln Arg Ala Cys Glu Ser 1315 1320 1325 ggc cct tgt cct cag tgg gct tat ggc aac tgg gga gag tgc act aag 4031 Gly Pro Cys Pro Gln Trp Ala Tyr Gly Asn Trp Gly Glu Cys Thr Lys 1330 1335 1340 ctg tgt ggt gga ggc ata aga aca aga ctg gtg gtc tct cag cgg tcc 4079 Leu Cys Gly Gly Gly Ile Arg Thr Arg Leu Val Val Ser Gln Arg Ser 1345 1350 1355 aac ggt gaa cgg ttt cca gat ttg agc tgt gaa att ctt gat aaa cct 4127 Asn Gly Glu Arg Phe Pro Asp Leu Ser Cys Glu Ile Leu Asp Lys Pro 1360 1365 1370 1375 ccc gat cgt gag cag tgt aac aca cat gct tgt cca cac gac gct gca 4175 Pro Asp Arg Glu Gln Cys Asn Thr His Ala Cys Pro His Asp Ala Ala 1380 1385 1390 tgg agt act ggc cct tgg agc tcg tgt tct gtc tct tgt ggt cga ggg 4223 Trp Ser Thr Gly Pro Trp Ser Ser Cys Ser Val Ser Cys Gly Arg Gly 1395 1400 1405 cat aaa caa cga aat gtt tac tgc atg gca aaa gat gga agc cat tta 4271 His Lys Gln Arg Asn Val Tyr Cys Met Ala Lys Asp Gly Ser His Leu 1410 1415 1420 gaa agt gat tac tgt aag cac ctg gct aag cca cat ggg cac aga aag 4319 Glu Ser Asp Tyr Cys Lys His Leu Ala Lys Pro His Gly His Arg Lys 1425 1430 1435 tgc cga gga gga aga tgc ccc aaa tgg aaa gct ggc gct tgg agt cag 4367 Cys Arg Gly Gly Arg Cys Pro Lys Trp Lys Ala Gly Ala Trp Ser Gln 1440 1445 1450 1455 tgc tct gtg tcc atg ggc cga ggc gta cag cag agg cat gtg ggc tgt 4415 Cys Ser Val Ser Met Gly Arg Gly Val Gln Gln Arg His Val Gly Cys 1460 1465 1470 cag atc gga aca cac aaa ata gcc aga gag acc gag tgc aac cca tac 4463 Gln Ile Gly Thr His Lys Ile Ala Arg Glu Thr Glu Cys Asn Pro Tyr 1475 1480 1485 acc aga ccg gag tcg gaa tgc gaa tgc caa ggc cca cgg tgt ccc ctt 4511 Thr Arg Pro Glu Ser Glu Cys Glu Cys Gln Gly Pro Arg Cys Pro Leu 1490 1495 1500 tac act tgg agg gca gag gaa tgg caa gaa tgc acc aag acc tgc ggc 4559 Tyr Thr Trp Arg Ala Glu Glu Trp Gln Glu Cys Thr Lys Thr Cys Gly 1505 1510 1515 gaa ggc tcc agg tac cgc aag gtg gtg tgt gtg gat gac aac aaa aac 4607 Glu Gly Ser Arg Tyr Arg Lys Val Val Cys Val Asp Asp Asn Lys Asn 1520 1525 1530 1535 gag gtg cat ggg gca cgc tgt gac gtg agc aag cgg ccg gtg gac cgt 4655 Glu Val His Gly Ala Arg Cys Asp Val Ser Lys Arg Pro Val Asp Arg 1540 1545 1550 gaa agc tgt agt ttg caa ccc tgc gag tat gtc tgg act aca gga gaa 4703 Glu Ser Cys Ser Leu Gln Pro Cys Glu Tyr Val Trp Thr Thr Gly Glu 1555 1560 1565 tgg tca gag tgc tca gtg acc tgt gga aaa ggc tac aaa caa agg ctt 4751 Trp Ser Glu Cys Ser Val Thr Cys Gly Lys Gly Tyr Lys Gln Arg Leu 1570 1575 1580 gtc tcg tgc agc gag att tac acc ggg aaa gag aat tat gaa tac agc 4799 Val Ser Cys Ser Glu Ile Tyr Thr Gly Lys Glu Asn Tyr Glu Tyr Ser 1585 1590 1595 tac caa acc acc atc aac tgc cca ggc acg cag ccc ccc agt gtt cac 4847 Tyr Gln Thr Thr Ile Asn Cys Pro Gly Thr Gln Pro Pro Ser Val His 1600 1605 1610 1615 ccc tgt tac ctg agg gag tgc cct gtc tcg gcc acc tgg aga gtt ggc 4895 Pro Cys Tyr Leu Arg Glu Cys Pro Val Ser Ala Thr Trp Arg Val Gly 1620 1625 1630 aac tgg ggg agc tgc tca gtg tct tgt ggt gtt gga gtg atg cag aga 4943 Asn Trp Gly Ser Cys Ser Val Ser Cys Gly Val Gly Val Met Gln Arg 1635 1640 1645 tct gtg caa tgt tta acc aat gag gac caa ccc agc cac tta tgc cac 4991 Ser Val Gln Cys Leu Thr Asn Glu Asp Gln Pro Ser His Leu Cys His 1650 1655 1660 act gat ctg aag cca gaa gaa cga aaa acc tgc cgt aat gtc tat aac 5039 Thr Asp Leu Lys Pro Glu Glu Arg Lys Thr Cys Arg Asn Val Tyr Asn 1665 1670 1675 tgt gag tta ccc cag aat tgc aag gag gta aaa aga ctt aaa ggt gcc 5087 Cys Glu Leu Pro Gln Asn Cys Lys Glu Val Lys Arg Leu Lys Gly Ala 1680 1685 1690 1695 agt gaa gat ggt gaa tat ttc ctg atg att aga gga aag ctt ctg aag 5135 Ser Glu Asp Gly Glu Tyr Phe Leu Met Ile Arg Gly Lys Leu Leu Lys 1700 1705 1710 ata ttc tgt gcg ggg atg cac tct gac cac ccc aaa gag tac gtg aca 5183 Ile Phe Cys Ala Gly Met His Ser Asp His Pro Lys Glu Tyr Val Thr 1715 1720 1725 ctg gtg cat gga gac tct gag aat ttc tcc gag gtt tat ggg cac agg 5231 Leu Val His Gly Asp Ser Glu Asn Phe Ser Glu Val Tyr Gly His Arg 1730 1735 1740 tta cac aac cca aca gaa tgt ccc tat aac ggg agc cgg cgc gat gac 5279 Leu His Asn Pro Thr Glu Cys Pro Tyr Asn Gly Ser Arg Arg Asp Asp 1745 1750 1755 tgc caa tgt cgg aag gat tac acg gcc gct ggg ttt tcc agt ttt cag 5327 Cys Gln Cys Arg Lys Asp Tyr Thr Ala Ala Gly Phe Ser Ser Phe Gln 1760 1765 1770 1775 aaa atc aga ata gac ctg acc agc atg cag ata atc acc act gac tta 5375 Lys Ile Arg Ile Asp Leu Thr Ser Met Gln Ile Ile Thr Thr Asp Leu 1780 1785 1790 cag ttt gca agg aca agc gaa gga cat ccc gtc cct ttt gcc aca gcc 5423 Gln Phe Ala Arg Thr Ser Glu Gly His Pro Val Pro Phe Ala Thr Ala 1795 1800 1805 ggg gat tgc tac agc gct gcc aag tgc cca cag ggt cgt ttt agc atc 5471 Gly Asp Cys Tyr Ser Ala Ala Lys Cys Pro Gln Gly Arg Phe Ser Ile 1810 1815 1820 aac ctt tat gga acc ggc ttg tct tta act gaa tct gcc aga tgg ata 5519 Asn Leu Tyr Gly Thr Gly Leu Ser Leu Thr Glu Ser Ala Arg Trp Ile 1825 1830 1835 tca caa ggg aat tat gct gtc tct gac atc aag aag tcg ccg gat ggt 5567 Ser Gln Gly Asn Tyr Ala Val Ser Asp Ile Lys Lys Ser Pro Asp Gly 1840 1845 1850 1855 acc cga gtc gta ggg aaa tgc ggt ggt tac tgt gga aaa tgc act cca 5615 Thr Arg Val Val Gly Lys Cys Gly Gly Tyr Cys Gly Lys Cys Thr Pro 1860 1865 1870 tcc tct ggt act ggc ctg gag gtg cga gtt tta tagctaaggt gctttgaaga 5668 Ser Ser Gly Thr Gly Leu Glu Val Arg Val Leu 1875 1880 ggaagccatt atggatggat gaaggatagt aatgcaatac ctccacctta atttgggtgc 5728 atgtgtatgt gtgtgtgtgt ttgtgtgtga cttgtatgct tgtgtgtgta aatgtgtgta 5788 catatacata tataca 5804 <210> SEQ ID NO 13 <211> LENGTH: 1882 <212> TYPE: PRT <213> ORGANISM: Homo sapiens ADAMTS-9 <220> FEATURE: <221> NAME/KEY: MOD_RES <222> LOCATION: (468) <223> OTHER INFORMATION: Xaa = Cys <221> NAME/KEY: MOD_RES <222> LOCATION: (521) <223> OTHER INFORMATION: Xaa = Tyr <400> SEQUENCE: 13 Ser Thr Met Gln Phe Val Ser Trp Ala Thr Leu Leu Thr Leu Leu Val 1 5 10 15 Arg Asp Leu Ala Glu Met Gly Ser Pro Asp Ala Ala Ala Ala Val Arg 20 25 30 Lys Asp Arg Leu His Pro Arg Gln Val Lys Leu Leu Glu Thr Leu Ser 35 40 45 Glu Tyr Glu Ile Val Ser Pro Ile Arg Val Asn Ala Leu Gly Glu Pro 50 55 60 Phe Pro Thr Asn Val His Phe Lys Arg Thr Arg Arg Ser Ile Asn Ser 65 70 75 80 Ala Thr Asp Pro Trp Pro Ala Phe Ala Ser Ser Ser Ser Ser Ser Thr 85 90 95 Ser Ser Gln Ala His Tyr Arg Leu Ser Ala Phe Gly Gln Gln Phe Leu 100 105 110 Phe Asn Leu Thr Ala Asn Ala Gly Phe Ile Ala Pro Leu Phe Thr Val 115 120 125 Thr Leu Leu Gly Thr Pro Gly Val Asn Gln Thr Lys Phe Tyr Ser Glu 130 135 140 Glu Glu Ala Glu Leu Lys His Cys Phe Tyr Lys Arg Leu Cys Gln Tyr 145 150 155 160 Gln Leu Arg Ala His Gly Arg His Gln Pro Leu Leu Arg Asn Glu His 165 170 175 Lys Asn Arg His Ser Lys Asp Lys Lys Lys Thr Arg Ala Arg Lys Trp 180 185 190 Gly Glu Arg Ile Asn Leu Ala Gly Asp Val Ala Ala Leu Asn Ser Gly 195 200 205 Leu Ala Thr Glu Ala Phe Ser Ala Tyr Gly Asn Lys Thr Asp Asn Thr 210 215 220 Arg Glu Lys Arg Thr His Arg Arg Thr Lys Arg Phe Leu Ser Tyr Pro 225 230 235 240 Arg Phe Val Glu Val Leu Val Val Ala Asp Asn Arg Met Val Ser Tyr 245 250 255 His Gly Glu Asn Leu Gln His Tyr Ile Leu Thr Leu Met Ser Ile Val 260 265 270 Ala Ser Ile Tyr Lys Asp Pro Ser Ile Gly Asn Leu Ile Asn Ile Val 275 280 285 Ile Val Asn Leu Ile Val Ile His Asn Glu Gln Asp Gly Pro Ser Ile 290 295 300 Ser Phe Asn Ala Gln Thr Thr Leu Lys Asn Phe Cys Gln Trp Gln His 305 310 315 320 Ser Asn Ser Pro Gly Gly Ile His His Asp Thr Ala Val Leu Leu Thr 325 330 335 Arg Gln Asp Ile Cys Arg Ala His Asp Lys Cys Asp Thr Leu Gly Leu 340 345 350 Ala Glu Leu Gly Thr Ile Cys Asp Pro Tyr Arg Ser Cys Ser Ile Ser 355 360 365 Glu Asp Ser Gly Leu Ser Thr Ala Phe Thr Ile Ala His Glu Leu Gly 370 375 380 His Val Phe Asn Met Pro His Asp Asp Asn Asn Lys Cys Lys Glu Glu 385 390 395 400 Gly Val Lys Ser Pro Gln His Val Met Ala Pro Thr Leu Asn Phe Tyr 405 410 415 Thr Asn Pro Trp Met Trp Ser Lys Cys Ser Arg Lys Tyr Ile Thr Glu 420 425 430 Phe Leu Asp Thr Gly Tyr Gly Glu Cys Leu Leu Asn Glu Pro Glu Ser 435 440 445 Arg Pro Tyr Pro Leu Pro Val Gln Leu Pro Gly Ile Leu Tyr Asn Val 450 455 460 Asn Lys Gln Xaa Glu Leu Ile Phe Gly Pro Gly Ser Gln Val Cys Pro 465 470 475 480 Tyr Met Met Gln Cys Arg Arg Leu Trp Cys Asn Asn Val Asn Gly Val 485 490 495 His Lys Gly Cys Arg Thr Gln His Thr Pro Trp Ala Asp Gly Thr Glu 500 505 510 Cys Glu Pro Gly Lys His Cys Lys Xaa Gly Phe Cys Val Pro Lys Glu 515 520 525 Met Asp Val Pro Val Thr Asp Gly Ser Trp Gly Ser Trp Ser Pro Phe 530 535 540 Gly Thr Cys Ser Arg Thr Cys Gly Gly Gly Ile Lys Thr Ala Ile Arg 545 550 555 560 Glu Cys Asn Arg Pro Glu Pro Lys Asn Gly Gly Lys Tyr Cys Val Gly 565 570 575 Arg Arg Met Lys Phe Lys Ser Cys Asn Thr Glu Pro Cys Leu Lys Gln 580 585 590 Lys Arg Asp Phe Arg Asp Glu Gln Cys Ala His Phe Asp Gly Lys His 595 600 605 Phe Asn Ile Asn Gly Leu Leu Pro Asn Val Arg Trp Val Pro Lys Tyr 610 615 620 Ser Gly Ile Leu Met Lys Asp Arg Cys Lys Leu Phe Cys Arg Val Ala 625 630 635 640 Gly Asn Thr Ala Tyr Tyr Gln Leu Arg Asp Arg Val Ile Asp Gly Thr 645 650 655 Pro Cys Gly Gln Asp Thr Asn Asp Ile Cys Val Gln Gly Leu Cys Arg 660 665 670 Gln Ala Gly Cys Asp His Val Leu Asn Ser Lys Ala Arg Arg Asp Lys 675 680 685 Cys Gly Val Cys Gly Gly Asp Asn Ser Ser Cys Lys Thr Val Ala Gly 690 695 700 Thr Phe Asn Thr Val His Tyr Gly Tyr Asn Thr Val Val Arg Ile Pro 705 710 715 720 Ala Gly Ala Thr Asn Ile Asp Val Arg Gln His Ser Phe Ser Gly Glu 725 730 735 Thr Asp Asp Asp Asn Tyr Leu Ala Leu Ser Ser Ser Lys Gly Glu Phe 740 745 750 Leu Leu Asn Gly Asn Phe Val Val Thr Met Ala Lys Arg Glu Ile Arg 755 760 765 Ile Gly Asn Ala Val Val Glu Tyr Ser Gly Ser Glu Thr Ala Val Glu 770 775 780 Arg Ile Asn Ser Thr Asp Arg Ile Glu Gln Glu Leu Leu Leu Gln Val 785 790 795 800 Leu Ser Val Gly Lys Leu Tyr Asn Pro Asp Val Arg Tyr Ser Phe Asn 805 810 815 Ile Pro Ile Glu Asp Lys Pro Gln Gln Phe Tyr Trp Asn Ser His Gly 820 825 830 Pro Trp Gln Ala Cys Ser Lys Pro Cys Gln Gly Glu Arg Lys Arg Lys 835 840 845 Leu Val Cys Thr Arg Glu Ser Asp Gln Leu Thr Val Ser Asp Gln Arg 850 855 860 Cys Asp Arg Leu Pro Gln Pro Gly His Ile Thr Glu Pro Cys Gly Thr 865 870 875 880 Gly Cys Asp Leu Arg Trp His Val Ala Ser Arg Ser Glu Cys Ser Ala 885 890 895 Gln Cys Gly Leu Gly Tyr Arg Thr Leu Asp Ile Tyr Cys Ala Lys Tyr 900 905 910 Ser Arg Leu Asp Gly Lys Thr Glu Lys Val Asp Asp Gly Phe Cys Ser 915 920 925 Ser His Pro Lys Pro Ser Asn Arg Glu Lys Cys Ser Gly Glu Cys Asn 930 935 940 Thr Gly Gly Trp Arg Tyr Ser Ala Trp Thr Glu Cys Ser Lys Ser Cys 945 950 955 960 Asp Gly Gly Thr Gln Arg Arg Arg Ala Ile Cys Val Asn Thr Arg Asn 965 970 975 Asp Val Leu Asp Asp Ser Lys Cys Thr His Gln Glu Lys Val Thr Ile 980 985 990 Gln Arg Cys Ser Glu Phe Pro Cys Pro Gln Trp Lys Ser Gly Asp Trp 995 1000 1005 Ser Glu Cys Leu Val Thr Cys Gly Lys Gly His Lys His Ser Gln Val 1010 1015 1020 Trp Cys Gln Phe Gly Glu Asp Arg Leu Asn Asp Arg Met Cys Asp Pro 1025 1030 1035 1040 Glu Thr Lys Pro Thr Ser Met Gln Thr Cys Gln Gln Pro Glu Cys Ala 1045 1050 1055 Ser Trp Gln Ala Gly Pro Trp Val Gln Cys Ser Val Thr Cys Gly Gln 1060 1065 1070 Gly Tyr Gln Leu Arg Ala Val Lys Cys Ile Ile Gly Thr Tyr Met Ser 1075 1080 1085 Val Val Asp Asp Asn Asp Cys Asn Ala Ala Thr Arg Pro Thr Asp Thr 1090 1095 1100 Gln Asp Cys Glu Leu Pro Ser Cys His Pro Pro Pro Ala Ala Pro Glu 1105 1110 1115 1120 Thr Arg Arg Ser Thr Tyr Ser Ala Pro Arg Thr Gln Trp Arg Phe Gly 1125 1130 1135 Ser Trp Thr Pro Cys Ser Ala Thr Cys Gly Lys Gly Thr Arg Met Arg 1140 1145 1150 Tyr Val Ser Cys Arg Asp Glu Asn Gly Ser Val Ala Asp Glu Ser Ala 1155 1160 1165 Cys Ala Thr Leu Pro Arg Pro Val Ala Lys Glu Glu Cys Ser Val Thr 1170 1175 1180 Pro Cys Gly Gln Trp Lys Ala Leu Asp Trp Ser Ser Cys Ser Val Thr 1185 1190 1195 1200 Cys Gly Gln Gly Arg Ala Thr Arg Gln Val Met Cys Val Asn Tyr Ser 1205 1210 1215 Asp His Val Ile Asp Arg Ser Glu Cys Asp Gln Asp Tyr Ile Pro Glu 1220 1225 1230 Thr Asp Gln Asp Cys Ser Met Ser Pro Cys Pro Gln Arg Thr Pro Asp 1235 1240 1245 Ser Gly Leu Ala Gln His Pro Phe Gln Asn Glu Asp Tyr Arg Pro Arg 1250 1255 1260 Ser Ala Ser Pro Ser Arg Thr His Val Leu Gly Gly Asn Gln Trp Arg 1265 1270 1275 1280 Thr Gly Pro Trp Gly Ala Cys Ser Ser Thr Cys Ala Gly Gly Ser Gln 1285 1290 1295 Arg Arg Val Val Val Cys Gln Asp Glu Asn Gly Tyr Thr Ala Asn Asp 1300 1305 1310 Cys Val Glu Arg Ile Lys Pro Asp Glu Gln Arg Ala Cys Glu Ser Gly 1315 1320 1325 Pro Cys Pro Gln Trp Ala Tyr Gly Asn Trp Gly Glu Cys Thr Lys Leu 1330 1335 1340 Cys Gly Gly Gly Ile Arg Thr Arg Leu Val Val Ser Gln Arg Ser Asn 1345 1350 1355 1360 Gly Glu Arg Phe Pro Asp Leu Ser Cys Glu Ile Leu Asp Lys Pro Pro 1365 1370 1375 Asp Arg Glu Gln Cys Asn Thr His Ala Cys Pro His Asp Ala Ala Trp 1380 1385 1390 Ser Thr Gly Pro Trp Ser Ser Cys Ser Val Ser Cys Gly Arg Gly His 1395 1400 1405 Lys Gln Arg Asn Val Tyr Cys Met Ala Lys Asp Gly Ser His Leu Glu 1410 1415 1420 Ser Asp Tyr Cys Lys His Leu Ala Lys Pro His Gly His Arg Lys Cys 1425 1430 1435 1440 Arg Gly Gly Arg Cys Pro Lys Trp Lys Ala Gly Ala Trp Ser Gln Cys 1445 1450 1455 Ser Val Ser Met Gly Arg Gly Val Gln Gln Arg His Val Gly Cys Gln 1460 1465 1470 Ile Gly Thr His Lys Ile Ala Arg Glu Thr Glu Cys Asn Pro Tyr Thr 1475 1480 1485 Arg Pro Glu Ser Glu Cys Glu Cys Gln Gly Pro Arg Cys Pro Leu Tyr 1490 1495 1500 Thr Trp Arg Ala Glu Glu Trp Gln Glu Cys Thr Lys Thr Cys Gly Glu 1505 1510 1515 1520 Gly Ser Arg Tyr Arg Lys Val Val Cys Val Asp Asp Asn Lys Asn Glu 1525 1530 1535 Val His Gly Ala Arg Cys Asp Val Ser Lys Arg Pro Val Asp Arg Glu 1540 1545 1550 Ser Cys Ser Leu Gln Pro Cys Glu Tyr Val Trp Thr Thr Gly Glu Trp 1555 1560 1565 Ser Glu Cys Ser Val Thr Cys Gly Lys Gly Tyr Lys Gln Arg Leu Val 1570 1575 1580 Ser Cys Ser Glu Ile Tyr Thr Gly Lys Glu Asn Tyr Glu Tyr Ser Tyr 1585 1590 1595 1600 Gln Thr Thr Ile Asn Cys Pro Gly Thr Gln Pro Pro Ser Val His Pro 1605 1610 1615 Cys Tyr Leu Arg Glu Cys Pro Val Ser Ala Thr Trp Arg Val Gly Asn 1620 1625 1630 Trp Gly Ser Cys Ser Val Ser Cys Gly Val Gly Val Met Gln Arg Ser 1635 1640 1645 Val Gln Cys Leu Thr Asn Glu Asp Gln Pro Ser His Leu Cys His Thr 1650 1655 1660 Asp Leu Lys Pro Glu Glu Arg Lys Thr Cys Arg Asn Val Tyr Asn Cys 1665 1670 1675 1680 Glu Leu Pro Gln Asn Cys Lys Glu Val Lys Arg Leu Lys Gly Ala Ser 1685 1690 1695 Glu Asp Gly Glu Tyr Phe Leu Met Ile Arg Gly Lys Leu Leu Lys Ile 1700 1705 1710 Phe Cys Ala Gly Met His Ser Asp His Pro Lys Glu Tyr Val Thr Leu 1715 1720 1725 Val His Gly Asp Ser Glu Asn Phe Ser Glu Val Tyr Gly His Arg Leu 1730 1735 1740 His Asn Pro Thr Glu Cys Pro Tyr Asn Gly Ser Arg Arg Asp Asp Cys 1745 1750 1755 1760 Gln Cys Arg Lys Asp Tyr Thr Ala Ala Gly Phe Ser Ser Phe Gln Lys 1765 1770 1775 Ile Arg Ile Asp Leu Thr Ser Met Gln Ile Ile Thr Thr Asp Leu Gln 1780 1785 1790 Phe Ala Arg Thr Ser Glu Gly His Pro Val Pro Phe Ala Thr Ala Gly 1795 1800 1805 Asp Cys Tyr Ser Ala Ala Lys Cys Pro Gln Gly Arg Phe Ser Ile Asn 1810 1815 1820 Leu Tyr Gly Thr Gly Leu Ser Leu Thr Glu Ser Ala Arg Trp Ile Ser 1825 1830 1835 1840 Gln Gly Asn Tyr Ala Val Ser Asp Ile Lys Lys Ser Pro Asp Gly Thr 1845 1850 1855 Arg Val Val Gly Lys Cys Gly Gly Tyr Cys Gly Lys Cys Thr Pro Ser 1860 1865 1870 Ser Gly Thr Gly Leu Glu Val Arg Val Leu 1875 1880 <210> SEQ ID NO 14 <211> LENGTH: 2625 <212> TYPE: DNA <213> ORGANISM: Mus musculus ADAMTS-9 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (2)..(2623) <400> SEQUENCE: 14 g cac act gcg gtc atc agc ctg tgc tcc gga atg atg ggc acg ttc cgc 49 His Thr Ala Val Ile Ser Leu Cys Ser Gly Met Met Gly Thr Phe Arg 1 5 10 15 tct cac gat gga gat tat ttc att gaa cca ctg cag tct gtg gat gag 97 Ser His Asp Gly Asp Tyr Phe Ile Glu Pro Leu Gln Ser Val Asp Glu 20 25 30 caa gag gat gaa gag gaa caa aac aaa ccc cac att att tat agg cac 145 Gln Glu Asp Glu Glu Glu Gln Asn Lys Pro His Ile Ile Tyr Arg His 35 40 45 agc acc cct cag agg gaa ccc tcc aca gga aag cat gcc tgt gcc acc 193 Ser Thr Pro Gln Arg Glu Pro Ser Thr Gly Lys His Ala Cys Ala Thr 50 55 60 tca gaa ctc aaa aat agt cac agt aaa gac aag cgg aaa atc aga atg 241 Ser Glu Leu Lys Asn Ser His Ser Lys Asp Lys Arg Lys Ile Arg Met 65 70 75 80 cga aaa cgg aga aag agg aat agc ctg gct gac gac gtg gca ctg cta 289 Arg Lys Arg Arg Lys Arg Asn Ser Leu Ala Asp Asp Val Ala Leu Leu 85 90 95 aag agc ggt ttg gca aca aag gtg ctc tct ggc tat agc aac cag aca 337 Lys Ser Gly Leu Ala Thr Lys Val Leu Ser Gly Tyr Ser Asn Gln Thr 100 105 110 aac aac aca agg gac aga tgg aac cac aaa aga acc aaa cgc ttt ctg 385 Asn Asn Thr Arg Asp Arg Trp Asn His Lys Arg Thr Lys Arg Phe Leu 115 120 125 tcc tac cca cgg ttt gta gag gtg atg gtg gtg gct gac cac agg atg 433 Ser Tyr Pro Arg Phe Val Glu Val Met Val Val Ala Asp His Arg Met 130 135 140 gtt tta tac cac gga gca aac ctt caa cat tat atc tta acc tta atg 481 Val Leu Tyr His Gly Ala Asn Leu Gln His Tyr Ile Leu Thr Leu Met 145 150 155 160 tcc att gta gct tct atc tat aaa gac tca agt att gga aat tta att 529 Ser Ile Val Ala Ser Ile Tyr Lys Asp Ser Ser Ile Gly Asn Leu Ile 165 170 175 aat att gtt att gtg aac tta gtt gtg att cat aat gaa cag gaa gga 577 Asn Ile Val Ile Val Asn Leu Val Val Ile His Asn Glu Gln Glu Gly 180 185 190 cct tac ata aat ttc aat gcc cag aca aca tta aag aac ttt tgc cag 625 Pro Tyr Ile Asn Phe Asn Ala Gln Thr Thr Leu Lys Asn Phe Cys Gln 195 200 205 tgg cag cac tca aag aac tac ttg ggt ggg att cag cac gac aca gcc 673 Trp Gln His Ser Lys Asn Tyr Leu Gly Gly Ile Gln His Asp Thr Ala 210 215 220 gtt ctg gtc aca agg gaa gat atc tgc aga gct cag gac aaa tgt gac 721 Val Leu Val Thr Arg Glu Asp Ile Cys Arg Ala Gln Asp Lys Cys Asp 225 230 235 240 acc tta ggt ctt gct gaa ctg gga acc att tgc gac ccc tac cga agc 769 Thr Leu Gly Leu Ala Glu Leu Gly Thr Ile Cys Asp Pro Tyr Arg Ser 245 250 255 tgt tcc att agt gaa gac agt ggg ctg agc aca gct ttc aca ata gct 817 Cys Ser Ile Ser Glu Asp Ser Gly Leu Ser Thr Ala Phe Thr Ile Ala 260 265 270 cac gag ctg ggc cat gtg ttt aat atg cct cac gat gac agc aat aaa 865 His Glu Leu Gly His Val Phe Asn Met Pro His Asp Asp Ser Asn Lys 275 280 285 tgc aaa gaa gaa gga gtt aag agt ccc cag cat gtc atg gca cca aca 913 Cys Lys Glu Glu Gly Val Lys Ser Pro Gln His Val Met Ala Pro Thr 290 295 300 ctg aac ttc tac acc aac ccc tgg atg tgg tca aag tgc agt cgg aaa 961 Leu Asn Phe Tyr Thr Asn Pro Trp Met Trp Ser Lys Cys Ser Arg Lys 305 310 315 320 tac atc act gag ttc cta gac act ggg tac gga gag tgc ttg ctg aat 1009 Tyr Ile Thr Glu Phe Leu Asp Thr Gly Tyr Gly Glu Cys Leu Leu Asn 325 330 335 gaa cct gca tcc agg acc tat cct ttg cct tcc caa ctg ccc ggc ctt 1057 Glu Pro Ala Ser Arg Thr Tyr Pro Leu Pro Ser Gln Leu Pro Gly Leu 340 345 350 ctc tac aac gtg aat aaa caa tgt gaa ctg att ttt ggg cca ggc tct 1105 Leu Tyr Asn Val Asn Lys Gln Cys Glu Leu Ile Phe Gly Pro Gly Ser 355 360 365 caa gtg tgc ccc tat atg atg cag tgc aga cgg ctc tgg tgc aat aat 1153 Gln Val Cys Pro Tyr Met Met Gln Cys Arg Arg Leu Trp Cys Asn Asn 370 375 380 gtg gat gga gca cac aaa ggc tgc aag act cag cac acg ccc tgg gca 1201 Val Asp Gly Ala His Lys Gly Cys Lys Thr Gln His Thr Pro Trp Ala 385 390 395 400 gat gga acc gag tgt gag cct gga aag cac tgc aag ttt gga ttt tgt 1249 Asp Gly Thr Glu Cys Glu Pro Gly Lys His Cys Lys Phe Gly Phe Cys 405 410 415 gtt ccc aaa gaa atg gag ggc cct gca att gat gga tcc tgg gga ggt 1297 Val Pro Lys Glu Met Glu Gly Pro Ala Ile Asp Gly Ser Trp Gly Gly 420 425 430 tgg agc cac ttt ggg acc tgc tca aga acg tgt gga gga ggc atc aaa 1345 Trp Ser His Phe Gly Thr Cys Ser Arg Thr Cys Gly Gly Gly Ile Lys 435 440 445 aca gcc atc aga gag tgc aac aga cca gag cca aaa aat ggt ggg aag 1393 Thr Ala Ile Arg Glu Cys Asn Arg Pro Glu Pro Lys Asn Gly Gly Lys 450 455 460 tac tgt gta gga agg aga atg aag ttc aaa tcc tgc aac acg gag ccc 1441 Tyr Cys Val Gly Arg Arg Met Lys Phe Lys Ser Cys Asn Thr Glu Pro 465 470 475 480 tgc atg aag cag aag cga gac ttc cga gag gag cag tgt gct cac ttt 1489 Cys Met Lys Gln Lys Arg Asp Phe Arg Glu Glu Gln Cys Ala His Phe 485 490 495 gat ggc aaa cac ttc aac atc aat ggt ctg ctg ccc agc gta cgc tgg 1537 Asp Gly Lys His Phe Asn Ile Asn Gly Leu Leu Pro Ser Val Arg Trp 500 505 510 ttt cct aag tac agc gga att ttg atg aag gac cgg tgc aag ttg ttc 1585 Phe Pro Lys Tyr Ser Gly Ile Leu Met Lys Asp Arg Cys Lys Leu Phe 515 520 525 tgc aga gtg gca gga aac aca gcc tac tac cag ctc cga gac aga gtg 1633 Cys Arg Val Ala Gly Asn Thr Ala Tyr Tyr Gln Leu Arg Asp Arg Val 530 535 540 att gac gga acc cct tgt ggc cag gac aca aat gac atc tgt gtc caa 1681 Ile Asp Gly Thr Pro Cys Gly Gln Asp Thr Asn Asp Ile Cys Val Gln 545 550 555 560 ggc ctt tgc cgg caa gct gga tgt gat cat att tta aac tca aag gtc 1729 Gly Leu Cys Arg Gln Ala Gly Cys Asp His Ile Leu Asn Ser Lys Val 565 570 575 cgg aaa gat aaa tgt ggg att tgt ggt gga gat aat tct tca tgc aaa 1777 Arg Lys Asp Lys Cys Gly Ile Cys Gly Gly Asp Asn Ser Ser Cys Lys 580 585 590 aca gtg gca gga aca ttt aac act gtc cat tat ggt tac aat act gtt 1825 Thr Val Ala Gly Thr Phe Asn Thr Val His Tyr Gly Tyr Asn Thr Val 595 600 605 gtc cga att ccg gct ggt gct acc agc att gac gtg cgt cag cac agc 1873 Val Arg Ile Pro Ala Gly Ala Thr Ser Ile Asp Val Arg Gln His Ser 610 615 620 ttc tca ggg aag tct gag gat gac aac tac cta gct tta tca aac agt 1921 Phe Ser Gly Lys Ser Glu Asp Asp Asn Tyr Leu Ala Leu Ser Asn Ser 625 630 635 640 aaa ggt gaa ttc ctg cta aat gga gac ttt gtt gtc tcc atg tcc aaa 1969 Lys Gly Glu Phe Leu Leu Asn Gly Asp Phe Val Val Ser Met Ser Lys 645 650 655 agg gag gtc cgc gtg ggg agc gcc gtc att gag tac agc gga tcg gac 2017 Arg Glu Val Arg Val Gly Ser Ala Val Ile Glu Tyr Ser Gly Ser Asp 660 665 670 aat gtg tgt gaa aga ctg aac tgt acg gac cgt atc gag gaa gaa ctt 2065 Asn Val Cys Glu Arg Leu Asn Cys Thr Asp Arg Ile Glu Glu Glu Leu 675 680 685 ctc ctt cag gtg ttg tcc gtg gga aag ctg tat aac cca gat gtg cgg 2113 Leu Leu Gln Val Leu Ser Val Gly Lys Leu Tyr Asn Pro Asp Val Arg 690 695 700 tac tca ttc aat att ccc att gag gac aaa cct cag caa ttt tac tgg 2161 Tyr Ser Phe Asn Ile Pro Ile Glu Asp Lys Pro Gln Gln Phe Tyr Trp 705 710 715 720 aac agt cac ggg ccg tgg caa gca tgc agc aag ccc tgc caa ggg gag 2209 Asn Ser His Gly Pro Trp Gln Ala Cys Ser Lys Pro Cys Gln Gly Glu 725 730 735 cgg aga cca aaa ctt gtt tgc acc agg gag tct gat cag cta acc gtt 2257 Arg Arg Pro Lys Leu Val Cys Thr Arg Glu Ser Asp Gln Leu Thr Val 740 745 750 tct gat caa aga tgt gac cgg ctg ccc cag cca gga cct gtc act gaa 2305 Ser Asp Gln Arg Cys Asp Arg Leu Pro Gln Pro Gly Pro Val Thr Glu 755 760 765 gcg tgc ggc aca gac tgt gac ttg agg tgg cac gtt gcc agc aag agc 2353 Ala Cys Gly Thr Asp Cys Asp Leu Arg Trp His Val Ala Ser Lys Ser 770 775 780 gaa tgc agt gcc cag tgt ggt ttg ggc tac cgt act tta gac atc cac 2401 Glu Cys Ser Ala Gln Cys Gly Leu Gly Tyr Arg Thr Leu Asp Ile His 785 790 795 800 tgt gcc aaa tac agc agg atg gac ggg aag acg gag aag gtg gat gac 2449 Cys Ala Lys Tyr Ser Arg Met Asp Gly Lys Thr Glu Lys Val Asp Asp 805 810 815 agt ttc tgt agc agt caa ccc aga ccg agt aac cag gag aaa tgc tca 2497 Ser Phe Cys Ser Ser Gln Pro Arg Pro Ser Asn Gln Glu Lys Cys Ser 820 825 830 gga gag tgc agc aca ggt gga tgg cgc tat tca gcc tgg acc gaa tgt 2545 Gly Glu Cys Ser Thr Gly Gly Trp Arg Tyr Ser Ala Trp Thr Glu Cys 835 840 845 tct aga agc tgt gat ggt ggt acc cac aga aga aga gca att tgt gtc 2593 Ser Arg Ser Cys Asp Gly Gly Thr His Arg Arg Arg Ala Ile Cys Val 850 855 860 aac acc cgc aat gat gtc ctg gat gac agc aa 2625 Asn Thr Arg Asn Asp Val Leu Asp Asp Ser 865 870 <210> SEQ ID NO 15 <211> LENGTH: 874 <212> TYPE: PRT <213> ORGANISM: Mus musculus ADAMTS-9 <400> SEQUENCE: 15 His Thr Ala Val Ile Ser Leu Cys Ser Gly Met Met Gly Thr Phe Arg 1 5 10 15 Ser His Asp Gly Asp Tyr Phe Ile Glu Pro Leu Gln Ser Val Asp Glu 20 25 30 Gln Glu Asp Glu Glu Glu Gln Asn Lys Pro His Ile Ile Tyr Arg His 35 40 45 Ser Thr Pro Gln Arg Glu Pro Ser Thr Gly Lys His Ala Cys Ala Thr 50 55 60 Ser Glu Leu Lys Asn Ser His Ser Lys Asp Lys Arg Lys Ile Arg Met 65 70 75 80 Arg Lys Arg Arg Lys Arg Asn Ser Leu Ala Asp Asp Val Ala Leu Leu 85 90 95 Lys Ser Gly Leu Ala Thr Lys Val Leu Ser Gly Tyr Ser Asn Gln Thr 100 105 110 Asn Asn Thr Arg Asp Arg Trp Asn His Lys Arg Thr Lys Arg Phe Leu 115 120 125 Ser Tyr Pro Arg Phe Val Glu Val Met Val Val Ala Asp His Arg Met 130 135 140 Val Leu Tyr His Gly Ala Asn Leu Gln His Tyr Ile Leu Thr Leu Met 145 150 155 160 Ser Ile Val Ala Ser Ile Tyr Lys Asp Ser Ser Ile Gly Asn Leu Ile 165 170 175 Asn Ile Val Ile Val Asn Leu Val Val Ile His Asn Glu Gln Glu Gly 180 185 190 Pro Tyr Ile Asn Phe Asn Ala Gln Thr Thr Leu Lys Asn Phe Cys Gln 195 200 205 Trp Gln His Ser Lys Asn Tyr Leu Gly Gly Ile Gln His Asp Thr Ala 210 215 220 Val Leu Val Thr Arg Glu Asp Ile Cys Arg Ala Gln Asp Lys Cys Asp 225 230 235 240 Thr Leu Gly Leu Ala Glu Leu Gly Thr Ile Cys Asp Pro Tyr Arg Ser 245 250 255 Cys Ser Ile Ser Glu Asp Ser Gly Leu Ser Thr Ala Phe Thr Ile Ala 260 265 270 His Glu Leu Gly His Val Phe Asn Met Pro His Asp Asp Ser Asn Lys 275 280 285 Cys Lys Glu Glu Gly Val Lys Ser Pro Gln His Val Met Ala Pro Thr 290 295 300 Leu Asn Phe Tyr Thr Asn Pro Trp Met Trp Ser Lys Cys Ser Arg Lys 305 310 315 320 Tyr Ile Thr Glu Phe Leu Asp Thr Gly Tyr Gly Glu Cys Leu Leu Asn 325 330 335 Glu Pro Ala Ser Arg Thr Tyr Pro Leu Pro Ser Gln Leu Pro Gly Leu 340 345 350 Leu Tyr Asn Val Asn Lys Gln Cys Glu Leu Ile Phe Gly Pro Gly Ser 355 360 365 Gln Val Cys Pro Tyr Met Met Gln Cys Arg Arg Leu Trp Cys Asn Asn 370 375 380 Val Asp Gly Ala His Lys Gly Cys Lys Thr Gln His Thr Pro Trp Ala 385 390 395 400 Asp Gly Thr Glu Cys Glu Pro Gly Lys His Cys Lys Phe Gly Phe Cys 405 410 415 Val Pro Lys Glu Met Glu Gly Pro Ala Ile Asp Gly Ser Trp Gly Gly 420 425 430 Trp Ser His Phe Gly Thr Cys Ser Arg Thr Cys Gly Gly Gly Ile Lys 435 440 445 Thr Ala Ile Arg Glu Cys Asn Arg Pro Glu Pro Lys Asn Gly Gly Lys 450 455 460 Tyr Cys Val Gly Arg Arg Met Lys Phe Lys Ser Cys Asn Thr Glu Pro 465 470 475 480 Cys Met Lys Gln Lys Arg Asp Phe Arg Glu Glu Gln Cys Ala His Phe 485 490 495 Asp Gly Lys His Phe Asn Ile Asn Gly Leu Leu Pro Ser Val Arg Trp 500 505 510 Phe Pro Lys Tyr Ser Gly Ile Leu Met Lys Asp Arg Cys Lys Leu Phe 515 520 525 Cys Arg Val Ala Gly Asn Thr Ala Tyr Tyr Gln Leu Arg Asp Arg Val 530 535 540 Ile Asp Gly Thr Pro Cys Gly Gln Asp Thr Asn Asp Ile Cys Val Gln 545 550 555 560 Gly Leu Cys Arg Gln Ala Gly Cys Asp His Ile Leu Asn Ser Lys Val 565 570 575 Arg Lys Asp Lys Cys Gly Ile Cys Gly Gly Asp Asn Ser Ser Cys Lys 580 585 590 Thr Val Ala Gly Thr Phe Asn Thr Val His Tyr Gly Tyr Asn Thr Val 595 600 605 Val Arg Ile Pro Ala Gly Ala Thr Ser Ile Asp Val Arg Gln His Ser 610 615 620 Phe Ser Gly Lys Ser Glu Asp Asp Asn Tyr Leu Ala Leu Ser Asn Ser 625 630 635 640 Lys Gly Glu Phe Leu Leu Asn Gly Asp Phe Val Val Ser Met Ser Lys 645 650 655 Arg Glu Val Arg Val Gly Ser Ala Val Ile Glu Tyr Ser Gly Ser Asp 660 665 670 Asn Val Cys Glu Arg Leu Asn Cys Thr Asp Arg Ile Glu Glu Glu Leu 675 680 685 Leu Leu Gln Val Leu Ser Val Gly Lys Leu Tyr Asn Pro Asp Val Arg 690 695 700 Tyr Ser Phe Asn Ile Pro Ile Glu Asp Lys Pro Gln Gln Phe Tyr Trp 705 710 715 720 Asn Ser His Gly Pro Trp Gln Ala Cys Ser Lys Pro Cys Gln Gly Glu 725 730 735 Arg Arg Pro Lys Leu Val Cys Thr Arg Glu Ser Asp Gln Leu Thr Val 740 745 750 Ser Asp Gln Arg Cys Asp Arg Leu Pro Gln Pro Gly Pro Val Thr Glu 755 760 765 Ala Cys Gly Thr Asp Cys Asp Leu Arg Trp His Val Ala Ser Lys Ser 770 775 780 Glu Cys Ser Ala Gln Cys Gly Leu Gly Tyr Arg Thr Leu Asp Ile His 785 790 795 800 Cys Ala Lys Tyr Ser Arg Met Asp Gly Lys Thr Glu Lys Val Asp Asp 805 810 815 Ser Phe Cys Ser Ser Gln Pro Arg Pro Ser Asn Gln Glu Lys Cys Ser 820 825 830 Gly Glu Cys Ser Thr Gly Gly Trp Arg Tyr Ser Ala Trp Thr Glu Cys 835 840 845 Ser Arg Ser Cys Asp Gly Gly Thr His Arg Arg Arg Ala Ile Cys Val 850 855 860 Asn Thr Arg Asn Asp Val Leu Asp Asp Ser 865 870 <210> SEQ ID NO 16 <211> LENGTH: 3885 <212> TYPE: DNA <213> ORGANISM: Homo sapiens ADAMTS-10 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(3246) <221> NAME/KEY: misc_feature <222> LOCATION: (3877) <223> OTHER INFORMATION: n=A <221> NAME/KEY: misc_feature <222> LOCATION: (3882) <223> OTHER INFORMATION: n=C <400> SEQUENCE: 16 tca cgc acg cct tcc ggt ctc aag atg agt tcc tgt cca gtc tgg aga 48 Ser Arg Thr Pro Ser Gly Leu Lys Met Ser Ser Cys Pro Val Trp Arg 1 5 10 15 gct atg aga tcg cct tcc cca ccc gcg tgg acc aca acg ggg cac tgc 96 Ala Met Arg Ser Pro Ser Pro Pro Ala Trp Thr Thr Thr Gly His Cys 20 25 30 tgg cct tct cgc cac ctc ctc ccc gga gca gcg ccg cgg cac ggg ggc 144 Trp Pro Ser Arg His Leu Leu Pro Gly Ala Ala Pro Arg His Gly Gly 35 40 45 cac agc cga gtc ccg cct ctt cta caa agt ggc ctc gcc agc acc cac 192 His Ser Arg Val Pro Pro Leu Leu Gln Ser Gly Leu Ala Ser Thr His 50 55 60 ttc ctg ctg aac ctg acc cgc agc tcc cgt cta ctg gca ggg cgc gtc 240 Phe Leu Leu Asn Leu Thr Arg Ser Ser Arg Leu Leu Ala Gly Arg Val 65 70 75 80 tcc gtg gag tac tgg aca cgg gag ggc ctg gcc tgg cag agg gcg gcc 288 Ser Val Glu Tyr Trp Thr Arg Glu Gly Leu Ala Trp Gln Arg Ala Ala 85 90 95 cgg ccc cac tgc ctc tac gct ggt cac ctg cag ggc cag gcc agc agc 336 Arg Pro His Cys Leu Tyr Ala Gly His Leu Gln Gly Gln Ala Ser Ser 100 105 110 tcc cat gtg gcc atc agc acc tgt gga ggc ctg cac ggc ctg atc gtg 384 Ser His Val Ala Ile Ser Thr Cys Gly Gly Leu His Gly Leu Ile Val 115 120 125 gca gac gag gaa gag tac ctg att gag ccc ctg cac ggt ggg ccc aag 432 Ala Asp Glu Glu Glu Tyr Leu Ile Glu Pro Leu His Gly Gly Pro Lys 130 135 140 ggt tct cgg agc ccg gag gaa agt gga cca cat tgt gtg tac aag cgt 480 Gly Ser Arg Ser Pro Glu Glu Ser Gly Pro His Cys Val Tyr Lys Arg 145 150 155 160 tcc tct ctg cgt cac ccc cac ctg gac aca gcc tgt gga gtg aga gat 528 Ser Ser Leu Arg His Pro His Leu Asp Thr Ala Cys Gly Val Arg Asp 165 170 175 gag aaa ccg tgg aaa ggg cgg cca tgg tgg ctg cgg acc ttg aag cca 576 Glu Lys Pro Trp Lys Gly Arg Pro Trp Trp Leu Arg Thr Leu Lys Pro 180 185 190 ccg cct gcc aga ccc ctg ggg aat gaa aca gag cgt ggc cag cca ggc 624 Pro Pro Ala Arg Pro Leu Gly Asn Glu Thr Glu Arg Gly Gln Pro Gly 195 200 205 ctg aag cga tcg gtc agc cga gag cgc tac gtg gag acc atg gat gtg 672 Leu Lys Arg Ser Val Ser Arg Glu Arg Tyr Val Glu Thr Met Asp Val 210 215 220 gct gac aag atg atg gtg gcc tat cac ggg cgc cgg gat gtg gag cag 720 Ala Asp Lys Met Met Val Ala Tyr His Gly Arg Arg Asp Val Glu Gln 225 230 235 240 tat gtc ctg gcc atc atg aac att gtt gcc aaa ctt ttc cag gac tcg 768 Tyr Val Leu Ala Ile Met Asn Ile Val Ala Lys Leu Phe Gln Asp Ser 245 250 255 agt ctg gga agc acc gtt aac atc ctc gta act cgc ctc atc ctg ctc 816 Ser Leu Gly Ser Thr Val Asn Ile Leu Val Thr Arg Leu Ile Leu Leu 260 265 270 acg gag gac cag ccc act ctg gag atc acc cac cat gcc ggg aag tcc 864 Thr Glu Asp Gln Pro Thr Leu Glu Ile Thr His His Ala Gly Lys Ser 275 280 285 cta gac agc ttc tgt aag tgg cag aaa tcc atc gtg aac cac agc ggc 912 Leu Asp Ser Phe Cys Lys Trp Gln Lys Ser Ile Val Asn His Ser Gly 290 295 300 cat ggc aat gcc att cca gag aac ggt gtg gct aac cat gac aca gca 960 His Gly Asn Ala Ile Pro Glu Asn Gly Val Ala Asn His Asp Thr Ala 305 310 315 320 gtg ctc atc aca cgc tat gac atc tgc atc tac aag aac aaa ccc tgc 1008 Val Leu Ile Thr Arg Tyr Asp Ile Cys Ile Tyr Lys Asn Lys Pro Cys 325 330 335 ggc aca cta ggc ctg gcc cgg tgg gcg gaa tgt gtg agc gcg aga gaa 1056 Gly Thr Leu Gly Leu Ala Arg Trp Ala Glu Cys Val Ser Ala Arg Glu 340 345 350 gct gca gcg tca atg agg aca ttg gct gcc aca agc gtt cac cat tgc 1104 Ala Ala Ala Ser Met Arg Thr Leu Ala Ala Thr Ser Val His His Cys 355 360 365 cac gag atc ggg cac aca ttc ggc atg aac cat gac ggc gtg gga aac 1152 His Glu Ile Gly His Thr Phe Gly Met Asn His Asp Gly Val Gly Asn 370 375 380 agc tgt ggg gcc cgt ggt cag gac cca gcc aag ctc atg gct gcc cac 1200 Ser Cys Gly Ala Arg Gly Gln Asp Pro Ala Lys Leu Met Ala Ala His 385 390 395 400 att acc atg aag acc aac cca ttc gtg tgg tca tcc tgc aac cgt gac 1248 Ile Thr Met Lys Thr Asn Pro Phe Val Trp Ser Ser Cys Asn Arg Asp 405 410 415 tac atc acc agc ttt cta gac tcg ggc ctg ggg ctc tgc ctg aac aac 1296 Tyr Ile Thr Ser Phe Leu Asp Ser Gly Leu Gly Leu Cys Leu Asn Asn 420 425 430 cgg ccc ccc aga cag gac ttt gtg tac ccg aca gtg gca ccg ggc caa 1344 Arg Pro Pro Arg Gln Asp Phe Val Tyr Pro Thr Val Ala Pro Gly Gln 435 440 445 gcc tac gat gca gat gag caa tgc cgc ttt cag cat gga gtc aaa tcg 1392 Ala Tyr Asp Ala Asp Glu Gln Cys Arg Phe Gln His Gly Val Lys Ser 450 455 460 cgt cag tgt aaa tac ggg gag gtc tgc agc gag ctg tgg tgt ctg agc 1440 Arg Gln Cys Lys Tyr Gly Glu Val Cys Ser Glu Leu Trp Cys Leu Ser 465 470 475 480 aag agc aac cgg tgc atc acc aac agc atc ccg gcc gcc gag ggc acg 1488 Lys Ser Asn Arg Cys Ile Thr Asn Ser Ile Pro Ala Ala Glu Gly Thr 485 490 495 ctg tgc cag acg cac acc atc gac aag ggg tgg tgc tac aaa cgg gtc 1536 Leu Cys Gln Thr His Thr Ile Asp Lys Gly Trp Cys Tyr Lys Arg Val 500 505 510 tgt gtc ccc ttt ggg tcg cgc cca gag ggt gtg gac gga gcc tgg ggg 1584 Cys Val Pro Phe Gly Ser Arg Pro Glu Gly Val Asp Gly Ala Trp Gly 515 520 525 ccg tgg act cca tgg ggc gac tgc agc cgg acc tgt ggc ggc ggc gtg 1632 Pro Trp Thr Pro Trp Gly Asp Cys Ser Arg Thr Cys Gly Gly Gly Val 530 535 540 tcc tct tct agt cgt cac tgc gac agc ccc agg cca acc atc ggg ggc 1680 Ser Ser Ser Ser Arg His Cys Asp Ser Pro Arg Pro Thr Ile Gly Gly 545 550 555 560 aag tac tgt ctg ggt gag aga agg cgg cac cgc tcc tgc aac acg gat 1728 Lys Tyr Cys Leu Gly Glu Arg Arg Arg His Arg Ser Cys Asn Thr Asp 565 570 575 gac tgt ccc cct ggc tcc cag gac ttc aga gaa gtg cag tgt gct gaa 1776 Asp Cys Pro Pro Gly Ser Gln Asp Phe Arg Glu Val Gln Cys Ala Glu 580 585 590 ttt gac agc atc cct ttc cgt ggg aaa ttc tac aag tgg aaa acg tac 1824 Phe Asp Ser Ile Pro Phe Arg Gly Lys Phe Tyr Lys Trp Lys Thr Tyr 595 600 605 cgg gga ggg ggc gtg aag gcc tgc tcg ctc acg agc cta gcg gaa ggc 1872 Arg Gly Gly Gly Val Lys Ala Cys Ser Leu Thr Ser Leu Ala Glu Gly 610 615 620 ttc aac ttc tac acg gag agg gcg gca gcc gtg gtg gac ggg aca ccc 1920 Phe Asn Phe Tyr Thr Glu Arg Ala Ala Ala Val Val Asp Gly Thr Pro 625 630 635 640 tgc cgt cca gac acg gtg gac att tgc gtc agt ggc gaa tgc aag cac 1968 Cys Arg Pro Asp Thr Val Asp Ile Cys Val Ser Gly Glu Cys Lys His 645 650 655 gtg ggc tgc gac cga gtc ctg ggc tcc gac ctg cgg gag gac aag tgc 2016 Val Gly Cys Asp Arg Val Leu Gly Ser Asp Leu Arg Glu Asp Lys Cys 660 665 670 cga gtg tgt ggc ggt gac ggc agt gcc tgc gag acc atc gag ggc gtc 2064 Arg Val Cys Gly Gly Asp Gly Ser Ala Cys Glu Thr Ile Glu Gly Val 675 680 685 ttc agc cca gcc tca cct ggg gcc ggg tac gag gat gtc gtc tgg att 2112 Phe Ser Pro Ala Ser Pro Gly Ala Gly Tyr Glu Asp Val Val Trp Ile 690 695 700 ccc aaa ggc tcc gtc cac atc ttc atc cag gat ctg aac ctc tct ctc 2160 Pro Lys Gly Ser Val His Ile Phe Ile Gln Asp Leu Asn Leu Ser Leu 705 710 715 720 agt cac ttg gcc ctg aag gga gac cag gag tcc ctg ctg ctg gag ggg 2208 Ser His Leu Ala Leu Lys Gly Asp Gln Glu Ser Leu Leu Leu Glu Gly 725 730 735 ctg cct ggg acc ccc cag ccc cac cgt ctg cct cta gct ggg acc acc 2256 Leu Pro Gly Thr Pro Gln Pro His Arg Leu Pro Leu Ala Gly Thr Thr 740 745 750 ttt caa ctg cga cag ggg cca gac cag gtc cag agc ctc gaa gcc ctg 2304 Phe Gln Leu Arg Gln Gly Pro Asp Gln Val Gln Ser Leu Glu Ala Leu 755 760 765 gga ccg att aat gca tct ctc atc gtc atg gtg ctg gcc cgg acc gag 2352 Gly Pro Ile Asn Ala Ser Leu Ile Val Met Val Leu Ala Arg Thr Glu 770 775 780 ctg cct gcc ctc cgc tac cgc ttc aat gcc ccc atc gcc cgt gac tcg 2400 Leu Pro Ala Leu Arg Tyr Arg Phe Asn Ala Pro Ile Ala Arg Asp Ser 785 790 795 800 ctg ccc ccc tac tcc tgg cac tat gcg ccc tgg acc aag tgc tcg gcc 2448 Leu Pro Pro Tyr Ser Trp His Tyr Ala Pro Trp Thr Lys Cys Ser Ala 805 810 815 cag tgt gca ggc ggt agc cag gtg cag gcg gtg gag tgc cgc aac cag 2496 Gln Cys Ala Gly Gly Ser Gln Val Gln Ala Val Glu Cys Arg Asn Gln 820 825 830 ctg gac agc tcc gcg gtc gcc ccc cac tac tgc agt gcc cac agc aag 2544 Leu Asp Ser Ser Ala Val Ala Pro His Tyr Cys Ser Ala His Ser Lys 835 840 845 ctg ccc aaa agg cag cgc gcc tgc aac acg gag cct tgc cct cca gac 2592 Leu Pro Lys Arg Gln Arg Ala Cys Asn Thr Glu Pro Cys Pro Pro Asp 850 855 860 tgg gtt gta ggg aac tgg tcg ctc tgc agc cgc agc tgc gat gca ggc 2640 Trp Val Val Gly Asn Trp Ser Leu Cys Ser Arg Ser Cys Asp Ala Gly 865 870 875 880 gtg cgc agt acg tcg gtc gtg tgc cag cgc cgc gtc tct gcc gcg gag 2688 Val Arg Ser Thr Ser Val Val Cys Gln Arg Arg Val Ser Ala Ala Glu 885 890 895 gag aag gcg ctg gac gac agc gca tgc ccg cag ccg cgc cca cct gta 2736 Glu Lys Ala Leu Asp Asp Ser Ala Cys Pro Gln Pro Arg Pro Pro Val 900 905 910 ctg gag gcc tgc cac ggc ccc act tgc cct ccg gag tgg gca acc ctc 2784 Leu Glu Ala Cys His Gly Pro Thr Cys Pro Pro Glu Trp Ala Thr Leu 915 920 925 gac tgg tct gag tgt acc cca agc tgt ggg cct ggt ctc cgc cac cga 2832 Asp Trp Ser Glu Cys Thr Pro Ser Cys Gly Pro Gly Leu Arg His Arg 930 935 940 gtg gtc ctt tgt aag agt gca gat caa cga tct act ctg ccc cct ggg 2880 Val Val Leu Cys Lys Ser Ala Asp Gln Arg Ser Thr Leu Pro Pro Gly 945 950 955 960 cac tgc ctt cct gca gcc aag cca cca tct act atg cga tgt aac ttg 2928 His Cys Leu Pro Ala Ala Lys Pro Pro Ser Thr Met Arg Cys Asn Leu 965 970 975 cgc cgc tgc cct cct gcc cgc tgg gtg acc agt gag tgg ggt gag tgt 2976 Arg Arg Cys Pro Pro Ala Arg Trp Val Thr Ser Glu Trp Gly Glu Cys 980 985 990 tcc aca cag tgt ggc ctc ggc cag cag cag cgc aca gtg cgc tgc acc 3024 Ser Thr Gln Cys Gly Leu Gly Gln Gln Gln Arg Thr Val Arg Cys Thr 995 1000 1005 agc cac acc ggc cag cca tct cga gag tgc act gaa gcc ttg cgg cca 3072 Ser His Thr Gly Gln Pro Ser Arg Glu Cys Thr Glu Ala Leu Arg Pro 1010 1015 1020 tcc acc atg cag cag tgt gag gcc aag tgt gac agt gtg gtg ccg cct 3120 Ser Thr Met Gln Gln Cys Glu Ala Lys Cys Asp Ser Val Val Pro Pro 1025 1030 1035 1040 gga gat ggc cca gaa gaa tgc aag gat gtg aac aag gtg gct tac tgc 3168 Gly Asp Gly Pro Glu Glu Cys Lys Asp Val Asn Lys Val Ala Tyr Cys 1045 1050 1055 ccc ctg gtg ctc aaa ttt cag ttc tgt agc cga gcc tac ttc cgc cag 3216 Pro Leu Val Leu Lys Phe Gln Phe Cys Ser Arg Ala Tyr Phe Arg Gln 1060 1065 1070 atg tgc tgc aaa acc tgc caa ggc cgc tag ggtacctgga accaacctgg 3266 Met Cys Cys Lys Thr Cys Gln Gly Arg 1075 1080 agcacaggct gaggcagggg acatcccact ggagagggca tgagggaaag gggggcttga 3326 attgaagggt gagatgcagt tgaaagttat ttattgggta accctacagg gctcctgact 3386 aaggggtgga gaagagctgg ctacccaggg accctctgct gtatcttgcc cagttgatag 3446 tgaagagaga ggactccttg ttgcacacat atttaagtcc ctagcacccc tcccaccctt 3506 tgatcggaat atgtactgtg aagagtgggg gtggggaggg gtgtgctggt gccctgcccc 3566 ctgcactgtt ctatccctac actctgagct ggggggattt atatctgcta tggggggagt 3626 aggcttgata ccacctccct gtagccctcc cccagactga cgaaggggaa gatccacccc 3686 aacctctgcc ctgcctgccc caggggggag ttcaacatcc aggccgttcc ccatcatggt 3746 gctacaagcc ctgccctggg gcccacacac tcctcaccaa gaagccttac attaaaaaag 3806 ttgtgttatc ctacaaaaaa aaaaaaaaac tcgagggggg gcccggtacc caattcgcgc 3866 tatagtaaat ngggtntta 3885 <210> SEQ ID NO 17 <211> LENGTH: 1081 <212> TYPE: PRT <213> ORGANISM: Homo sapiens ADAMTS-10 <400> SEQUENCE: 17 Ser Arg Thr Pro Ser Gly Leu Lys Met Ser Ser Cys Pro Val Trp Arg 1 5 10 15 Ala Met Arg Ser Pro Ser Pro Pro Ala Trp Thr Thr Thr Gly His Cys 20 25 30 Trp Pro Ser Arg His Leu Leu Pro Gly Ala Ala Pro Arg His Gly Gly 35 40 45 His Ser Arg Val Pro Pro Leu Leu Gln Ser Gly Leu Ala Ser Thr His 50 55 60 Phe Leu Leu Asn Leu Thr Arg Ser Ser Arg Leu Leu Ala Gly Arg Val 65 70 75 80 Ser Val Glu Tyr Trp Thr Arg Glu Gly Leu Ala Trp Gln Arg Ala Ala 85 90 95 Arg Pro His Cys Leu Tyr Ala Gly His Leu Gln Gly Gln Ala Ser Ser 100 105 110 Ser His Val Ala Ile Ser Thr Cys Gly Gly Leu His Gly Leu Ile Val 115 120 125 Ala Asp Glu Glu Glu Tyr Leu Ile Glu Pro Leu His Gly Gly Pro Lys 130 135 140 Gly Ser Arg Ser Pro Glu Glu Ser Gly Pro His Cys Val Tyr Lys Arg 145 150 155 160 Ser Ser Leu Arg His Pro His Leu Asp Thr Ala Cys Gly Val Arg Asp 165 170 175 Glu Lys Pro Trp Lys Gly Arg Pro Trp Trp Leu Arg Thr Leu Lys Pro 180 185 190 Pro Pro Ala Arg Pro Leu Gly Asn Glu Thr Glu Arg Gly Gln Pro Gly 195 200 205 Leu Lys Arg Ser Val Ser Arg Glu Arg Tyr Val Glu Thr Met Asp Val 210 215 220 Ala Asp Lys Met Met Val Ala Tyr His Gly Arg Arg Asp Val Glu Gln 225 230 235 240 Tyr Val Leu Ala Ile Met Asn Ile Val Ala Lys Leu Phe Gln Asp Ser 245 250 255 Ser Leu Gly Ser Thr Val Asn Ile Leu Val Thr Arg Leu Ile Leu Leu 260 265 270 Thr Glu Asp Gln Pro Thr Leu Glu Ile Thr His His Ala Gly Lys Ser 275 280 285 Leu Asp Ser Phe Cys Lys Trp Gln Lys Ser Ile Val Asn His Ser Gly 290 295 300 His Gly Asn Ala Ile Pro Glu Asn Gly Val Ala Asn His Asp Thr Ala 305 310 315 320 Val Leu Ile Thr Arg Tyr Asp Ile Cys Ile Tyr Lys Asn Lys Pro Cys 325 330 335 Gly Thr Leu Gly Leu Ala Arg Trp Ala Glu Cys Val Ser Ala Arg Glu 340 345 350 Ala Ala Ala Ser Met Arg Thr Leu Ala Ala Thr Ser Val His His Cys 355 360 365 His Glu Ile Gly His Thr Phe Gly Met Asn His Asp Gly Val Gly Asn 370 375 380 Ser Cys Gly Ala Arg Gly Gln Asp Pro Ala Lys Leu Met Ala Ala His 385 390 395 400 Ile Thr Met Lys Thr Asn Pro Phe Val Trp Ser Ser Cys Asn Arg Asp 405 410 415 Tyr Ile Thr Ser Phe Leu Asp Ser Gly Leu Gly Leu Cys Leu Asn Asn 420 425 430 Arg Pro Pro Arg Gln Asp Phe Val Tyr Pro Thr Val Ala Pro Gly Gln 435 440 445 Ala Tyr Asp Ala Asp Glu Gln Cys Arg Phe Gln His Gly Val Lys Ser 450 455 460 Arg Gln Cys Lys Tyr Gly Glu Val Cys Ser Glu Leu Trp Cys Leu Ser 465 470 475 480 Lys Ser Asn Arg Cys Ile Thr Asn Ser Ile Pro Ala Ala Glu Gly Thr 485 490 495 Leu Cys Gln Thr His Thr Ile Asp Lys Gly Trp Cys Tyr Lys Arg Val 500 505 510 Cys Val Pro Phe Gly Ser Arg Pro Glu Gly Val Asp Gly Ala Trp Gly 515 520 525 Pro Trp Thr Pro Trp Gly Asp Cys Ser Arg Thr Cys Gly Gly Gly Val 530 535 540 Ser Ser Ser Ser Arg His Cys Asp Ser Pro Arg Pro Thr Ile Gly Gly 545 550 555 560 Lys Tyr Cys Leu Gly Glu Arg Arg Arg His Arg Ser Cys Asn Thr Asp 565 570 575 Asp Cys Pro Pro Gly Ser Gln Asp Phe Arg Glu Val Gln Cys Ala Glu 580 585 590 Phe Asp Ser Ile Pro Phe Arg Gly Lys Phe Tyr Lys Trp Lys Thr Tyr 595 600 605 Arg Gly Gly Gly Val Lys Ala Cys Ser Leu Thr Ser Leu Ala Glu Gly 610 615 620 Phe Asn Phe Tyr Thr Glu Arg Ala Ala Ala Val Val Asp Gly Thr Pro 625 630 635 640 Cys Arg Pro Asp Thr Val Asp Ile Cys Val Ser Gly Glu Cys Lys His 645 650 655 Val Gly Cys Asp Arg Val Leu Gly Ser Asp Leu Arg Glu Asp Lys Cys 660 665 670 Arg Val Cys Gly Gly Asp Gly Ser Ala Cys Glu Thr Ile Glu Gly Val 675 680 685 Phe Ser Pro Ala Ser Pro Gly Ala Gly Tyr Glu Asp Val Val Trp Ile 690 695 700 Pro Lys Gly Ser Val His Ile Phe Ile Gln Asp Leu Asn Leu Ser Leu 705 710 715 720 Ser His Leu Ala Leu Lys Gly Asp Gln Glu Ser Leu Leu Leu Glu Gly 725 730 735 Leu Pro Gly Thr Pro Gln Pro His Arg Leu Pro Leu Ala Gly Thr Thr 740 745 750 Phe Gln Leu Arg Gln Gly Pro Asp Gln Val Gln Ser Leu Glu Ala Leu 755 760 765 Gly Pro Ile Asn Ala Ser Leu Ile Val Met Val Leu Ala Arg Thr Glu 770 775 780 Leu Pro Ala Leu Arg Tyr Arg Phe Asn Ala Pro Ile Ala Arg Asp Ser 785 790 795 800 Leu Pro Pro Tyr Ser Trp His Tyr Ala Pro Trp Thr Lys Cys Ser Ala 805 810 815 Gln Cys Ala Gly Gly Ser Gln Val Gln Ala Val Glu Cys Arg Asn Gln 820 825 830 Leu Asp Ser Ser Ala Val Ala Pro His Tyr Cys Ser Ala His Ser Lys 835 840 845 Leu Pro Lys Arg Gln Arg Ala Cys Asn Thr Glu Pro Cys Pro Pro Asp 850 855 860 Trp Val Val Gly Asn Trp Ser Leu Cys Ser Arg Ser Cys Asp Ala Gly 865 870 875 880 Val Arg Ser Thr Ser Val Val Cys Gln Arg Arg Val Ser Ala Ala Glu 885 890 895 Glu Lys Ala Leu Asp Asp Ser Ala Cys Pro Gln Pro Arg Pro Pro Val 900 905 910 Leu Glu Ala Cys His Gly Pro Thr Cys Pro Pro Glu Trp Ala Thr Leu 915 920 925 Asp Trp Ser Glu Cys Thr Pro Ser Cys Gly Pro Gly Leu Arg His Arg 930 935 940 Val Val Leu Cys Lys Ser Ala Asp Gln Arg Ser Thr Leu Pro Pro Gly 945 950 955 960 His Cys Leu Pro Ala Ala Lys Pro Pro Ser Thr Met Arg Cys Asn Leu 965 970 975 Arg Arg Cys Pro Pro Ala Arg Trp Val Thr Ser Glu Trp Gly Glu Cys 980 985 990 Ser Thr Gln Cys Gly Leu Gly Gln Gln Gln Arg Thr Val Arg Cys Thr 995 1000 1005 Ser His Thr Gly Gln Pro Ser Arg Glu Cys Thr Glu Ala Leu Arg Pro 1010 1015 1020 Ser Thr Met Gln Gln Cys Glu Ala Lys Cys Asp Ser Val Val Pro Pro 1025 1030 1035 1040 Gly Asp Gly Pro Glu Glu Cys Lys Asp Val Asn Lys Val Ala Tyr Cys 1045 1050 1055 Pro Leu Val Leu Lys Phe Gln Phe Cys Ser Arg Ala Tyr Phe Arg Gln 1060 1065 1070 Met Cys Cys Lys Thr Cys Gln Gly Arg 1075 1080 <210> SEQ ID NO 18 <211> LENGTH: 1642 <212> TYPE: DNA <213> ORGANISM: Mus musculus ADAMTS-10 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (2)..(1351) <221> NAME/KEY: misc_feature <222> LOCATION: (354) <223> OTHER INFORMATION: n=C <221> NAME/KEY: misc_feature <222> LOCATION: (338) <223> OTHER INFORMATION: n=C <221> NAME/KEY: misc_feature <222> LOCATION: (1511) <223> OTHER INFORMATION: n=A, T, G, C, or I <221> NAME/KEY: misc_feature <222> LOCATION: (1553) <223> OTHER INFORMATION: n=A, T, G, C, or I <221> NAME/KEY: misc_feature <222> LOCATION: (1584) <223> OTHER INFORMATION: n=A, T, G, C, or I <221> NAME/KEY: misc_feature <222> LOCATION: (1616) <223> OTHER INFORMATION: n=A, T, G, C, or I <221> NAME/KEY: misc_feature <222> LOCATION: (1642) <223> OTHER INFORMATION: n=A, T, G, C, or I <400> SEQUENCE: 18 a gca gca gct gtg gtg gat gga aca ccc tgc cgc cct gac acg gtg gac 49 Ala Ala Ala Val Val Asp Gly Thr Pro Cys Arg Pro Asp Thr Val Asp 1 5 10 15 att tgt gtc agc ggc gag tgc aag cat gta ggc tgt gac agg ctc ctg 97 Ile Cys Val Ser Gly Glu Cys Lys His Val Gly Cys Asp Arg Leu Leu 20 25 30 ggt tct gat ctc cga gag gac aaa tgc cgt gtg tgt ggg ggt gat ggc 145 Gly Ser Asp Leu Arg Glu Asp Lys Cys Arg Val Cys Gly Gly Asp Gly 35 40 45 agt gcc tgt gag acc att gaa ggt gtc ttt agc cca gct ttg cca gga 193 Ser Ala Cys Glu Thr Ile Glu Gly Val Phe Ser Pro Ala Leu Pro Gly 50 55 60 act ggg tat gag gac gtc gtc tgg atc ccc aaa ggc tcg gtc cac att 241 Thr Gly Tyr Glu Asp Val Val Trp Ile Pro Lys Gly Ser Val His Ile 65 70 75 80 ttc atc caa gat ctg aac ctg tcc ctg agt cac ctg gcc cta aag ggg 289 Phe Ile Gln Asp Leu Asn Leu Ser Leu Ser His Leu Ala Leu Lys Gly 85 90 95 gac caa gag tct ctg cta ctg gag ggg cta cct ggg acc ccc caa cct 337 Asp Gln Glu Ser Leu Leu Leu Glu Gly Leu Pro Gly Thr Pro Gln Pro 100 105 110 nac cgc ctt ccc ctg gnt ggg acc aca ttt cat cta cgg cag ggg ccg 385 Xaa Arg Leu Pro Leu Xaa Gly Thr Thr Phe His Leu Arg Gln Gly Pro 115 120 125 gac cag gca cag agc ctg gaa gcc ctg gga ccc att aat gca tct ctc 433 Asp Gln Ala Gln Ser Leu Glu Ala Leu Gly Pro Ile Asn Ala Ser Leu 130 135 140 atc atc atg gtg ctg gcc cag gca gag ttg cct gct ctc cac tac cgc 481 Ile Ile Met Val Leu Ala Gln Ala Glu Leu Pro Ala Leu His Tyr Arg 145 150 155 160 ttc aat gca ccc att gcc cgg gat gca ctg cct ccc tac tcc tgg cac 529 Phe Asn Ala Pro Ile Ala Arg Asp Ala Leu Pro Pro Tyr Ser Trp His 165 170 175 tat gcc ccc tgg acc aaa tgc tca gcc cag tgt gca ggc ggc agc cag 577 Tyr Ala Pro Trp Thr Lys Cys Ser Ala Gln Cys Ala Gly Gly Ser Gln 180 185 190 gtg caa gta gtg gag tgc cga aat cag ctg gac agc tca gca gtg gcc 625 Val Gln Val Val Glu Cys Arg Asn Gln Leu Asp Ser Ser Ala Val Ala 195 200 205 cca cac tac tgt agt ggc cac agt aaa ttg ccc aag agg cag cgt gcc 673 Pro His Tyr Cys Ser Gly His Ser Lys Leu Pro Lys Arg Gln Arg Ala 210 215 220 tgc aac aca gaa cca tgt cca cca gat tgg gtt gta gga aac tgg tca 721 Cys Asn Thr Glu Pro Cys Pro Pro Asp Trp Val Val Gly Asn Trp Ser 225 230 235 240 cgc tgc agc cgt agc tgt gac gct ggt gtg cgt agc cgc tca gtg gtg 769 Arg Cys Ser Arg Ser Cys Asp Ala Gly Val Arg Ser Arg Ser Val Val 245 250 255 tgc caa cgc cgg gtg tct gct gca gag gaa aaa gcc tta gac gac agt 817 Cys Gln Arg Arg Val Ser Ala Ala Glu Glu Lys Ala Leu Asp Asp Ser 260 265 270 gcc tgt cca cag cca cgc cca cct gtg ctg gag gcc tgc caa ggc cca 865 Ala Cys Pro Gln Pro Arg Pro Pro Val Leu Glu Ala Cys Gln Gly Pro 275 280 285 atg tgc cct cct gag tgg gca acc ctc gac tgg tct gag tgt acc cca 913 Met Cys Pro Pro Glu Trp Ala Thr Leu Asp Trp Ser Glu Cys Thr Pro 290 295 300 agc tgt ggg cct ggt ctc cgc cac cga gtg gtc ctt tgt aag agt gca 961 Ser Cys Gly Pro Gly Leu Arg His Arg Val Val Leu Cys Lys Ser Ala 305 310 315 320 gat caa cga tct act ctg ccc cct ggg cac tgc ctt cct gca gcc aag 1009 Asp Gln Arg Ser Thr Leu Pro Pro Gly His Cys Leu Pro Ala Ala Lys 325 330 335 cca cca tct act atg cga tgt aac ttg cgc cgc tgc cct cct gcc cgc 1057 Pro Pro Ser Thr Met Arg Cys Asn Leu Arg Arg Cys Pro Pro Ala Arg 340 345 350 tgg gtg acc agt gag tgg ggt gag tgt tcc aca cag tgt ggc ctc ggc 1105 Trp Val Thr Ser Glu Trp Gly Glu Cys Ser Thr Gln Cys Gly Leu Gly 355 360 365 cag cag cag cgc aca gtg cgc tgc acc agc cac acc ggc cag cca tct 1153 Gln Gln Gln Arg Thr Val Arg Cys Thr Ser His Thr Gly Gln Pro Ser 370 375 380 cga gag tgc act gaa gcc ttg cgg cca tcc acc atg cag cag tgt gag 1201 Arg Glu Cys Thr Glu Ala Leu Arg Pro Ser Thr Met Gln Gln Cys Glu 385 390 395 400 gcc aag tgt gac agt gtg gtg ccg cct gga gat ggc cca gaa gaa tgc 1249 Ala Lys Cys Asp Ser Val Val Pro Pro Gly Asp Gly Pro Glu Glu Cys 405 410 415 aag gat gtg aac aag gtg gct tac tgc ccc ctg gtg ctc aaa ttt cag 1297 Lys Asp Val Asn Lys Val Ala Tyr Cys Pro Leu Val Leu Lys Phe Gln 420 425 430 ttc tgt agc cga gcc tac ttc cgc cag atg agc tgc aaa acc tgc caa 1345 Phe Cys Ser Arg Ala Tyr Phe Arg Gln Met Ser Cys Lys Thr Cys Gln 435 440 445 ggc cgc tagggtacct ggaaccaacc tggagcacag gctgaggcag gggacatccc 1401 Gly Arg 450 actggagagg gcatgaggga aaggggggct tgaattgaag ggtgagatgc aagttgaaag 1461 tatttatttg ggtaacccct acagggcttc tgacttaagg ggtggagaan agctggctac 1521 cccagggacc cttttgttgg atcttggccc anttgatagt gaagagagag gacttcttgg 1581 tgnacacatt tttaagtcct tagacccttc caccnttgat cggatatgtc tgggaagagg 1641 n 1642 <210> SEQ ID NO 19 <211> LENGTH: 450 <212> TYPE: PRT <213> ORGANISM: Mus musculus ADAMTS-10 <220> FEATURE: <221> NAME/KEY: MOD_RES <222> LOCATION: (113) <223> OTHER INFORMATION: Xaa = His <221> NAME/KEY: MOD_RES <222> LOCATION: (118) <223> OTHER INFORMATION: Xaa = Ala <400> SEQUENCE: 19 Ala Ala Ala Val Val Asp Gly Thr Pro Cys Arg Pro Asp Thr Val Asp 1 5 10 15 Ile Cys Val Ser Gly Glu Cys Lys His Val Gly Cys Asp Arg Leu Leu 20 25 30 Gly Ser Asp Leu Arg Glu Asp Lys Cys Arg Val Cys Gly Gly Asp Gly 35 40 45 Ser Ala Cys Glu Thr Ile Glu Gly Val Phe Ser Pro Ala Leu Pro Gly 50 55 60 Thr Gly Tyr Glu Asp Val Val Trp Ile Pro Lys Gly Ser Val His Ile 65 70 75 80 Phe Ile Gln Asp Leu Asn Leu Ser Leu Ser His Leu Ala Leu Lys Gly 85 90 95 Asp Gln Glu Ser Leu Leu Leu Glu Gly Leu Pro Gly Thr Pro Gln Pro 100 105 110 Xaa Arg Leu Pro Leu Xaa Gly Thr Thr Phe His Leu Arg Gln Gly Pro 115 120 125 Asp Gln Ala Gln Ser Leu Glu Ala Leu Gly Pro Ile Asn Ala Ser Leu 130 135 140 Ile Ile Met Val Leu Ala Gln Ala Glu Leu Pro Ala Leu His Tyr Arg 145 150 155 160 Phe Asn Ala Pro Ile Ala Arg Asp Ala Leu Pro Pro Tyr Ser Trp His 165 170 175 Tyr Ala Pro Trp Thr Lys Cys Ser Ala Gln Cys Ala Gly Gly Ser Gln 180 185 190 Val Gln Val Val Glu Cys Arg Asn Gln Leu Asp Ser Ser Ala Val Ala 195 200 205 Pro His Tyr Cys Ser Gly His Ser Lys Leu Pro Lys Arg Gln Arg Ala 210 215 220 Cys Asn Thr Glu Pro Cys Pro Pro Asp Trp Val Val Gly Asn Trp Ser 225 230 235 240 Arg Cys Ser Arg Ser Cys Asp Ala Gly Val Arg Ser Arg Ser Val Val 245 250 255 Cys Gln Arg Arg Val Ser Ala Ala Glu Glu Lys Ala Leu Asp Asp Ser 260 265 270 Ala Cys Pro Gln Pro Arg Pro Pro Val Leu Glu Ala Cys Gln Gly Pro 275 280 285 Met Cys Pro Pro Glu Trp Ala Thr Leu Asp Trp Ser Glu Cys Thr Pro 290 295 300 Ser Cys Gly Pro Gly Leu Arg His Arg Val Val Leu Cys Lys Ser Ala 305 310 315 320 Asp Gln Arg Ser Thr Leu Pro Pro Gly His Cys Leu Pro Ala Ala Lys 325 330 335 Pro Pro Ser Thr Met Arg Cys Asn Leu Arg Arg Cys Pro Pro Ala Arg 340 345 350 Trp Val Thr Ser Glu Trp Gly Glu Cys Ser Thr Gln Cys Gly Leu Gly 355 360 365 Gln Gln Gln Arg Thr Val Arg Cys Thr Ser His Thr Gly Gln Pro Ser 370 375 380 Arg Glu Cys Thr Glu Ala Leu Arg Pro Ser Thr Met Gln Gln Cys Glu 385 390 395 400 Ala Lys Cys Asp Ser Val Val Pro Pro Gly Asp Gly Pro Glu Glu Cys 405 410 415 Lys Asp Val Asn Lys Val Ala Tyr Cys Pro Leu Val Leu Lys Phe Gln 420 425 430 Phe Cys Ser Arg Ala Tyr Phe Arg Gln Met Ser Cys Lys Thr Cys Gln 435 440 445 Gly Arg 450 <210> SEQ ID NO 20 <211> LENGTH: 1803 <212> TYPE: DNA <213> ORGANISM: Homo sapiens ADAMTS-R1 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (51)..(1634) <400> SEQUENCE: 20 gaattcggca cgaggcagtg tccgattctg attccggcaa ggatccaagc atg gaa 56 Met Glu 1 tgc tgc cgt cgg gca act cct ggc aca ctg ctc ctc ttt ctg gct ttc 104 Cys Cys Arg Arg Ala Thr Pro Gly Thr Leu Leu Leu Phe Leu Ala Phe 5 10 15 ctg ctc ctg agt tcc agg acc gca cgc tcc gag gag gac cgg gac ggc 152 Leu Leu Leu Ser Ser Arg Thr Ala Arg Ser Glu Glu Asp Arg Asp Gly 20 25 30 cta tgg gat gcc tgg ggc cca tgg agt gaa tgc tca cgc acc tgc ggg 200 Leu Trp Asp Ala Trp Gly Pro Trp Ser Glu Cys Ser Arg Thr Cys Gly 35 40 45 50 ggt ggg gcc gcc aac tct ctg agg cgc tgc ctg agc agc aag agc tgt 248 Gly Gly Ala Ala Asn Ser Leu Arg Arg Cys Leu Ser Ser Lys Ser Cys 55 60 65 gaa gga aga aat atc cga tac aga aca tgc agt aat gtg gac tgc cca 296 Glu Gly Arg Asn Ile Arg Tyr Arg Thr Cys Ser Asn Val Asp Cys Pro 70 75 80 cca gaa gca ggt gat ttc cga gct cag caa tgc tca gct cat aat gat 344 Pro Glu Ala Gly Asp Phe Arg Ala Gln Gln Cys Ser Ala His Asn Asp 85 90 95 gtc aag cac cat ggc cag ttt tat gaa tgg ctt cct gtg tct aat gac 392 Val Lys His His Gly Gln Phe Tyr Glu Trp Leu Pro Val Ser Asn Asp 100 105 110 cct gac aac cca tgt tca ctc aag tgc caa gcc aaa gga aca acc ctg 440 Pro Asp Asn Pro Cys Ser Leu Lys Cys Gln Ala Lys Gly Thr Thr Leu 115 120 125 130 gtt gtt gaa cta gca cct aag gtc tta gat ggt acg cgt tgc tat aca 488 Val Val Glu Leu Ala Pro Lys Val Leu Asp Gly Thr Arg Cys Tyr Thr 135 140 145 gaa tct ttg gat atg tgc atc agt ggt tta tgc caa att gtt ggc tgc 536 Glu Ser Leu Asp Met Cys Ile Ser Gly Leu Cys Gln Ile Val Gly Cys 150 155 160 gat cac cag ctg gga agc acc gtc aag gaa gat aac tgt ggg gtc tgc 584 Asp His Gln Leu Gly Ser Thr Val Lys Glu Asp Asn Cys Gly Val Cys 165 170 175 aac gga gat ggg tcc acc tgc cgg ctg gtc cga ggg cag tat aaa tcc 632 Asn Gly Asp Gly Ser Thr Cys Arg Leu Val Arg Gly Gln Tyr Lys Ser 180 185 190 cag ctc tcc gca acc aaa tcg gat gat act gtg gtt gca att ccc tat 680 Gln Leu Ser Ala Thr Lys Ser Asp Asp Thr Val Val Ala Ile Pro Tyr 195 200 205 210 gga agt aga cat att cgc ctt gtc tta aaa ggt cct gat cac tta tat 728 Gly Ser Arg His Ile Arg Leu Val Leu Lys Gly Pro Asp His Leu Tyr 215 220 225 ctg gaa acc aaa acc ctc cag ggg act aaa ggt gaa aac agt ctc agc 776 Leu Glu Thr Lys Thr Leu Gln Gly Thr Lys Gly Glu Asn Ser Leu Ser 230 235 240 tcc aca gga act ttc ctt gtg gac aat tct agt gtg gac ttc cag aaa 824 Ser Thr Gly Thr Phe Leu Val Asp Asn Ser Ser Val Asp Phe Gln Lys 245 250 255 ttt cca gac aaa gag ata ctg aga atg gct gga cca ctc aca gca gat 872 Phe Pro Asp Lys Glu Ile Leu Arg Met Ala Gly Pro Leu Thr Ala Asp 260 265 270 ttc att gtc aag att cgt aac tcg ggc tcc gct gac agt aca gtc cag 920 Phe Ile Val Lys Ile Arg Asn Ser Gly Ser Ala Asp Ser Thr Val Gln 275 280 285 290 ttc atc ttc tat caa ccc atc atc cac cga tgg agg gag acg gat ttc 968 Phe Ile Phe Tyr Gln Pro Ile Ile His Arg Trp Arg Glu Thr Asp Phe 295 300 305 ttt cct tgc tca gca acc tgt gga gga ggt tat cag ctg aca tcg gct 1016 Phe Pro Cys Ser Ala Thr Cys Gly Gly Gly Tyr Gln Leu Thr Ser Ala 310 315 320 gag tgc tac gat ctg agg agc aac cgt gtg gtt gct gac caa tac tgt 1064 Glu Cys Tyr Asp Leu Arg Ser Asn Arg Val Val Ala Asp Gln Tyr Cys 325 330 335 cac tat tac cca gag aac atc aaa ccc aaa ccc aag ctt cag gag tgc 1112 His Tyr Tyr Pro Glu Asn Ile Lys Pro Lys Pro Lys Leu Gln Glu Cys 340 345 350 aac ttg gat cct tgt cca gcc agt gac gga tac aag cag atc atg cct 1160 Asn Leu Asp Pro Cys Pro Ala Ser Asp Gly Tyr Lys Gln Ile Met Pro 355 360 365 370 tat gac ctc tac cat ccc ctt cct cgg tgg gag gcc acc cca tgg acc 1208 Tyr Asp Leu Tyr His Pro Leu Pro Arg Trp Glu Ala Thr Pro Trp Thr 375 380 385 gcg tgc tcc tcc tcg tgt ggg ggg ggc atc cag agc cgg gca gtt tcc 1256 Ala Cys Ser Ser Ser Cys Gly Gly Gly Ile Gln Ser Arg Ala Val Ser 390 395 400 tgt gtg gag gag gac atc cag ggg cat gtc act tca gtg gaa gag tgg 1304 Cys Val Glu Glu Asp Ile Gln Gly His Val Thr Ser Val Glu Glu Trp 405 410 415 aaa tgc atg tac acc cct aag atg ccc atc gcg cag ccc tgc aac att 1352 Lys Cys Met Tyr Thr Pro Lys Met Pro Ile Ala Gln Pro Cys Asn Ile 420 425 430 ttt gac tgc cct aaa tgg ctg gca cag gag tgg tct ccg tgc aca gtg 1400 Phe Asp Cys Pro Lys Trp Leu Ala Gln Glu Trp Ser Pro Cys Thr Val 435 440 445 450 acg tgt ggc cag ggc ctc aga tac cgt gtg gtc ctc tgc atc gac cat 1448 Thr Cys Gly Gln Gly Leu Arg Tyr Arg Val Val Leu Cys Ile Asp His 455 460 465 cga gga atg cac aca gga ggc tgt agc cca aaa aca aag ccc cac ata 1496 Arg Gly Met His Thr Gly Gly Cys Ser Pro Lys Thr Lys Pro His Ile 470 475 480 aaa gag gaa tgc atc gta ccc act ccc tgc tat aaa ccc aaa gag aaa 1544 Lys Glu Glu Cys Ile Val Pro Thr Pro Cys Tyr Lys Pro Lys Glu Lys 485 490 495 ctt cca gtc gag gcc aag ttg cca tgg ttc aaa caa gct caa gag cta 1592 Leu Pro Val Glu Ala Lys Leu Pro Trp Phe Lys Gln Ala Gln Glu Leu 500 505 510 gaa gaa gga gct gct gtg tca gag gag ccc tcg taa gtt gta 1634 Glu Glu Gly Ala Ala Val Ser Glu Glu Pro Ser Val Val 515 520 525 aaagcacaga ctgttctata tttgaaactt ttgtttaaag aaagcagtgt ctcactggtt 1694 gtagctttca tgggttctga actaagtgta atcatctcac caaagctttt tggctctcaa 1754 attaaagatt gattagtttc aaaaaaaaaa aaaaaaaaga tgcggccgc 1803 <210> SEQ ID NO 21 <211> LENGTH: 525 <212> TYPE: PRT <213> ORGANISM: Homo sapiens ADAMTS-R1 <400> SEQUENCE: 21 Met Glu Cys Cys Arg Arg Ala Thr Pro Gly Thr Leu Leu Leu Phe Leu 1 5 10 15 Ala Phe Leu Leu Leu Ser Ser Arg Thr Ala Arg Ser Glu Glu Asp Arg 20 25 30 Asp Gly Leu Trp Asp Ala Trp Gly Pro Trp Ser Glu Cys Ser Arg Thr 35 40 45 Cys Gly Gly Gly Ala Ala Asn Ser Leu Arg Arg Cys Leu Ser Ser Lys 50 55 60 Ser Cys Glu Gly Arg Asn Ile Arg Tyr Arg Thr Cys Ser Asn Val Asp 65 70 75 80 Cys Pro Pro Glu Ala Gly Asp Phe Arg Ala Gln Gln Cys Ser Ala His 85 90 95 Asn Asp Val Lys His His Gly Gln Phe Tyr Glu Trp Leu Pro Val Ser 100 105 110 Asn Asp Pro Asp Asn Pro Cys Ser Leu Lys Cys Gln Ala Lys Gly Thr 115 120 125 Thr Leu Val Val Glu Leu Ala Pro Lys Val Leu Asp Gly Thr Arg Cys 130 135 140 Tyr Thr Glu Ser Leu Asp Met Cys Ile Ser Gly Leu Cys Gln Ile Val 145 150 155 160 Gly Cys Asp His Gln Leu Gly Ser Thr Val Lys Glu Asp Asn Cys Gly 165 170 175 Val Cys Asn Gly Asp Gly Ser Thr Cys Arg Leu Val Arg Gly Gln Tyr 180 185 190 Lys Ser Gln Leu Ser Ala Thr Lys Ser Asp Asp Thr Val Val Ala Ile 195 200 205 Pro Tyr Gly Ser Arg His Ile Arg Leu Val Leu Lys Gly Pro Asp His 210 215 220 Leu Tyr Leu Glu Thr Lys Thr Leu Gln Gly Thr Lys Gly Glu Asn Ser 225 230 235 240 Leu Ser Ser Thr Gly Thr Phe Leu Val Asp Asn Ser Ser Val Asp Phe 245 250 255 Gln Lys Phe Pro Asp Lys Glu Ile Leu Arg Met Ala Gly Pro Leu Thr 260 265 270 Ala Asp Phe Ile Val Lys Ile Arg Asn Ser Gly Ser Ala Asp Ser Thr 275 280 285 Val Gln Phe Ile Phe Tyr Gln Pro Ile Ile His Arg Trp Arg Glu Thr 290 295 300 Asp Phe Phe Pro Cys Ser Ala Thr Cys Gly Gly Gly Tyr Gln Leu Thr 305 310 315 320 Ser Ala Glu Cys Tyr Asp Leu Arg Ser Asn Arg Val Val Ala Asp Gln 325 330 335 Tyr Cys His Tyr Tyr Pro Glu Asn Ile Lys Pro Lys Pro Lys Leu Gln 340 345 350 Glu Cys Asn Leu Asp Pro Cys Pro Ala Ser Asp Gly Tyr Lys Gln Ile 355 360 365 Met Pro Tyr Asp Leu Tyr His Pro Leu Pro Arg Trp Glu Ala Thr Pro 370 375 380 Trp Thr Ala Cys Ser Ser Ser Cys Gly Gly Gly Ile Gln Ser Arg Ala 385 390 395 400 Val Ser Cys Val Glu Glu Asp Ile Gln Gly His Val Thr Ser Val Glu 405 410 415 Glu Trp Lys Cys Met Tyr Thr Pro Lys Met Pro Ile Ala Gln Pro Cys 420 425 430 Asn Ile Phe Asp Cys Pro Lys Trp Leu Ala Gln Glu Trp Ser Pro Cys 435 440 445 Thr Val Thr Cys Gly Gln Gly Leu Arg Tyr Arg Val Val Leu Cys Ile 450 455 460 Asp His Arg Gly Met His Thr Gly Gly Cys Ser Pro Lys Thr Lys Pro 465 470 475 480 His Ile Lys Glu Glu Cys Ile Val Pro Thr Pro Cys Tyr Lys Pro Lys 485 490 495 Glu Lys Leu Pro Val Glu Ala Lys Leu Pro Trp Phe Lys Gln Ala Gln 500 505 510 Glu Leu Glu Glu Gly Ala Ala Val Ser Glu Glu Pro Ser 515 520 525 <210> SEQ ID NO 22 <211> LENGTH: 518 <212> TYPE: PRT <213> ORGANISM: Homo sapiens ADAMTS-5 <220> FEATURE: <221> NAME/KEY: MOD_RES <222> LOCATION: (99) <223> OTHER INFORMATION: Xaa = Met <400> SEQUENCE: 22 Gly His Leu Leu Gly Leu Ser His Asp Asp Ser Lys Phe Cys Glu Glu 1 5 10 15 Thr Phe Gly Ser Thr Glu Asp Lys Arg Leu Met Ser Ser Ile Leu Thr 20 25 30 Ser Ile Asp Ala Ser Lys Pro Trp Ser Lys Cys Thr Ser Ala Thr Ile 35 40 45 Thr Glu Phe Leu Asp Asp Gly His Gly Asn Cys Leu Leu Asp Leu Pro 50 55 60 Arg Lys Gln Ile Leu Gly Pro Glu Glu Leu Pro Gly Gln Thr Tyr Asp 65 70 75 80 Ala Thr Gln Gln Cys Asn Leu Thr Phe Gly Pro Asp Tyr Ser Val Cys 85 90 95 Pro Gly Xaa Asp Val Cys Ala Arg Leu Trp Cys Ala Val Val Arg Gln 100 105 110 Gly Gln Met Val Cys Leu Thr Lys Lys Leu Pro Ala Val Glu Gly Thr 115 120 125 Pro Cys Gly Lys Gly Arg Ile Cys Leu Gln Gly Lys Cys Val Asp Lys 130 135 140 Thr Lys Lys Lys Tyr Tyr Ser Thr Ser Ser His Gly Asn Trp Gly Ser 145 150 155 160 Trp Gly Ser Trp Gly Gln Cys Ser Arg Ser Cys Gly Gly Gly Val Gln 165 170 175 Phe Ala Tyr Arg His Cys Asn Asn Pro Ala Pro Arg Asn Asn Gly Arg 180 185 190 Tyr Cys Thr Gly Lys Arg Ala Ile Tyr His Ser Cys Ser Leu Met Pro 195 200 205 Cys Pro Pro Asn Gly Lys Ser Phe Arg His Glu Gln Cys Glu Ala Lys 210 215 220 Asn Gly Tyr Gln Ser Asp Ala Lys Gly Val Lys Thr Phe Val Glu Trp 225 230 235 240 Val Pro Lys Tyr Ala Gly Val Leu Pro Ala Asp Val Cys Lys Leu Thr 245 250 255 Cys Arg Ala Lys Gly Thr Gly Tyr Tyr Val Val Phe Ser Pro Lys Val 260 265 270 Thr Asp Gly Thr Glu Cys Arg Pro Tyr Ser Asn Ser Val Cys Val Arg 275 280 285 Gly Lys Cys Val Arg Thr Gly Cys Asp Gly Ile Ile Gly Ser Lys Leu 290 295 300 Gln Tyr Asp Lys Cys Gly Val Cys Gly Gly Asp Asn Ser Ser Cys Thr 305 310 315 320 Lys Ile Val Gly Thr Phe Asn Lys Lys Ser Lys Gly Tyr Thr Asp Val 325 330 335 Val Arg Ile Pro Glu Gly Ala Thr His Ile Lys Val Arg Gln Phe Lys 340 345 350 Ala Lys Asp Gln Thr Arg Phe Thr Ala Tyr Leu Ala Leu Lys Lys Lys 355 360 365 Asn Gly Glu Tyr Leu Ile Asn Gly Lys Tyr Met Ile Ser Thr Ser Glu 370 375 380 Thr Ile Ile Asp Ile Asn Gly Thr Val Met Asn Tyr Ser Gly Trp Ser 385 390 395 400 His Arg Asp Asp Phe Leu His Gly Met Gly Tyr Ser Ala Thr Lys Glu 405 410 415 Ile Leu Ile Val Gln Ile Leu Ala Thr Asp Pro Thr Lys Pro Leu Asp 420 425 430 Val Arg Tyr Ser Phe Phe Val Pro Lys Lys Ser Thr Pro Lys Val Asn 435 440 445 Ser Val Thr Ser His Gly Ser Asn Lys Val Gly Ser His Thr Ser Gln 450 455 460 Pro Gln Trp Val Thr Gly Pro Trp Leu Ala Cys Ser Arg Thr Cys Asp 465 470 475 480 Thr Gly Trp His Thr Arg Thr Val Gln Cys Gln Asp Gly Asn Arg Lys 485 490 495 Leu Ala Lys Gly Cys Pro Leu Ser Gln Arg Pro Ser Ala Phe Lys Gln 500 505 510 Cys Leu Leu Lys Lys Cys 515 <210> SEQ ID NO 23 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: synthetic construct <400> SEQUENCE: 23 Ser Val Ser Ile Glu Arg Phe Val Glu Thr Leu Val Val Ala Asp Lys 1 5 10 15 <210> SEQ ID NO 24 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: synthetic construct <400> SEQUENCE: 24 Glu Val Ala Glu Ala Ala Asn Phe Leu Ala Leu Arg Ser Glu Asp Pro 1 5 10 15 Asp Lys Tyr <210> SEQ ID NO 25 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: synthetic construct <400> SEQUENCE: 25 Val Lys Glu Asp Val Glu Asn Pro Lys Ala Val Val Asp Gly Asp Trp 1 5 10 15 Gly Pro <210> SEQ ID NO 26 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: synthetic construct <400> SEQUENCE: 26 Gln His Pro Phe Gln Asn Glu Asp Tyr Arg Pro Arg Ser Ala Ser Pro 1 5 10 15 Ser Arg Thr His 20 <210> SEQ ID NO 27 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: synthetic construct <400> SEQUENCE: 27 Pro Gln Asn Cys Lys Glu Val Lys Arg Leu Lys Gly Ala Ser Glu Asp 1 5 10 15 Gly Glu Tyr Phe 20 <210> SEQ ID NO 28 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: synthetic construct <400> SEQUENCE: 28 Gln Glu Leu Glu Glu Gly Ala Ala Val Ser Glu Glu Pro Ser 1 5 10 <210> SEQ ID NO 29 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: synthetic construct <400> SEQUENCE: 29 Tyr Tyr Pro Glu Asn Ile Lys Pro Lys Pro Lys Leu Gln Glu 1 5 10 <210> SEQ ID NO 30 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: synthetic construct <400> SEQUENCE: 30 His Ile Lys Val Arg Gln Phe Lys Ala Lys Asp Gln Thr Arg Phe 1 5 10 15 <210> SEQ ID NO 31 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: synthetic construct <400> SEQUENCE: 31 Cys Glu Ala Lys Asn Gly Tyr Gln Ser Asp Ala Lys Gly Val Lys Thr 1 5 10 15 Phe Val Glu Trp Val Pro Lys Tyr Ala Gly 20 25 

What is claimed is:
 1. An isolated mammalian protein selected from the group consisting of an ADAMTS-5 protein, 5 an ADAMTS-6 protein, an ADAMTS-7 protein, an ADAMTS-8 protein,. an ADAMTS-9 protein, an ADAMTS-10 protein, and an ADAMTS-R1 protein.
 2. The isolated mammalian protein of claim 1 wherein said protein comprises an amino acid sequence which is at least 95% identical to a sequence selected from the group consisting of amino acid 262 through amino acid 930 of SEQ ID NO: 2; amino acid 1 through amino acid 518 of SEQ ID NO: 4; amino acid 245 through amino acid 860 of SEQ ID NO: 6; amino acid 233 through amino acid 997 of SEQ ID NO: 8; amino acid 229 through amino acid 905 of SEQ ID NO: 10; amino acid 1 through amino acid 245 of SEQ ID NO: 12; amino acid 236 through amino acid 1882 of SEQ ID NO: 14; amino acid 1 through amino acid 874 of SEQ ID NO: 16; amino acid 212 through amino acid 1081 of SEQ ID NO: 18; amino acid 1 through amino acid 450 of SEQ ID NO: 20; and amino acid 1 through amino acid 547 of SEQ ID NO:
 22. 3. The isolated protein of claim 2 wherein said amino acid sequence further comprises a prepropeptide sequence at the amino terminus thereof.
 4. The isolated protein of claim 1 wherein said protein is a human ADAMTS-5 protein or a mouse ADAMTS-5 protein.
 5. The isolated protein of claim 1 wherein said protein is a human ADAMTS-6 protein.
 6. The isolated protein of claim 1 wherein said protein is a human ADAMTS-7 protein.
 7. The isolated protein of claim 1 wherein said protein is a mouse ADAMTS-8 or a human ADAMTS-8 protein.
 8. The isolated protein of claim 1 wherein said protein is a human ADAMTS-9 or a mouse ADAMTS-9 protein.
 9. The isolated protein of claim 1 wherein said protein is a human ADAMTS-10 or a mouse ADAMTS-10 protein.
 10. The isolated protein of claim 1 wherein said protein is a human ADAMTS-R1 protein.
 11. An isolated polynucleotide comprising a sequence which encodes a mammalian protein 30 selected from the group consisting of an ADAMTS-5 protein, an ADAMTS-6 protein, an ADAMTS-7 protein, an ADAMTS-8 protein, an ADAMTS-9 protein, an ADAMTS-10 protein, and an ADAMTS-R1 protein.
 12. The isolated polynucleotide of claim 11 wherein said protein comprises an amino acid sequence which is at.least 95% identical to a sequence selected from the group consisting of: amino acid 262 through amino acid 930 of SEQ ID NO: 2; amino acid -1 through amino acid 518 of SEQ ID NO: 4; amino acid 245 through amino acid 860 of SEQ ID NO: 6; amino acid 233 through amino acid 997 of SEQ ID NO: 8; amino acid 229 through amino acid 905 of SEQ ID NO: 10; amino acid 1 through amino acid 245 of SEQ ID NO: 12; amino acid 236 through amino acid.1882 of SEQ ID NO: 14; amino acid 1 through amino acid 874 of SEQ ID NO: 16; amino acid 212 through amino acid 1081 of SEQ ID NO: 18; amino acid 1 through amino acid 450 of SEQ ID NO: 20; and amino acid 1 through amino acid 547 of SEQ ID NO:
 22. 13. The isolated polynucleotide of claim 11 wherein said nucleotide sequence encodes a protein having a signal sequence at the amino terminus thereof.
 14. The isolated polynucleotide of claim 11 wherein said polynucleotide comprises a sequence selected from the group consisting of: nucleotide 800 through nucleotide 2810 of SEQ ID NO: 1 or an allelic variant thereof; nucleotide 1 through nucleotide 1519 of SEQ ID NO: 3 or an allelic variant thereof; nucleotide 754 through nucleotide 2602 of SEQ ID NO: 5 or an allelic variant thereof; nucleotide 708 through nucleotide 3003 of SEQ ID NO: 7 or an allelic variant thereof; nucleotide 962 through nucleotide 2992 of SEQ ID NO: 9 or an allelic variant thereof; nucleotide 1 through nucleotide 739 of SEQ ID NO: 11 or an allelic variant thereof; nucleotide 708 through nucleotide 5648 of SEQ ID NO: 13 or an allelic variant thereof; nucleotide 1 through nucleotide 2625 of SEQ ID NO: 15 or an allelic variant thereof; nucleotide 634 through nucleotide 3243 of SEQ ID NO: 17 or an allelic variant thereof; nucleotide 1 through nucleotide 1642 of SEQ ID NO: 19 or an allelic variant thereof, and nucleotide 51 through nucleotide 1625 of SEQ ID NO: 21 or an allelic variant thereof.
 15. The isolated polynucleotide of claim 11 wherein said polynucleotide hybridizes under stringent conditions to a nucleic acid molecule comprising a sequence complementary to the protein encoding sequence of SEQ ID NO: 1; SEQ ID NO: 3; SEQ ID NO: 5; SEQ ID NO: 7; SEQ ID NO: 9; SEQ ID NO: 11; SEQ ID NO: 13; SEQ ID NO: 15; SEQ ID NO: 17; SEQ ID NO: 19; or SEQ ID NO:
 21. 16. An isolated polynucleotide having a sequence which is complementary to the protein encoding sequence of the polynucleotide of claim
 11. 17. An expression vector comprising a polynucleotide of claim
 11. 18. A host cell transformed or transfected with an expression vector of claim
 17. 19. A method for producing an ADAMTS-N protein or an ADAMTS-RI protein, said method comprising the steps of (a) culturing a host cell of claim 18 under conditions suitable for expression of an ADAMTS-N protein or an ADAMTS-R1 protein; and (b) recovering said ADAMTS-N protein or said ADAMTS-R1 protein from the host cell culture.
 20. An antibody that binds to a protein selected from the group consisting of an ADAMTS-5 protein, an ADAMTS-6 protein, an ADAMTS-7 protein, an ADAMTS-8 protein, an ADAMTS-9 protein, an ADAMTS-10 protein and an ADAMTS-RI protein.
 21. An oligopeptide for producing an antibody that binds to an ADAMTS-N protein or an ADAMTS-R1 protein wherein said oligopeptide has a sequence selected from the group consisting of: a) SVSIERFVETLVVADK, SEQ ID NO: 23; b) EVAEAANFLALRSEDPDKY, SEQ ID NO: 24; c) VKEDVENPKAVVDGDWGP, SEQ ID NO: 25; d) QHPFQNEDYRPRSASPSRTH, SEQ ID NO: 26; e) PQNCKEVKRLKGASEDGEYF, SEQ ID NO:
 27. f) QELEEGAAVSEEPS, SEQ ID NO: 28 g) YYPENIKPKPKLQE; SEQ ID NO:
 29. h) HIKVRQFKAKDQTRF; and i) CEAKNGYQSDAKGVKTFVEWVPKYAG, SEQ ID NO:
 30. 